var title_f11_29_11728="Hemolok clip";
var content_f11_29_11728=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F74988&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F74988&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hem-o-lok clip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 352px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Teleflex Medical Incorporated. Copyright &copy; 2010.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_29_11728=[""].join("\n");
var outline_f11_29_11728=null;
var title_f11_29_11729="Type III AC joint spr PI";
var content_f11_29_11729=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F55686&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F55686&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 494px\">",
"   <div class=\"ttl\">",
"    Type III acromioclavicular joint sprain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 474px; height: 440px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_29_11729=[""].join("\n");
var outline_f11_29_11729=null;
var title_f11_29_11730="Calculator: Blood ethanol concentration estimation";
var content_f11_29_11730=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"BloodEthanolConc_form\" name=\"BloodEthanolConc_form\" onkeydown=\"clrResults();\" onkeyup=\"BloodEthanolConc_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Blood ethanol concentration estimation",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <div id=\"calc_equation\">",
"      <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"       <tr>",
"        <td align=\"left\" bgcolor=\"#6c9a9c\">",
"         <span class=\"medCalcFontFormuli\">",
"          BloodEthanolConcentration = (VolumeIngested * ConcentrationIngested * 0.8) / (Weight * 0.6)",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"     </div>",
"    </center>",
"    <div id=\"calc_main\">",
"     <center>",
"      <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"       <tr>",
"        <td align=\"right\" width=\"50%\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Input:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Volume Ingested",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Volume_Ingested_param\" onblur=\"BloodEthanolConc_fx(); minMaxCheck();\" onchange=\"BloodEthanolConc_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"160\">",
"             <select class=\"medCalcFontSelect\" name=\"Volume_Ingested_unit\" onchange=\"BloodEthanolConc_fx();\" style=\"width:150px;\">",
"              <option value=\"1000|0|L\">",
"               L",
"              </option>",
"              <option value=\"10|0|cL\">",
"               cL",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mL\">",
"               mL",
"              </option>",
"              <option value=\"28.413075|0|ounce (UK)\">",
"               ounce (UK)",
"              </option>",
"              <option value=\"29.57352956|0|ounce (US)\">",
"               ounce (US)",
"              </option>",
"              <option value=\"568.2615|0|pint (UK)\">",
"               pint (UK)",
"              </option>",
"              <option value=\"473.176473|0|pint (US)\">",
"               pint (US)",
"              </option>",
"              <option value=\"1136.523|0|quart (UK)\">",
"               quart (UK)",
"              </option>",
"              <option value=\"946.352946|0|quart (US)\">",
"               quart (US)",
"              </option>",
"              <option value=\"14.78677|0|tablespoon (US)\">",
"               tablespoon (US)",
"              </option>",
"              <option value=\"15|0|tablespoon (metric)\">",
"               tablespoon (metric)",
"              </option>",
"              <option value=\"4.928922|0|teaspoon (US)\">",
"               teaspoon (US)",
"              </option>",
"              <option value=\"5|0|teaspoon (metric)\">",
"               teaspoon (metric)",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Concentration Ingested",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Concentration_Ingested_param\" onblur=\"BloodEthanolConc_fx(); minMaxCheck();\" onchange=\"BloodEthanolConc_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"160\">",
"             <select class=\"medCalcFontSelect\" name=\"Concentration_Ingested_unit\" onchange=\"BloodEthanolConc_fx();\" style=\"width:150px;\">",
"              <option selected=\"selected\" value=\"1|0|Percent Ethanol\">",
"               Percent Ethanol",
"              </option>",
"              <option value=\"0.571|0|Proof (U.K./Australia)\">",
"               Proof (U.K./Australia)",
"              </option>",
"              <option value=\"0.5|0|Proof (U.S.)\">",
"               Proof (U.S.)",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Weight",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Weight_param\" onblur=\"BloodEthanolConc_fx(); minMaxCheck();\" onchange=\"BloodEthanolConc_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"160\">",
"             <select class=\"medCalcFontSelect\" name=\"Weight_unit\" onchange=\"BloodEthanolConc_fx();\" style=\"width:150px;\">",
"              <option selected=\"selected\" value=\"1|0|kg\">",
"               kg",
"              </option>",
"              <option value=\"0.45359237|0|lb\">",
"               lb",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Result:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Blood Ethanol Concentration",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"Blood_Ethanol_Concentration_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"            <td valign=\"top\">",
"             <span class=\"medCalcFontOne\">",
"              <select class=\"medCalcFontSelect\" name=\"Blood_Ethanol_Concentration_unit\" onchange=\"BloodEthanolConc_fx();\" style=\"width:150px;\">",
"               <option value=\"100|0|gm/L\">",
"                gm/L",
"               </option>",
"               <option value=\"1000|0|gm/dL\">",
"                gm/dL",
"               </option>",
"               <option selected=\"selected\" value=\"1|0|mg/dL\">",
"                mg/dL",
"               </option>",
"               <option value=\"100|0|mg/mL\">",
"                mg/mL",
"               </option>",
"               <option value=\"4.505|0|mmol/L\">",
"                mmol/L",
"               </option>",
"              </select>",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td colspan=\"3\">",
"             &nbsp;",
"             <br/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"center\" colspan=\"3\">",
"             <span class=\"medCalcFontOneBold\">",
"              Decimal Precision:",
"             </span>",
"             <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"BloodEthanolConc_fx();\">",
"              <option>",
"               0",
"              </option>",
"              <option>",
"               1",
"              </option>",
"              <option selected=\"selected\">",
"               2",
"              </option>",
"              <option>",
"               3",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <center>",
"          <span class=\"medCalcFontOne\">",
"           <input name=\"reset\" type=\"reset\" value=\"Reset form\"/>",
"          </span>",
"         </center>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <span class=\"medCalcFontOneBold\">",
"      Notes",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       0.8 g/mL is the specific gravity of ethanol and 0.6 is the volume of distribution of ethanol.",
"      </li>",
"      <li>",
"       In the U.S.",
"       <b>",
"        Percent Ethanol",
"       </b>",
"       of beverages is",
"       <b>",
"        Proof",
"       </b>",
"       / 2 while in the U.K. and Australia",
"       <b>",
"        Percent Ethanol",
"       </b>",
"       of beverages is",
"       <b>",
"        Proof",
"       </b>",
"       / 1.75",
"      </li>",
"      <li>",
"       For example, 80 proof vodka is 40 percent ethanol in the US, but is 46 percent ethanol in the UK or Australia.  Use the pull-down unit selector to choose the appropriate",
"       <b>",
"        Concentration Ingested",
"       </b>",
"       unit.",
"      </li>",
"      <li>",
"       A swallow in a toddler is about 5 mL (1 teaspoon.)",
"      </li>",
"     </ul>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <span class=\"medCalcFontOneBold\">",
"      <br/>",
"      &nbsp;",
"      <br/>",
"     </span>",
"     <span class=\"medCalcFontOneBold\">",
"      Ethanol content in beverages, medications, and household products",
"     </span>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <center>",
"      <table border=\"1\" cellpadding=\"4\" class=\"medCalcFontOne\" summary=\"MedCalc 3000 Table\" width=\"50%\">",
"       <tr>",
"        <td align=\"center\" bgcolor=\"#cccccc\">",
"         <b>",
"          Item",
"         </b>",
"        </td>",
"        <td align=\"center\" bgcolor=\"#cccccc\">",
"         <b>",
"          % Ethanol content by volume",
"         </b>",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"left\">",
"         <b>",
"          Beverage",
"          <sup>",
"           *",
"          </sup>",
"         </b>",
"        </td>",
"        <td align=\"center\">",
"         &nbsp;",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"left\">",
"         &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nonalcoholic beer",
"        </td>",
"        <td align=\"center\">",
"         0.32",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"left\">",
"         &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beer",
"        </td>",
"        <td align=\"center\">",
"         3.2-14",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"left\">",
"         &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Wine",
"        </td>",
"        <td align=\"center\">",
"         8-22",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"left\">",
"         &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liquor",
"        </td>",
"        <td align=\"center\">",
"         20-95",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"left\">",
"         <b>",
"          Medications",
"         </b>",
"        </td>",
"        <td align=\"center\">",
"         &nbsp;",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"left\">",
"         &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cold/allergy",
"        </td>",
"        <td align=\"center\">",
"         5-16",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"left\">",
"         &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cough medicine",
"        </td>",
"        <td align=\"center\">",
"         2-25",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"left\">",
"         <b>",
"          Household Products",
"         </b>",
"        </td>",
"        <td align=\"center\">",
"         &nbsp;",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"left\">",
"         &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Aftershave lotion",
"        </td>",
"        <td align=\"center\">",
"         15-80",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"left\">",
"         &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Glass cleaners",
"        </td>",
"        <td align=\"center\">",
"         10",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"left\">",
"         &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mouthwashes",
"        </td>",
"        <td align=\"center\">",
"         15-25",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"left\">",
"         &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Perfumes/colognes",
"        </td>",
"        <td align=\"center\">",
"         25-95",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <span class=\"medCalcFontOne\">",
"      Reproduced with permission from: Kleinschmidt, KC. Ethanol. In: Haddad and Winchester's C",
"linical Management of Poisoning and Drug Overdose, 4th ed, Shannon, MW, Borron, SW, Burns,",
"MJ. Saunders Elsevier, Philadelphia, 2007. Illustration used with permission of Elsevier",
"Inc. All rights reserved. Copyright &copy;2005 Elsevier Inc.",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      *Typical content for beer, wine, and liquor is 5, 14, and 40 percent, respectively.",
"     </span>",
"    </div>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_29_11730=[" ",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function BloodEthanolConc_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.BloodEthanolConc_form){",
"",
"",
"doCalc = true;",
"if (Volume_Ingested_param.value.indexOf(',') >= 0){ Volume_Ingested_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Volume_Ingested_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Volume_Ingested_unit.options[Volume_Ingested_unit.selectedIndex].value.split('|');",
"Volume_Ingested = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Concentration_Ingested_param.value.indexOf(',') >= 0){ Concentration_Ingested_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Concentration_Ingested_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Concentration_Ingested_unit.options[Concentration_Ingested_unit.selectedIndex].value.split('|');",
"Concentration_Ingested = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Weight_param.value.indexOf(',') >= 0){ Weight_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Weight_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Weight_unit.options[Weight_unit.selectedIndex].value.split('|');",
"Weight = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = decpts.options[decpts.selectedIndex].text;",
"Blood_Ethanol_Concentration =  (Volume_Ingested * Concentration_Ingested * 0.8) / (Weight * 0.6);",
"",
"unit_parts = Blood_Ethanol_Concentration_unit.options[Blood_Ethanol_Concentration_unit.selectedIndex].value.split('|');",
"if (doCalc) Blood_Ethanol_Concentration_param.value = fixDP((Blood_Ethanol_Concentration - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.BloodEthanolConc_form){",
"",
"if (Concentration_Ingested_param.value && Concentration_Ingested < 0) {",
"Concentration_Ingested = 0;",
"Concentration_Ingested_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Concentration Ingested is 0 Percent Ethanol.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Concentration_Ingested_param.value && Concentration_Ingested > 100) {",
"Concentration_Ingested_param.value = \"\";",
"clrResults();",
"Concentration_Ingested = 0;",
"doCalc = false;",
"alert(\"The maximum value for Concentration Ingested is 100 Percent Ethanol.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.BloodEthanolConc_form){",
"",
"Blood_Ethanol_Concentration_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
""].join("\n");
var outline_f11_29_11730=null;
var title_f11_29_11731="Overview of schwannomatosis";
var content_f11_29_11731=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of schwannomatosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/29/11731/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/29/11731/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/29/11731/contributors\">",
"     James M Gilchrist, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/29/11731/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/29/11731/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/29/11731/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/29/11731/contributors\">",
"     Helen V Firth, DM, FRCP, DCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/29/11731/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/29/11731/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/29/11731/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neurofibromatoses consist of three distinct clinical and genetic conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Neurofibromatosis type 1 (NF1)",
"     </li>",
"     <li>",
"      Neurofibromatosis type 2 (NF2)",
"     </li>",
"     <li>",
"      Schwannomatosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Schwannomatosis, a presumed third major form of neurofibromatosis, is characterized by multiple schwannomas but without vestibular schwannomas, thus differentiating it from NF2 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11731/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will provide an overview of schwannomatosis. Neurofibromatosis type 1 and type 2 are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=see_link\">",
"     \"Neurofibromatosis type 1 (von Recklinghausen's disease)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/14/20712?source=see_link\">",
"     \"Neurofibromatosis type 2\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial schwannomatosis appears to have autosomal dominant inheritance, though most patients with schwannomatosis have no familial occurrence. Mutations in the SMARCB1 gene with a chromosome 22q11 locus have been identified in some families and individuals with schwannomatosis and may be responsible for approximately 45 percent of familial schwannomatosis cases and up to 10 percent of sporadic cases [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11731/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Schwannomatosis-derived schwannomas contain a multitude of truncating mutations of the NF2 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11731/abstract/4\">",
"     4",
"    </a>",
"    ] but the multiple tumors do not share the same mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11731/abstract/5\">",
"     5",
"    </a>",
"    ], indicating dramatic somatic instability without germline mutation.",
"   </p>",
"   <p>",
"    The NF2 gene locus has been excluded as the germline cause of familial schwannomatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11731/abstract/6\">",
"     6",
"    </a>",
"    ]. However, there is evidence that a \"four-hit\" mechanism involving both the SMARCB1 and NF2 genes on chromosome 22 underlies the development of some tumors in a subset of patients with schwannomatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11731/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. This arises from a germline mutation of SMARCB1 and a somatic mutation of NF2, combined with loss of wild-type alleles at both loci. Additional genetic loci may also be involved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Schwannomatosis is an uncommon disorder, although its precise population frequency is unknown. The annual incidence of newly identified schwannomatosis cases in one study from Finland was 1 per 1,700,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11731/abstract/9\">",
"     9",
"    </a>",
"    ]. Patients with schwannomatosis account for 2 to 5 percent of all patients undergoing schwannoma resection [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11731/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with schwannomatosis can develop intracranial and peripheral schwannomas involving spinal roots, plexuses, and peripheral nerves, but sparing the vestibular nerve.",
"   </p>",
"   <p>",
"    The major clinical manifestation of schwannomatosis is pain. A review of 52 patients followed in the United States and Germany observed that symptoms of schwannomatosis typically began in the second and third decade, with pain as the presenting symptom in two-thirds [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11731/abstract/1\">",
"     1",
"    </a>",
"    ]. Approximately one-half of affected patients remained neurologically normal over 8 to 18 years of follow-up. All patients required multiple surgical procedures, mainly for tumors causing intractable pain. There was no decrease in lifespan.",
"   </p>",
"   <p>",
"    Approximately one-third of patients with schwannomatosis have multiple schwannomas restricted to a single limb or segment of spine [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11731/abstract/1\">",
"     1",
"    </a>",
"    ]. One report detailed a single family with four affected members who had both multiple schwannomas and multiple meningiomas associated with a heterozygous mutation in the SMARCB1 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11731/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pathologically, schwannomas are encapsulated tumors made entirely of benign neoplastic Schwann cells. Schwannomas show a biphasic architecture of Antoni A (dense) and B (loose) patterns, as well as nuclear palisading (Verocay bodies), and a fibrous capsule containing the parent nerve. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/24/23946?source=see_link&amp;anchor=H30353409#H30353409\">",
"     \"Peripheral nerve tumors\", section on 'Schwannoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of schwannomatosis is clinical. Diagnostic criteria for definite, possible, and segmental schwannomatosis have been proposed (",
"    <a class=\"graphic graphic_table graphicRef57973 \" href=\"UTD.htm?24/22/24940\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11731/abstract/1\">",
"     1",
"    </a>",
"    ]. The presence of a vestibular schwannoma is currently an exclusion criterion for schwannomatosis, and rather points to a diagnosis of neurofibromatosis type 2. However, at least one report suggests that a unilateral vestibular schwannoma can occur rarely in patients who most likely have schwannomatosis on the basis of family history, presence of a pathogenic SMARCB1 gene mutation, or absence of a germline NF2 mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11731/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most cases of schwannomatosis are sporadic, and the role of molecular genetic testing or prenatal diagnosis (eg, for SMARCB1 mutations) is not yet defined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of schwannomatosis is directed toward pain control using a variety of medications (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/46/18150?source=see_link\">",
"     dextromethorphan",
"    </a>",
"    &nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    , and short-acting opioids combined with nonsteroidal antiinflammatory drugs) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11731/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical resection is employed for symptomatic tumors causing refractory pain [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11731/abstract/1\">",
"     1",
"    </a>",
"    ]. Surgery is sometimes performed electively to preserve neurologic function when enlarging tumors begin to impinge on the spinal cord.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Schwannomatosis is now considered to be a third variety of neurofibromatosis and is characterized by multiple schwannomas but typically without vestibular schwannomas, thus differentiating it from neurofibromatosis type 2. Familial schwannomatosis appears to have autosomal dominant inheritance, though most patients with schwannomatosis have no familial occurrence. Mutations in the SMARCB1 gene have been identified in some families and individuals with the disorder. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major clinical manifestation of schwannomatosis is pain. Symptoms typically began in the second and third decade. Available data suggest that approximately one-half of affected patients remain neurologically normal for 8 to 18 years after diagnosis. All patients require surgical procedures, mainly for tumors causing intractable pain. There is no evidence of a decrease in lifespan. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of schwannomatosis is clinical (",
"      <a class=\"graphic graphic_table graphicRef57973 \" href=\"UTD.htm?24/22/24940\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of schwannomatosis is directed toward pain control. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11731/abstract/1\">",
"      MacCollin M, Chiocca EA, Evans DG, et al. Diagnostic criteria for schwannomatosis. Neurology 2005; 64:1838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11731/abstract/2\">",
"      Rousseau G, Noguchi T, Bourdon V, et al. SMARCB1/INI1 germline mutations contribute to 10% of sporadic schwannomatosis. BMC Neurol 2011; 11:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11731/abstract/3\">",
"      Smith MJ, Wallace AJ, Bowers NL, et al. Frequency of SMARCB1 mutations in familial and sporadic schwannomatosis. Neurogenetics 2012; 13:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11731/abstract/4\">",
"      Jacoby LB, Jones D, Davis K, et al. Molecular analysis of the NF2 tumor-suppressor gene in schwannomatosis. Am J Hum Genet 1997; 61:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11731/abstract/5\">",
"      Kaufman DL, Heinrich BS, Willett C, et al. Somatic instability of the NF2 gene in schwannomatosis. Arch Neurol 2003; 60:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11731/abstract/6\">",
"      MacCollin M, Willett C, Heinrich B, et al. Familial schwannomatosis: exclusion of the NF2 locus as the germline event. Neurology 2003; 60:1968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11731/abstract/7\">",
"      Hadfield KD, Newman WG, Bowers NL, et al. Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis. J Med Genet 2008; 45:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11731/abstract/8\">",
"      Sestini R, Bacci C, Provenzano A, et al. Evidence of a four-hit mechanism involving SMARCB1 and NF2 in schwannomatosis-associated schwannomas. Hum Mutat 2008; 29:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11731/abstract/9\">",
"      Antinheimo J, Sankila R, Carp&eacute;n O, et al. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas. Neurology 2000; 54:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11731/abstract/10\">",
"      Bacci C, Sestini R, Provenzano A, et al. Schwannomatosis associated with multiple meningiomas due to a familial SMARCB1 mutation. Neurogenetics 2010; 11:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11731/abstract/11\">",
"      Smith MJ, Kulkarni A, Rustad C, et al. Vestibular schwannomas occur in schwannomatosis and should not be considered an exclusion criterion for clinical diagnosis. Am J Med Genet A 2012; 158A:215.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5269 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-18C9BB78CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_29_11731=[""].join("\n");
var outline_f11_29_11731=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5269\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5269|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/22/24940\" title=\"table 1\">",
"      Criteria schwannomatosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=related_link\">",
"      Neurofibromatosis type 1 (von Recklinghausen's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/14/20712?source=related_link\">",
"      Neurofibromatosis type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/24/23946?source=related_link\">",
"      Peripheral nerve tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_29_11732="Nitrous oxide: Drug information";
var content_f11_29_11732=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nitrous oxide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/27/30131?source=see_link\">",
"    see \"Nitrous oxide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F201351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Dental Gases;",
"     </li>",
"     <li>",
"      General Anesthetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F201344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Surgical sedation and analgesia:",
"     </b>",
"     Concentrations of 25% to 50% nitrous oxide with oxygen. For general anesthesia, concentrations of 40% to 70% via mask or endotracheal tube. Minimal alveolar concentration (MAC), which can be considered the ED",
"     <sub>",
"      50",
"     </sub>",
"     of inhalational anesthetics, is 105%; therefore delivery in a hyperbaric chamber is necessary to use as a complete anesthetic. When administered at 70%, reduces the MAC of other anesthetics by half.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dental: Sedation and analgesia:",
"     </b>",
"     Concentrations of 25% to 50% nitrous oxide with oxygen",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F201347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F201345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F201330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Supplied in blue cylinders",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F201320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F201331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sedation, analgesia, and amnesia; principal adjunct to inhalation and intravenous general anesthesia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5977825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F201349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache, dizziness, confusion, CNS excitation",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;\">",
"     Gastrointestinal: Possibly nausea and vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Apnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Personnel exposed to unscavenged nitrous oxide have an increased risk of renal and hepatic diseases and peripheral neuropathy similar to that of vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency. Female dental personnel who were exposed to unscavenged nitrous oxide for more than 5 hours/week were significantly less fertile than women who were not exposed, or who were exposed to lower levels of scavenged or unscavenged nitrous oxide.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F201334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nitrous oxide or any component of the formulation; nitrous oxide should not be administered without oxygen",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F201324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Addictive: May be associated with abuse and/or addiction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Prolonged use may produce bone marrow suppression; patients with vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency (pernicious anemia) and those with other nutritional deficiencies (alcoholics) are at increased risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nausea/vomiting: Occurs postoperatively in ~15% of patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neurologic effects: Prolonged use may produce neurologic dysfunction; patients with vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency (pernicious anemia) and those with other nutritional deficiencies (alcoholics) are at increased risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Oxygen use: Oxygen should be briefly administered during emergence from prolonged anesthesia with nitrous oxide to prevent diffusion hypoxia.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F201327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14191241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nitrous oxide crosses the placenta in concentrations ~80% of those in the maternal plasma. The half-life in the neonate is ~3 minutes and it is quickly eliminated from neonatal lungs with the onset of breathing (Rooks, 2011). Infertility, spontaneous abortion, and congenital abnormalities have been reported following prolonged occupational exposure (Becker, 2008; Brodsky, 1986; Rooks, 2011). Adverse events are related to dose and duration of exposure and risks may be decreased with proper administration procedures (Rooks, 2011). May be used when needed for dental treatments that cannot be postponed during pregnancy; use for labor analgesia is considered acceptable (Becker, 2008; Rooks, 2011). Avoid use in pregnant women during the first two trimesters of pregnancy, those with medical conditions that increase the risk of vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency,  or infertile women undergoing",
"     <i>",
"      in vitro",
"     </i>",
"     fertilization (Brodsky, 1986; Rooks, 2011).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Kinox (FR);",
"     </li>",
"     <li>",
"      Maxicool (IL);",
"     </li>",
"     <li>",
"      Niontix (CZ, DK, FI, NL, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F201323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     General CNS depressant action; may act similarly as inhalant general anesthetics by stabilizing axonal membranes to partially inhibit action potentials leading to sedation; may partially act on opiate receptor systems to cause mild analgesia; central sympathetic stimulating action supports blood pressure, systemic vascular resistance, and cardiac output; it does not depress carbon dioxide drive to breath. Nitrous oxide increases cerebral blood flow and intracranial pressure while decreasing hepatic and renal blood flow; has analgesic action similar to morphine.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F201333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Inhalation: 2-5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid via lungs; blood/gas partition coefficient is 0.47",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Body: &lt;0.004%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily exhaled gases; skin (minimal amounts)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Babich S and Burakoff RP, &ldquo;Occupational Hazards of Dentistry. A Review of Literature From 1990,&rdquo;",
"      <i>",
"       N Y State Dent J",
"      </i>",
"      , 1997, 63(8):26-31.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baird PA, &ldquo;Occupational Exposure to Nitrous Oxide - Not a Laughing Matter,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1992, 327(14):1026-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/29/11732/abstract-text/1518538/pubmed\" id=\"1518538\" target=\"_blank\">",
"        1518538",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Becker DE and Rosenberg M, \"Nitrous Oxide and the Inhalation Anesthetics,\"",
"      <i>",
"       Anesth Prog",
"      </i>",
"      , 2008, 55(4):124-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/29/11732/abstract-text/19108597/pubmed\" id=\"19108597\" target=\"_blank\">",
"        19108597",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brodsky JB and Cohen EN, \"Adverse Effects of Nitrous Oxide,\"",
"      <i>",
"       Med Toxicol",
"      </i>",
"      , 1986, 1(5):362-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/29/11732/abstract-text/3537624/pubmed\" id=\"3537624\" target=\"_blank\">",
"        3537624",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Campagna JA, Miller KW, and Forman SA, &ldquo;Mechanisms of Action of Inhaled Anesthetics,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 348(21):2110-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/29/11732/abstract-text/12761368/pubmed\" id=\"12761368\" target=\"_blank\">",
"        12761368",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/29/11732/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen EN, Gift HC, Brown BW, et al, &ldquo;Occupational Disease in Dentistry and Chronic Exposure to Trace Anesthetic Gases,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 1980, 101(1):21-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/29/11732/abstract-text/6930434/pubmed\" id=\"6930434\" target=\"_blank\">",
"        6930434",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dunning DG, McFarland K, and Safarik M, &ldquo;Nitrous-Oxide Use. II. Risks, Compliance, and Exposure Levels Among Nebraska Dentists and Dental Assistants,&rdquo;",
"      <i>",
"       Gen Dent",
"      </i>",
"      , 1997, 45(1):82-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/29/11732/abstract-text/9171486/pubmed\" id=\"9171486\" target=\"_blank\">",
"        9171486",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Howard WR, &ldquo;Nitrous Oxide in the Dental Environment: Assessing the Risk, Reducing the Exposure,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 1997, 128(3):356-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/29/11732/abstract-text/9066222/pubmed\" id=\"9066222\" target=\"_blank\">",
"        9066222",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Johnsen KG, &ldquo;Nitrous Oxide Safety,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 1997, 128(8):1066-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Nitrous Oxide in the Dental Office. ADA Council on Scientific Affairs; ADA Council on Dental Practice,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 1997, 128(3):364-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/29/11732/abstract-text/9066223/pubmed\" id=\"9066223\" target=\"_blank\">",
"        9066223",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Petersen JK, &ldquo;Nitrous Oxide Analgesia in Dental Practice,&rdquo;",
"      <i>",
"       Acta Anaesthesiol Scand",
"      </i>",
"      , 1994, 38(8):773-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/29/11732/abstract-text/7887096/pubmed\" id=\"7887096\" target=\"_blank\">",
"        7887096",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Quarnstrom F, &ldquo;Nitrous Oxide,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 1997, 128(6):690, 692.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/29/11732/abstract-text/9188225/pubmed\" id=\"9188225\" target=\"_blank\">",
"        9188225",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rooks JP, \"Safety and Risks of Nitrous Oxide Labor Analgesia: A Review,\"",
"      <i>",
"       J Midwifery Womens Health",
"      </i>",
"      , 2011, 56(6):557-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/29/11732/abstract-text/22060215/pubmed\" id=\"22060215\" target=\"_blank\">",
"        22060215",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rowland AS, Baird DD, Weinberg CR, et al, &ldquo;Reduced Fertility Among Women Employed as Female Dental Assistants Exposed to High Levels of Nitrous Oxide,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1992, 327(14):993-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/29/11732/abstract-text/1298226/pubmed\" id=\"1298226\" target=\"_blank\">",
"        1298226",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schuyt HC, Brakel K, Oostendorp SG, et al, &ldquo;Abortions Among Dental Personnel Exposed to Nitrous Oxide,&rdquo;",
"      <i>",
"       Anaesthesia",
"      </i>",
"      , 1986, 41(1):82-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/29/11732/abstract-text/3946781/pubmed\" id=\"3946781\" target=\"_blank\">",
"        3946781",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wynn RL, &ldquo;Nitrous Oxide and Fertility, Part I,&rdquo;",
"      <i>",
"       Gen Dent",
"      </i>",
"      , 1993, 41(2):122-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/29/11732/abstract-text/8330725/pubmed\" id=\"8330725\" target=\"_blank\">",
"        8330725",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wynn RL, &ldquo;Nitrous Oxide and Fertility, Part II,&rdquo;",
"      <i>",
"       Gen Dent",
"      </i>",
"      , 1993, 41(3):212, 214.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/29/11732/abstract-text/8243958/pubmed\" id=\"8243958\" target=\"_blank\">",
"        8243958",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10086 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-13CD9D8202-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_29_11732=[""].join("\n");
var outline_f11_29_11732=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201351\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201344\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201347\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201345\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201330\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201320\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201331\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5977825\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201349\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201334\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201324\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299770\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201327\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14191241\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038705\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201323\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201333\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10086\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10086|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/27/30131?source=related_link\">",
"      Nitrous oxide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_29_11733="Approach for the acute management of ventricular arrhythmia";
var content_f11_29_11733=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F83895&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F83895&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    Approach for the acute management of ventricular arrhythmia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 440px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An algorithmic approach for the acute management of ventricular arrhythmia associated with genetic disorders.",
"    <div class=\"footnotes\">",
"     VF: ventricular fibrillation; PMVT: polymorphic ventricular tachycardia, possible torsade de pointes.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_29_11733=[""].join("\n");
var outline_f11_29_11733=null;
var title_f11_29_11734="Molluscum penis 1";
var content_f11_29_11734=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F81042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F81042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Molluscum contagiosum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 267px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAELAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5s1C0f7e0ksapHMq3G5D8m1lDcH8SMdjxVzULlbqddWjSKGeMJmKBSil1QASgdiSMkevPQ8MuLW7bEUKbkVJFDSqE2qhJyCTgErjoefeoGCNpDPI0oe3KRRpGo24YszOx/DA459eADZmZjM0iF2OWB5PXOa07KNgs02xtkMcU7YwzBchSR7ZYcH1FNhDQwR3aossBBjMeePMGcDH5N+lbKvFYWmmrtEiXunTI/lII2WQvIuHPVsFUIGcdOlJIbZn29u13b6haRosjwR/bYXxg+Wo+cD2KncfdPrVT7LNNdQeXIcvjySU2BvoOwHqansRFK/kzOkkxAMUgPDBhyhPY88Z75B65EscMkk8xuZW+zhXMjqDlioJEXqMkAYz784osFyWHUBDeuphS8tmyZIJfuNuGNwI5BAIw3Y+oyDaspLSPSTawiSO+NztSZ3CrsyDg+v8AKs+ORnVREnl5VldYlzkDBAyenH8VTWzxxwbxEHlIxtD+hwM9/ukj8OOlDY0db9sFiRNduqyMxEkizBvNO09D7ehxjdjmtqJBcXrwysbeO5WJsG3YsAGViwABCgo5I4OfQZrmoYvtsyx30zRKsIEzysT8zjgg4OVwFOPcGumsZjf65bWstuNlzJBHbpkqjYISOJ9uNxEa5BP0zkVLOmDdzqJbS/1IJaaCNZhhAAeSYrEI+4LHaMk5zgAYGMtWZYaJb2ekRLb6pdy2lzcJDd2sNyu5l8zaNvT5mUEBDjOc5ruJ9O0+xtpFtrKwcxNmeZy0szsD/q1LkgO3ALEHbkd+mBqTJpWl6a8KObkX0JgiWPl5AScZPck+mOnNS9NzrULizCDUL+SCGw1i0hjBkmitJ9jySk7Q0ykKhx8xwMkgkbjzjUhtdU1i2ns4JJISXBuhPcTwzxIOWLpuZRuO0A4IwTjpUnh2ze2huLu6lurm8kdJ2FumfNJXPBPX0Gegye5NdF/Zcksj3V22bo4bKTbVhHVUVlwc9+TyecdKXMaqnGJzEvhoWySXtrZzJcSHc11NqRKqw6uTtDfxexP61i+FLW5trSaC3nmlhW8mhlD3Bji3O4KyfLzg7wCgJ+8D6mvRItAt3n8ye1LuCrEzzNJj1JVyf6YzWBr48i21+KU20UF08M0I8xQ7SMEicBFG7oiE9vepu+hdo9TRj0yfeUDxRx7drxwIobA6q2TuA6AkZJqrqFzbWFk8sdxHbzQL8iKcnKn+PoQh+4dwIOSBk4Fa8k1zcXE8ah9Mt5PmaRoFkkIPI2qOE6tycnpxVSWw0mzdbh2a4vA/mC4uZB5qvkYZSeQ2B16+mKGy4q+iIdKtpdWYajPbFbZ8bLZ22uWRsESAfdCEH93nJPLdlGyQhQIINztn5mAQdffkn36VlwxXLzvdI3m2jnZODnczAYDMAMFsKBuXqAMg4zWjZzWlz+7gI2sQoEhwGGM5Q5w3XHBPTtUXNVHuWfJBiZmVBhAo2p1x346df1qC9gtY4xLIg2KA5JOcnp1POTwBWhK0dpbl3uFijVMuyAD5fX378c+1VWFxqLGbY8NunzQQyAFnPTfIMccche3U80XFymSbBIBKJEcq8heTaoyPcKewH0rO1iwVbu1uLOESrPLGs0O4AShckEr/AHhjr7DPFdDfb2thIRIfL5OxcDqM/jx06msvUFWGa1khbzYlVpQ2cKcsi5B74DMccVSkS6asZ1zaROLdJJZHtvLKQz4CsOrbCO4+8Pwx6VjT6JDdWZtdSiSUtykzcg/jjr6Z612klikr3VtcRBo3K3MYjPCknDkH1DANx/epWtXkdrW7t1ZsFRKR8sg656/Ken07cVcZmFSjFo8F8V+BrywLzafCLuxKlmiVvnXHJOO/0HpXn1xaISwjBJHQY5+lfV2owCJA25yzkq527dp9uw5yPyrzvxx4K0+XGrWZ8l1ytx5SkZX++V9R1OO3Nac19zzquHcdYngMic/Kc+1XtCaF9XsYr+c29sZBFLNt3GONvlLYyM4Bziruv6TNp98be6QLIV8yOReVlQ9GX1rOCRvCudizpnr/AB+lFrM5i5pbxWk9xbX8DeXPEUkXJBjPVJE9QOPXIJxUCJBatf290kglABhMfzAHP6qQev0qtcSO0gZwWO3auTyB2q9ebbjyGV0R/JDJ23joyH0IYNj1yKaYiqkroxiMSSRk4CMDjn+If3T05FJOyRo3lJIsTsGUyHLDHbI6/Xitu2sw/hNrrcnmx3i25BPzYZMj+X6VT12N5LGxkEGzzAEAXoxHf8arlaQrq5mJIFuRKpGSc49Pet5NYgtYbUWciyiORLi4srqPdbTup6EA9COCDg+9YVuEBXziwCt8w7Ad60k0C9k03Ub6ziWa10/Y9y4YZVHbCHHUjPFEXJLQGl1Ox8Oa/pAbxPcaLoP2VtQ0G4tbm3kkEsEEruuHhJ+ZV6YDFiD3NedzEMyxlcBRg+ualt7gwrN5QwJYij84yM/44/KrOmGKS7hZ42eUYUR8kuxwBj/Cj4rINtSKyiEEqXAIXY3RxkVoM8cguHlSNfObcpjOAD/kVJqdo39uS2aqMWp8t19H/iz7g8fhVT5FulVlURxrycYBpbKwy5bEiBDtJ+YhSOORyKsi+uW2lNqFcqcd6WB0MbRx9HxtYg5HqPrU2o6RHBZtPLKkP7resedzdcD8TSaKUuhRRbi4he6VMWcMy72J/iPOP5fpXTWVzasNzhUMRzwfzNYOpm6h0mxs1bbZb/OWP+9JjqfWoikhWMvGWVuSQeg96HboCueg2s6vOqWarJLNz7LXb+E/CCW8TT6i0c0i87FYHbXA+GrBmto7jT1cRx/elYdT7Gu703VJRP5q2Z+z2qbHZT95j/nrQ7I0jzM63Sru3huHht1G4gD5jyfxrpbexcyefHwx4PvXjs+pSDURdwBkjDAOp6/jXqll4lhbShLnkIMALyx9BWb12OiMeXRluTUntLidZcHjgd8gUaRdpey+aH6sCFI7+9ZlgPtbGa9lG6Yh2jK9B6frS3yDSb6KWFxsdgdoHHNT5FeZ6CsiJbBhnOOfes6+Zri3cIQTVK11FHiIduRwatQXUTZ2OCPahjXczoLVWidZIwW9TUEGmeTIzxgdjW25RBkdBwOtIk0TN94Y6AUi7ux8FXIaG1tbW7LASIWRi2TERI6hT7ZHP50xFWCISvKPPcsWDNwU4AOD94kkn8K0rmxQ6y8V8ZGnFqsqorZ/fEZ2MexLk8dQTj1NVLYRxxGNxMHAwxAX5FdM52kdDn1GOO+K6NjytyO2tJJbO8hgiWSRZCP3bbjwpOVx1BCvUKSSvbRgtnyW81Btzv3Y64+nQ+prW0m9m0+aG6spSs8ASRJIh9x0cMu8Efd688cGquuWsdnqAuLWMizvB51uN+8rE+cIW4+deQfdaQynPbeXdrFGw/ehXhcnCshGQDnj2PuK67RBbXdq9zqO4RzNb27zTSZAjwwkTYFJONqneMlMocHORgJGklgVGXkt8tg9Gh4LEdsAndgDIy2egrW0GZJ9T07TdQikNvdSJDlWAMeWXEsROApZOOcg89MDDWgmU4tNuI9TNtAxCOS0UyuAZFxkcqSM464PrVrULdLCzYbYg5dSihThyOTkH0OM1U0W8ETK5QTbWeYIsxjcEKSSzcbeCOec9BWzrEV9cxRQSYutTMxtniRC8i4LfKSeFHONo+9gE8ipa7GkXoW9D+yP4dvJ7wfvAcJODtIdkBy2eMEq3HrgDFX9Nt530uIOZLW9lC3Nvw4MYU8MOMbSxB4PB4IFYGjsqW97btbLcuAWUK2GTOPmRcHd0656Z9665HM1raLJeCy+xK6iGaQLLMxVthKkjaHBjBwScZbjApPubU3bRno9pqGhT2tpPJcWttHDapcvDcNsKSOAQDuwckEt7gqR1rJ8Taxp11f2bR6hELexmtbgCOYH5mlVeQuQPl8xiAf4k7ism31d7xrS08P21wLyOFfKbygRdkEfJIHIXylJwGYEj+HGcGa6vomluJr9dUl1RtQTy5IpMW0coZVZIdrAZCAfMRuG3+Hms3udsW2rHWxa3u+TTtK1C9nkcmMizkiAUAAZBGSAox2HUZ4p5HijUpC7/ZdPiBG1TKFwM8ZEQZsnrxIPSpNDfS7rzZNKnnZQVSTbdzK5Ykk7/myvJI+brjvVy9fM72/nxmeRwywLPLNIOOTsVv54HPapkbxRCvhuwsYmuNdvLvUHc7T5krxLIeoGxTluccMzHpUISK71a1t9PghjsYGE0qwR4DugIG5uM4BJx2yM8jAuyaPbQSRgpJNKSWyVCh84GXI5C98fgcgc7tnarHAjAxmUrtKxoAAQOgUYAX/PNS2WlbUruly6qm57aMnG7aS5x157D6ZpFtIvN8ySJXlVQC058xox+H061fEKGRPMKxkcqxG7Cnvj86heaN5JLe0jW5MbKGYEbEI6gnpkegGealstabELxQ2dpLKEIjRQBsOQzHGFAIySTgD04qlDaTWtkZmMVxMXJu7b5WR3ZtzGMZwJBk4/vAY64NakemB5Vurrc82TtLcpGpHRFHfjBb7xz1xxVs7RG8bpsEbbWJBwVbtjv9KQ+boVdPtLZ4oJgxnRx5iSGTdt9Su4DYcgfTp7VawI4vM3LnOVVjuDHAJyO1VFV9OuGRZAsF0zFQD92XqVHYBhk9+VPc0+Z2AYg7SWyW2ZGfTgnB4PNFw3ZFMqhhvUxoynBI5OOv4dqwNZsZ4F1Oe2j3bITujY/wAWGbemeh+7kfdJ54PNdKIyrbCoeNz0VD65Jzxnp3+lV9iuVHlssb8AN97byCAfxpofMUYLy2mitb+B1lt5ZMZHBBfgqR1BDbcj2qwwDhcSZ3thip+bGBx7iudg02aXRra50/dFdvaqkq7Mo5j+Xa6dDgjG4EEHo3Y60+oRwT2nmSR27zHCJISqs+B8oY8Fgc4GQcHp2qkRJ2JLmMNvhCKVORlhlcnjsOc1jzQS2c5dCJLZMgBm+ZB0xnuOeM+mM10RCuhacFH3YMbDlPfNVhKsIX7QTsckFwuQPmHfvjP0q4toykkzyLxH4fhcXEN2AukTzmSN0Tc9lIOpTPIXk7o+OOQOCK8c8QaVc6NqdxZXJjdomO14m3JIvZ1PcEYNfWV5b2kto9tKgO9chkYhs5ypBHQ8cH3rxvxz4bWACCeVmt14t7l0AMBJ/wBXJjgr/tDGO4Fap30PNr0bPmR5MvkmFVmB+ZPlcclXHUH2poXzNNUqCXgn2nPdXHQ/ip/OrlzYvaz3ljMrK4OYw2OTjjH1B/HirV5a2lpoCTR3W+6volc26pgRbWwST69fzq+U5L2K9m8YsbxXZg+BtJ5Bbpg++M1Jrk0moXltaWIdshSqKOjbcHA/CstJG2SQZOw4fjqSo/wzUltdPa3SSwSsk6pjd6E9waalpYVupFcR/Z7iSNmzjhh61b07VJY7u6KExRXcJt5Y0HDKQOD+IBrLYnzHDNkk4JJ6/WtfSY4YYZbieCR1jQg4GVLHp83Qd6UW76A1pqVbDyobhvtm4xj92yqOWHcfXFbfhHUtP0aS81aYTPqdsv8AxKo9itH5pP35c9lXJGP4sVnaJdrZ3VtLJAkytK2VKbsgqV6e2c/hUs1gsqq5uERhiMEJgEDjcR9OapLS6E97FaK6kCeYkhMzkl3PJZieSffNOhYmUeb++IOSPU/4Ulw1tbSNGYvMK5BdWyjD+8P/ANVSaM+PMl8vegzlGbGfap12KNJgyASlx52MoF/g/wDr4qO7C3UqLApWIAZJJJPqSTStKv2PzhgAcbcYA9qLS4aFVcR7ifmO4cUmykkWbaFmjEkrZeMlUV/8K1rOCK3sjIzAyyMVG4+vtVbS/sZnS41Zm+zkF9q9WY9BUMmoo84fyiqbuN/8PpStZXZafRHqngyOK20Ew3EgIlUiMDn14/xrV04fYHjt2cRW4b594+Yse+K4Pw1rkiOsnkBhGMRA9mPeuk+yCWB7nU73ZK2W4foR0HFJs2hGyudpq1hBeKHtl23BG0gDAb/GqXh7Q5oLwvdZZlOAGOQPal8La80tp5dx2U7Z+fm/MUybXLpL3zYwHtUJy+0lT+VTazNFO6sztLW2gilzMqgDkBW5xT1mtNQ1CGNZVIBwBuz061xB1u91mV4bGN18rlnLhfwrf8L2a6fCVvFb7Q5BDtxk0uWwcyeiPR59NgNkAq8YzWFHai3lI+YBj2PUVqQ3m2BERt4x/ninyxJKmT1HNRY0T7kcQjmTaQ4z2zTZbLyo2ZMkjnGcU6AhM44PPB70xrveTE/ftQO58GC6eRULhnleN3lYAsSMkgn3Byc+9LBeG4kilkAluCDFIvRpVxjGehOMeh4qK1mMWpSTxRiRI0do1c7RtAx+OBxjvUEnkQ3uwhmtG54PO08jnuR/Sum55djYsLW8h1JYtKlMF2yHA8zCuhU/LnjhgSu09enXit3UZZdX06Fo4oLX7MfJn0+XeUTe+R5eSTtOWcDdkN5uOozxsc0G2RLgNJ5hylwxIIIJ7dweMj8vfqdM1DddBpIYWhjQxCWQlWZZAAA3UHYW3AgY6nvQJkZuLWO7iitESGCMBbUyoMq4GD5h6OHyd6nBXPAIXBiuVe1fc9tPEEwsaj79pcIxwhyDkBieCclHXutaItodLt7O4v7aQx6hExiDMhFxEZWjO4c7SCrr2dTtPSl05LXyfJuxcrBdEwWN6XJnhcDDIwACuqgruQ4YBkZTjKliKugWllcwyzalc2dvGg+YSsWklI42rGmX5DH+6uTyQBVaQKBBGtuH8x1USbisihAMHCnbuYY5OSCvXuYY4zbF5kzJPse3kXIKucqEKHHdSOvPB9aitpzDJEFV4Sj7CoPCk4JH5/1qXsUtzqx9k1TVZkvAzXKMsFxcRkgNtXlkA4Uklt3YnnuQbdreJo99fWtzI728LBneMGNygQAIR0bqV2+/oDin4NuYbHQ7m9uLh9+H2xKAQ7YwI/X5sjv09ar6bJ9sNzHJHmeV423Sk+XIQ/zAnOBuDPg9eMcZ5k2TsrI7XSbVJdHt5DqkgHlA3Vz5pcpglVDjoBnOF6gDI+Zlrq/C2kpelXu7TyksFzBZqWVjuGDNtP8AAcMADyPm3c15vZ6FLZCS6QD7TbGKRZ4WKzJnlVODxnBG7nnOfb1Lwxrz3luF1IhNQ0vLRyt8plg25lhb/aCDzFz97Z6q5Ob0O6m20r7F+70S2k1OI2+nWzTrESrz2cZjdlGV3jAyCpZSfcMOUFb+mzSXWjWr6HZW1hZTokvzAKZRjOPLQDjJ6nGeMDvUd9qNw2txWFqULQhgsfJy5KhnY84jjAOeOWIHUYrQlSy00wW91KA2xdsTHdIwHC/IvJBPPSspM7YryLEUH2cfKyMnzHgfMxHVmLE5HB474FRT30cQJaTmTkRxgs02ORtQcsMZ6cfhRbrcSeXI26zhGQfNG+WQk5O1PuqOnXPTkCpEsoUllmVHkuJlAaWSQtIQBgBmPOBjIA49BUXKSV7MjgW4uIjJdJHaRv8AMQH+ZgRk5I4B6DHOCeCDWhaqkKRSeTtjKkKoOcYP3cH37+tOEChHLR4CgDgcNwRznv371OFEbKrcowJZgAVUnGePw/Ohkt3K/lpdWckVx5bqxBdJUDj1AwRgEcYHbHqKFRclNwyAMl8Haf8Aazzn6+9TblKsN4TgMWHHOeAPUHP4c03KSLuYr907F65HbrjHr/8ArouCWpTYAA7mWRi4BYEcEHspH5EVYRYzvZW4246ZHPIHvn8x3qSUHyAVVvLGCUOR9ScY544OO3aqsqs0ISJyDIDuyc5xkY479f8APNItLmHna8W5VGwjOAeMBsE/oR/nFNeE+bnO5Q2DGeAQOvPuP60AYmZW3nA/5aL+GRjt2x25qYss+4Ow2pgMFc4BPTORk/5+lNMTVtjKsoHTUrq1kjfG43kJUj5kf/WKM9dr5OPRlNQ22mRXujguFaKSPy2PEiSpngMr5Vx04NX7pkmtX37RIpzb/PtIfBAZW7DjJ9entUNpmO3SEL5sUarGHY7WwOMkdCe/GO/FO5STMF7W/wBGj/0Ex3FjHwbOeQ7FAHHlycunT7pEg7AKKgGv6YzwpqDz6PLIMRi+IETHnhZQShI7ZKn1FdNOECkuwUl8DC5KnPX2+tV5Fe4iJSNjgt5ithjz1BHRvbNWpGcqatdaGRKqrGsp2yW7fMkiv8nPTDDj6djXL69LYS20sGozRxzOQBsYFm4yMIOeM/UZroLrwxoaRSznR9OZlG5hJCoV+MEkDAHOBj24rLvLWxs7ZjpenJCWAAZUWOLvw0uB7cEZ6VqmclSLPGfE+gzzJBNDbyRXCYUrtwGXJ2sFGeDg9O4OBXKXsSmAbVCq7MQvXyywwyk/3c4II9cHmvb9Y0O4u5W8wteXyAeYYwNiHqAMnA+nOR9Qa82vtPk0rVybqxS50+6ZmNmspjLMB83lvglJB1HBGRhgw4OiPOqRs7nAwpukGdykrlT6kUydwzgE9OCfpXQyWNlEbeWO5ZrFpxsnZCrIO6SKMlWxzxkHqM4OKt+JNM1KY6fPb7NzGNiq79uTjJI6/SixmZUFs8/MZGc8KeC309avvqF0NKXTI2KQM25wepYYH4DgVC7y7YpZ5JWmckl2bOAemP8APepNPb/SVllO7ygZFL85x61S7CYsrfZbiQTfeC4QA9DikgdpQ+zAHMrZPGBgYqpdyNcyh3xuI7Dr3q5pEltbXDSXiGSGIKWhDFfN55U+xoTu7BsiGSVy5VlBUrjaasWbRxg74/nUbSBx+dV/tYmud5iVQWLYHQZ7D6VdjysZuSigD5XJPJH0pDLhuGSPIZfKkAWSPaMcHtTGuGAVgg2gMcD3pFgkuVVLcZ3At6AAd6fJbx/aLaK2y7bSXZmzk0dNQW+hoaRJBEsfn+bJk84QcfTNS3kf2mYrDHtckbEYgnHqSKfY2LNF5ifKRxiug0uzjhAc5Mp6MBUOR0Rptk/hq0+2ToLdkWJJArK33uO+K9et/DdgjQvcSPPFwwTov415lp9kLVDdWVz5dyhBaNhlXUfyNdjouvKiCG8OJN4aPP8AEp9M+lPSw1GSep6TbQafDaosVorsEHYECqf2C0izImAzDGzAGPWqVx4hUWm2KMDgdBmsa31ieR1BUOzvglV4qE9bmrjdWQaZoty2tyT2kUaQvkEdyQf5V0U9jMzoGKhc5KgfyrPtLy6XU2YRusfYetbcMVxcXCuT8gxkelJyNI0rIliSRZ4wpfjpnrWldtOFDKpLdzTghW4UMCAD39K0JJo9uxiCfShaiasZEGqDaUcZkHXnH0q4lr57GQDnFVNWsEePzU4I5BzyaTRtRlVTHJg445NAao+KNImOr6HJpk5ja6tpHubV5HVC6ld00e5iOu0Mo5+bIAJeqqiDULC2gsI/LuFlETKwVnk3jgL3OCG/76FZ12zWl95QDRm3IjYA85HDfrmrFhOLM3N5bH5nElvCZcE/OpBb6hSeexIIre55liF4xBvEY3jCnDjhgRkHGP8APFTJeuNPlto5Z/JJX92XGwHoT9e30zTrUhLcx7SLgnYGJwVH933B61avbi5v54TM6GNAyxxxxhEiTJPygdBk/rSGb1ks8mpQq1uLrTZhJLLBOxMfmPGoZlKtkMSoyR3C5zisyEtbfarKa9jO/a/zk5jmwQu0DqdpKt/veoFUQ9vKI4Z41cvbmNZXBBSQSsVY+xBCn/ez2qvqEklw6XTgG5nYiZec71PJP1GD65Bp30FYs6rdbYw0XmKJ3D/M2CjAAnjv94c1cW3W6upPtDbQLtUcKRuKBWJP4haZdot3bJ5QjzYzAuV/55MThj9MbT/wD3ptncOYkTy2klLPckMOGwBtx34KtkfhUspGzJ5lvqBWGB4XLfLDtBw/lkjPOMgDP1zV/wAN2zQXUMc8SkAqwjKjLEAqBznjPUdDmkv7a0uNSjSxzOYoIRv37wZEjMtw/XBG9ig9cVqpO516e5kuZmtYbUt50dshYgMM4VuvzNgHI9alrWxvTfU65Liytry4hunlbS28q1juHwxtpTGJWBOM+WSARjJXDeuQzxBpf9m6bFfaYLsLBsL+a5iDAgHCk/N1+ZTgbTzypYVhPb39vp9xfzbjcxyx3cu+EKBlghXcrjAwSpwoyBXocOmfb7my0OQss1opuL2VkG/ygypBEFGQnJk+UE5CcknNRLXU7qPu+69mWPh2IbzTLZZbho7yZFy0Mm03AXG5XIO4SJyXQnq5YZU5ruLZILOKZIYYohMFeURxYJHqzdcfN39etedajpdxa3z6naSxC2nXfKkyMItybVUv5fzIwHKyL8w2/wAQJFb9v4sisvJtvEizWolIRLi4Csr8jP7xRskHT5l2t6oME1jJHXG6ST2OsugJZEAKOqZKgdOw/E88/UVPbRL9liZAdkgIYgZyBtA7cY4/SsaXVdNsUW8fULNInJCMsqusgxnEe0neMY6D+I0w6vcXMZGn6RdSwOw/f38v2OAKQMMFIMh6jogHvgVI30sdLJCwLrEpklSMbtq569SB2+vtVC41fT7WUQG58y4Vj/o9v+/kjO7phM47cms+PT559767qb3AkXa1pbMbe3AwM5w2+XjgB2x32jNaVxNptrJDBpUCWlmifJbWsfyEkc8Dj6/SglRu7bk3nv8AaGHk7FYZYuoUdOwHzDGB+vNV3jKW/wDqoLgqUxH5u3bxnHTnJAJI6ZNOkJmZWto7hNuG3cIOSB1znnngDj86J/PMrWkJhcKfupLlcbSeeM4wAeSOnpRcaVuo21aU2/lz2MYkYLs2XeSSByuCoGPcknAqFZtkoaS1nQYbc3yyn7v3sIxJ744/KpFlmeCT5UWPKncVYknoT1/+vyOlNnEmVLuqqshGEOCemcd/brntUtmiWo5biaJZIotqo2VMeflbpgcnnvweetI0jpu+9GQQVIOeOcA9vXqe2PSpLgosBzKTcJwUAGAPw445/wDrVWluJIoGt1IRAuSCcE85H4d+3egcVfYsXMTNaJGY5Nkg83y9oGF6+vPfjg1RijG7y22IZTySvAx14NKjPcFHLGQtgBQcnIHOD269P1p1xLLNdygoqnGWB+UA9v1xT8y0mvdFREWAqRtO3BI58zOBz7c1Snt4y+5zJvCj+MjeM8DGeemMdePwrTgilmbZGcMnzKSRx/TGT/niqSp5DzcckhyVGV3dQCR6fXiqTJ6sqwwWUbbypaQE/vpCS4x1IJ6H261U1PbDbSsHb7S5jjBwcMxYAAryWPOenINalxGqWbo7Fmx8vRj654644/X0rP1CIMbQhm2l9ysVLZUKcD/voj3HHpVxZlONzn2s0W2kt7eBbeQNuVy7IzBvUj5SCSTjHGTgiuP8UWEN6rJc2syzwsGYON4Lf7y/nnivS3XMcgcO67gDFjJB57Docfnwaw7mwLKZ1lSSQn5WU4YAA4APQ9utbRkcFaij5y1G3ksLy6a1U3EIUfaEf5gyN0P0z36gjrmqcrxeVPB5fmW1wVk+dcy27DjcG7jnB7HuMgGvT/Gmgi/sp7yxhWK+gH7xASCy4O5SpPOeD7HpXlauBON58yPAMbAbSB71oedJcrsUbvAmAyWwv4Z9BVnT8eTLGvzMykhM/e45A9Djn8MVNNar58YQF4JGwoGC6n0I65qrAFjvBhx8hDIw9exNFtSRsEbyBcAgY+92x70XMckccYZWET5dGI++M4znvWnqE4jmxaxlEmLMu0/KFPVV9t2arMFjtyhcbSAxTHy9f0NDQBY2hG6TbujiG9yKsRxxTOglmWKN2wxx0H41WtZ/JaSMktC64P8ASr7yRyyW7MoMUY+6vTNLQepEC0aO0Dl4R8nJwcVv6HphFj5hU+ZMc8j5gvpVHda3Yitre1CkPueXPLDA4x/Wu00Gbzr6FBEI4lAUbvT/ABpN62NIRvqWdL0wJZ4KHzW4Celadto9ysiQsDvbjgV3ulaIJgt4wRXUfKCKuT20sVwjJbq0zjAPYVLSZ1Qny7HnT6cYb8RXAZ3b5UUdff8ACtnWbdJrGGKONEngbAHXFXL22exu4bid/MuHY5bsPanWumzPvuJAcOwYe9JWRbfNuWrC+EmnRxyhVmVQG4wa6jwvb2ssp4XMS/rXPG1tJUXf/wAfC/IjA4Jz9Pxrd8P6NNa2nlyOpLDIOSCPSk2NReiR0dnYRTzswAOORxyKvWsaQzqhIwTxmsXTHu4neEBN6HDMc8j1FbXkskLOxO7rkDnNSW23oW7+aCLL5x25rNtAlxOWLdOMDvVWFWvrrDZKDB5Pet+LTkiVWUkd+KLia5dzP1FXVNqAY6AVgT2VwkiSIPlzk4rrI/3r7ZAAO1TS26xwNjoB6U1cXMloz87Yle4uDHGg8x3yMnpn1z2FOvXie4WKBx5MeEQ84I7sfqef0q3axOmh3N3HsabHlnD/ADJESAzEe5IUf8CrIXA5OSPyrY8ws+YI9yqo3cAPuJ6d1FW45jFbO7OTIRtjAXGMk8H+ffoPWqKSbVXYuWXPzHOBmmSEMdqfMAevr6mkBrLC2pWlzOokZLRVMxznam4APj0y2D6FhVdJPMvYwwOIwS4J7d+R7D86isL6TTr6K6tijNEeEZco4I+ZWB6gjgjuKv3cafZJr/S4NlmZAJV3b2t2bkKSeSvBwe+OeRT3EFtJI51CNWxm2IkDHB5lVgPwYr+Rqy1wwvLplIkjG2EBDyVGCSvuck/jWbasYEW3I/eXDqZMnGEByFP1PJ+gp8bzSi6a23uYo9xwpO1MgMePqM59aBnQ6PqEUOn+TIpw8n74IDvZBkbFx90fMck9c8etdHHcw3F5pl2zpbzyJIog2mMJjaVYnhc5zhRwNq9TXK+Gyk0sEUiK3lPHJIJz8qjIVn+gyuc9voa6pYbOTWphLte1jf7PcR+WFZt3JKj+IKVBx7mhpmlNrY9H10reeBdRlVWQNp0jCMDPCZGP+AncM+qmun8IX32nXtb1abYDNcpBuCjkQxqrEDPdndseprzN9QTQtP13w8z+batBKbOf+L94AfK3c5UlsjJHQ+orqfA+qpF4ZV32291LdNLEADsCyOdgX2+Vsn1Q5NTudlN6naYElvpkcgKo7zeYhJG9WikJU/qee4pLKQXEU1okuJ7dVWZJEBWVDkI5Uj5gwH4HI61ApJuLRI9twUWZmZlIJ6Yf2zvIxV2+tUucljIJ4nZlliYK0OABwehBAGVIwcdK55+Z6lNWWhWtdLksLma40w2FlM4JHkxBCeAMEYIPHfGfc4xVkXGpNKz3BikjdcsbX92Rz1O7PGcdMdanWS8jWFJlguFEu5pIz5ZO3Kg4OQB908e9BuXkY4ttuyMlSemDwRz1PVsd6zNfkSiS3EMavb3MT8BxJGXxz7EjB/pVuC6s1kkRHKkbi2OB8hBIwecjdnp3HXOarxG7uAVjQDaPMJjYOVA67SRwMH0J4og0+G5En2wPNKq4ikLhtoJxnLdhkcDB4AHpQQ7W1ZfknW6tkeFZo3CF3DKfTaWOSCB14OD37YNqO1WSJ3K7ZmZVxI7YOV+7jt9fT6is2CIW0iwxxAkvgxxlwCQCA4B4P3lI6degrQt4ZTagiMlN2UEP3nIBAx379+SfoKpMxkuXZle5RvOUONjs5JcrwWHbpjtjA46etS3E0EltB5UbIyx4fGSegODntmrkK26NvZVnkAdfl3DGCcH0xz2rLvpWd9okIUsWZ5GypIBPQDuM4PIqWOPvO3YLWWJX3XIdYS4yqncxXBJGR9evqDUcql3ZAz5Td8wwzc8dvb8etLHJtgIVRGmCQDKFAXgkjAz2/lTisvlSMsMOSwLDfynHIGcHkjP8qDS1ncicGMsUjVZSAhUYYkg4HB4P5dh0qMbFGGlD5bnfzk/h7d/X8KsKQsCoineHO3PyhV9TyRk5x+XWiUyIC+CryENkIcdcH734UikyPzxLKXZV2KMCTGPTn6YH4809nd4jJGiI5VuhHHuO2enH/wBemyg/IHR9vlj514Lc45z0GPr0pGLxtImQoGcMwBxjp0H+eOeaYrLoNjBVXkBBYjcAAMYPYgdB16Zqs8fk3L3DOTJgoeeFzjORj27+9SEByyEeWudxYDnbnqO5HT8qft82VTuCuoJU44Ix2+uOnbNNA1YpXKEbYraExuq7DLjqCeDjvz059+KoTxzTbnlnQqwGcIPnGeuecHPPtj2rVUgbQ4KhSyqeh49+9V2X5t7HbIy9RggsBnr+ma0TMJwOR13Q7fZI2ViLfN5qgBjjnPoc+leGeN9DutA1i5a4gH2GeTcjwqNhBOcA8hW4JH4jpX0vOsLQyxYPl8fIx+5kYx/Lp/8AWrz7xv4fW80e7tj+7M3zABurA5QjPfn8s1vGR5lekeN6UNP+1XdreLNdpdRtHpd1bqVlin3Axkr3B5Rl7bsjOBnm7mNra6ZXG2WNsMp65q7qNq1o4gdZo7mFtk8Ug2tHIPT/ABpn2lmiCufMYPku43NuPOcnt1zVuzOJIuqzXXhmPMQ329+w8wKAMSRg4J69Y8j6mqAnkQxqjsrd2AwPpjv+NasYjudPaOJIoG8ySdY4zkKqJwpHXqSQxz/Ss66iAYyZV03ldw6Hjt7UMEOgCsxY7ASc8Db+nT9K0TbqYhc27I8YIWVV4aPPcr6f7Q49cVXk065tra3lngkjS5G6MsMZBGRx9OfxrWtIYxHGi8FvvEHkjvUvzNIq+xbs7CMWqtkCQc5z1rtvCkNvPf2nzKEA3c9q5jT44obhbe8YJb9UbnP0966fRrOG2YzKHeOV8RlTxkckVNzeMbnscN1avaxRq2xicYParU1mV8q5U5I/8dXrXEWl9/pcX+jl4YVwxB6E/wD1q2f+EjV5xHskFu3ynccDPbmka2sUdURNS1oGL/VRD5QTw30/GttrIQ2EQdtoUcH39Kw9GsN2rmDeyh5DIc5wB2P9fwrtJrFbjZ5pLMuVwKl6GkYt6swfDunGW9lvLqP9wpxGp5z6/rXTyKkjIVcpz8uO/wCNaen2BSBRtG3HTFR3Fg5yLUhc9VbkGpbKWhNtt7doJsqGb92xz61LPKrwMFwcgjisuWGRUVblxheVAHep9Li3A7zy3rRcLdWaOlWaxRBiMFquSyHgJ2496rqvlZCDG85Pv71chTCEkduKZnJ31ZRkDkggEZ5zjFV72adYm2ZK45rWmKCFgcE9Kw9QkVVKxsWZhtxnjrTEfBM17IdQnYxqkTIYREOUCr0HvyAfrVBjEzs2woCfug5x9K2l043ZcWsVw1yI5p5FIyuxAWJGOegb8BVFLB5HCJGWcDLfKRgnjB+h71qcBSZ8qVAJB4BY9vSg/I4LBcn+HFaEulXcMrxSRHdGdrKSOD+dWV00RgkQ3BnCgkYz39McCkNRZlQ2sk0ioiEsf88Vp2E9xppeazbc2wxyllBiaM8MpzncOPoD05ANRxxyPazCMrHCrYcM2C3oDxkjrVu2spbyT7PGGZ9vmIV+UAAZ6U0w5blCVCGE9tHtibdwckqSD3P6Z/XrSadKbaFplX5ZIZbeTBPUrxn8x+Va1rB5l5EirKVA2SjIG7ngZPQ9ee1V2tWilMAKvHIokDLjnHRhjvgkY+oPIppicWifShNZah5oiDloWwrfMHVlKsv4gsK7IWdk1nbLOUubHdGqhX+YxsMgjB4YZPHZhjHUVxIuAtmis2Wg+4FIBbLZAzWwk09tNHb2zq0gj8yOUlhHs2lmABAO5WY8Dvn1zT0GnbY3NRd9VtZbV3LX7TII8DaJIog+92OfvYjX6lm+tdraMkmn6PLbqrRQwGW7AJ3hZnkfCY4OxGDY6jJ7muFsZbU+JrSS3R5FaFERHIJkfftyo6BTlwAOncnrXoXgN4W0vTxbQur2i4mywbeSAwGMdcEjPTb6YqJHXh3qd9ZwrHcxTrc/aC6IiO+RlC45IPXpjg9MHvxqmQvGqu4wdpfnuFGATngZA9ucVyfh1/MtRhvNiRhASBkjHAUA9SM9u2PWuhDFYTudSG+VmxnILAkjPtkfUVhPc9ansmy9EvmRKQAvJG3txzz6ZAcevH0qwqs8/wAiAsCpCHhfl5HBzng9c859arxyRyxTCWTZOI08tSM7nHBI9sjH064psV0RJvgYRSqm5Qo7A8Dnvxnv3rLY1abLdpI8cke2BZGJ/dq5DE4DAqTnsCOoz371HbTtHHIAuUIVwjMSeBncD0yAc/iabBIVka482MSRHeQAVcHsQe38/Y4qzG5tLcwqqpC8TKA46qQOQeRjBGfSmTt0J5HhNsEhWTKORnqgU4xz655yPStW2Y280sdrcLIjNvZ0UjoAM+3GfyrF0+SK4EjTtIsineSyhnyRwPfPXPtx0NXVkAb5ixj8wINwAOzI5PbmmrmUop6Fxo0eMR8beRt5xjPXIORjPX2qCXT3ZHFvH5kkSNIxBwR16Dp/nFaFzJDHpodWid5XPljORkED9KpT7TDIBuQuEBcNt+Toe/OeuO4qpRSMoyl0M2OMXPmIgmO5lAwB85zy3cYO1scjr1PSo/OkuXWRXiVCQolZueByAMYAzxk56UTRsYCZi0cCKFSUnDPz8uRngZB6Z/AU64YWuUgO8MTtj6rnooJx0wef/r1mdK8iaGPLIFWV5pSwaQnLNweoxweOg96axZvOlhcbCAC4cZz3bj69AP61CttAm3z/ADfNTaFdl3ZPOVOeQPu9qkkXzHXyH2xMQhAABYjvwcAc8c/xdRQkLS5DK6JEpjUfvCU3lSSRjJy3T8PSiWNYpHBk+7wJDxtHOOD6ZPTrT0M2/MixpsBj27SpBxnPcjp2+gpjAQhHnjL3DkjAwO4xjvgYPPqfSgrZ2KxdI1jkyHbYVKqCSfT2x/8AXpWEkSN5zKCDyqr6+hz1p6uDHuZNiA7GVcEnpgY9e+QO57ZpGJRfmjGSFzv+b6Y/nTKZAMLDJENjEgk7l3kr1559PywagmVIJWK5JALLhiQMHg/Ucg5H9KldFBZ45CXU4LHqPQEdv8ahkEatL5SFGG5QoBAVuNvXtz681SIaImTPV9wYkbmAwgIx+PsevX2rGuohGEkVyOh3k7w3cj2HXnHH41uh3V5VYEBtoZFAHPQMMcZ6rxx+PFZ91E8m1RcIkjMpygBAyPc+n8j61pF6nLVjdWZ4r8WdC2WlvqUFv+8t5dlxKnBMZxtJHXgn9a8vXIfMmWXcQdvUYr6U8TafG+kXcVyWmhNu5YTL8yEA5GenavnjXrCbS72WznA3gB1YfxKeQf6fWtkzyqsOVkVnchZMYRC4MZbJUlWBB9se30qKLLsEf51PBbtj+h9qbbS4niEwDpwMEZ25AOR9M1aiieJWkYEE5yQMKcEjI/LH4U2zJI2L7UrvVZ7dp23RQIIYl7Af5x+Valjaefi4K+UUGAPX6CsvSHWZUhz8jsOQMY/Gu60KACYxmPPlHOJDjI70pNvVmtOK2I9F0M6hOgmJaMqWCqOWA5OPcdfzr0PQ7UaDpUlpeCK5tbq8iktpsco4jk+Uj/aGBkdxUHhtLWG7Miui+WN+OmPcfyq348L3Gm22t6FEQLW4S4mhY/JIItzlgOx4PTrmpWm5u9tDZsNNefTMpbkSu3mSbTjBParVzpDnTkaYEKsgzxzW7oN5b3UAuLcD7LcIJBn5SARnmoZ7g3mqCzQkwRfvHOevt/KoZtFdzKtd1neSXUqkQNwNw5XH9K1dBvjfw+aFwu9iOO2addWjXEwgAGx+CRz8taOl2cdmBCgwjdB7VNzVpIvrfkoI4+fwqxDNgDKZJ4pkOmBJg45B/SrN0RFjjP4UambtsjHu45JrxeOCfSr8Nntw6DjqRnk01pSzgjkfWrUMrRjJ5B/SgG3YkMWQCRz0q9A6iIBhjjjisyS9iM6qGA9qbr+pRWOnu4YFwvGO9UjKS6GT4i1VIZGhjP7w8ACofDVhcTsbm6IYE/JjnArL0TTJtWLXd6QpY5C+grrAghsJbcTSxKyFQ0L7HXI6q3Y+9Fy2rLzPiewlGjqt40fm/bI5oPNDDaqSQyRtgdyVcfTFT6XaTaTYXF+0kcUCBVe2eby5pYpMjA9tynIHPPvVHWNPR3tJLWOCOaSMnaCGWT5Sd3H3T2xj6iuh0aHTruOyhmtDaSzR+S7iMMGyysrIwB5Yb8c+vpWpxqOupnX1imqa1GmjWb2oYJiMEYGeBxn5e/Xmpr3S7yxjiW+tmly5bZA+d2OH3nGSeAcdPet7WLlrXUVe5e2kkj8uJlM8RBCkkEhM4JHYE/rWncXt3eTQi10WddSaQKhlkRI8MpYFI2CseBxkgfWlodEYrqcRpVzqNgpng2Rm5wpyucnJxxjqcnA/pTINNmtddhjjkkSQyDDFfnVWbacgdwe1eifDoaJawxf2vBNBemPNrLeIT5ik4Kxg/Io3cE5/PtF8QPDr6PDaa9DIkzCRJbiSJwY2UsMBSOOB0x6VJfs1KN10MfWPCzabaw6lBNb36S7nMDRlZph/GQBlcr1B447VxlzmRInfa01swCFZFCmP0JxkEZU88cNXsPg+R5ZZUiidzgNEjlWVQzlwOeNuc5ri/ifaWk2szS2VtGk2wNciEDZuxlhkEjHfA9aq/UyqUrLzOGuY2trtlhcwSq+w+TKG3IxzkHuMZ6duarW2pSx2drGZvNjjnaYQS/MqFgQ23/eAUn1IFPtZo4mhDRsw8sbD3UjnGfQgEcc8+1QzQxQ3IuNsiqTujgyHZRngnpjHPBwTxxjmqTOV6G/ps5i1lWjkG8W3lggZEJfIZfwEpGR0I49a9G0O9t9OlkkEiiGUtFOI2JEOG/dvuHUDkc843dhXjNvKdxjZi0bAhiD1Y8H8K9F0/VDptnKxKma3VnEm0skuRwjj68e+SMnrSZtSlZnovh24UWl1cLMqx3d/PMi4wRlgIyOxBAU577gO9dZE6fZ5IYmEhkj2kgEANgHB5weBnn8jnjzrQrz7HbWyqDLpscaxLJt/eIoUcHjLKpOeOV6cjp3AvNzRriJoJCJtqnCOvG0gjjvgHv8ATisZI9WlO1kaloRvUs5jZgRub5gGwcYIyQMD35yKlgJAmkkK+WxUiPAO1Cecd+Dj8PYVnq9s2EaR2kDMibCAWGPlweenPX1NWlbzriAtKNkkeXPUqT95hkdPx6/U1m4nTzJmoYpkdBG5dmXaqq2RnB4J6fMvf1ANMRpCVTyhuix8rqRgDg5Uewx+HviqTLLDeSSxNHET95eArsRw2M8E5wT/ADxU481Zo0UNMiplSc8ucZQ+vH4Zx6mlYEWbuRJGM0ZeGSNQEfqhLE5HXkE5yP8ACrcMonjkXcNyPiRW7dPTqBxjvUTSuhwix7Z4eYyAflzjk9uh/D0qF4Gt7iG43HZLiBirkhdxwh7kgE4+jH0qg0sWLO3igkZZn3EgFAvzcH09OfbvVsXDTOyYIjYDIwN2V7fTPp1qjqUqxS2cX/LR98ckKSM8hOAc7RxkbSMe9WSsMMMYt7SbzVzncdoHHHQ9P55zzSYpPm1e7CSeVI1H7prhwEkMP3WJwOvUjjPAHTBxmmiHayiMxhkZd3z5LYyc88DBxxx6d6ckcKxWzTEh2RVdQ/I6nH19uvpUd4xjdtqgEqSjSJhQ2MY7YHI59hU+pK7IWd3t2CoZ45ZI1CAA5IBySB3OQeajTbFYTMm9Y2ZiDkl+mRux6jjGT+tFg5DuxlnmbzMEopBbocDjgZJyDjuRUqQDydrkFYzlQpwF9C7Z5JGTj2/CmU2o6EUtvI8ctvcSsSzKxiA6MRnqOScHHPriopZbaPcbeNBIIyNgT1+nUjrn04ps1y91kQOI4QxLzMfmI454Gefb9KkSIxxlbTDBk3HklckdCf736dMnila5SVviJ7eBMgICBsA+Uc56ZHbOD+uPamXsBh6xtnAK7hw2OQT61bspLb5hIQ8YbO/duOW5JyQDkZ5GMj8qdrd7HM8cFuh+ZgYsZ5JPOM/Wq5UkZqTcrWOeZCGk84Ki7T82Ny8deT7449sUcuSI3Luo2YAzzkcAH0GfXnniqd5qMNtJErRSTzToZvKiQsyqDjJA5AOCagVLu6cJtELF87pchmH3cduO/P8A+trsbuDtdli4WMbXmkESqp6En8Py7exPFV9RmSKN5iY8wyBDgc57Ln1Bxj36U2XT7iZzFLIZeCyhesjYJDE545/h/wAiGC0dnt3uJ90ZUoQqqEZ+SWKnqevOe3arRzVUl1MvxGl1dWSWMMEkt1fHyzNxtUnkjBPXHGOp615x8TdA+0aBbajFcNLNAzExbBvij4UqcdccHn0NelXpuZtRggC+XHBwxZSrO7ZGQRnoqjB9T6Vi6/p0cmnyfYmMly0hLlmHzjf91j3YYxn3PbFaI82tG+h877I2uAd7o685ABB4H5Vr6a8EsLQXSuWDZgkHucsp/PI96W8sJba8UXEIETfvoW7Mh7f0ohCrKd42RPzt55542+44pnGkzqNCsY1BhlZMtgo44Vu4Iz2P9a7vTNOiR7aS3CuWwrqU4B/3gQenbNcBp2oL9kjs7qCaRoHJjlbC4B5ZHPYE/MM9Du/vGvSdE0vxBawrPDNpNrbMd5AWS6cHr1yq8+2aNtzVa7GtpOjXbajKj6ZHeW6KcBZvJkwR0AYbT+JFburXlnb6JdQ3ej6naQDTJZSZLYyLu5RTviLKAfn5OOnai1tNSv47KS88U6hZ+cApTT44rXn03bWb9a4K7tLbxFqF1YWE1/fstxJA95dXckq/Z4VxjOed0jORjHUVLs9DSLa1PQ/DV1ptn4e0wS61YySfZIjIGuFTHyjoCeo/WtVrvRHy1jrGmycb223KZI79/fn9ajHhfw7ps1hK2mRNdvGE8zzHJJ24wAW6c4q7L4J8PQ3K6lY6bDp2rqCVubMtEwz/AHsHDZ75BqJWN4SaNPRZ7WaAC3ure5fjcYJA4X2yKn1W4t4LiOMvl1/hCsT+gNZVhLrEVykV8Tc2+4BZDHhvqGQYb6Mqn3Nb93M9rCdjEsePaloVrcr/ANqtJhbW3uZG9dvlrn6vj9AanijaVt180Y44jQEgfVu/5AfWq9uCyicrk+h7Vba/tngbIG9RigTVtgtXgaZgeg7HjFWZZohwpG7oOay7FReSOyAhVOCanFoGkKhyB6jtTQmjN1q2ZoTLGWVxyuB2+lYlmZp9iXpLknoeldw1iHiCuT0/GsbW9ONvArxY4P5UxKSL9lD5aL5ZwDxwKNRUDcgI3bTgnkA+p/wrLi1eRbYAJ8wHXHXNNmv1i02ae7IUBcdck+tOw9dz5YvfDpbT7W7u/Na3nUyyyiFYxncB8mBlsBlyTgZz1xTrnSoLSPToru1DW7blkYueUKYAKg8HOPmA6/lXQahqtlqNmtpb3U93KYZIDaqPLS0kG0ESNgghcH7pOcA1S0G3iu10+4ubtfOmkhgDnDMuJNvHZRj86tqzJhGMkXNFaFdQlks42hjDBIprXy4PNRVA2NEV2mUAZPA3dR1rSuZNUv8AVra6sLnTr+GVXt45Hga3fYh3BiMnGRnGQOB26Vn6bYWrXVxbapfWsdneTAhZZkjztONxZunP0PXBANT6sLPT7lElvFu7mzm8yL7KG2XCFSomR9pBAYgMoGGwPXhalxSi7X9Cx4Z1adGmSb7NZvpplvLabzlUBZDluDwy9VK8ZGPas7xTc/29N5lxoY08zPGts1gqLE4OGaQkspJJxhSCV9c1HfRxi+k0/UHuBcRupIFo8JX5Q58xAPlAzjjI74FaNnZpf6x5bQ3DPbJuidkLybiMnO7gDGST6DPvSe1rGqim782nn/X3GfpQvrk2sVnZ65LdSI+22kW3UB0+/l35VBnOSCOce9Z1yNWkXU4ruf7MLjCb7lVYzyeZgoDGNoOWJBJA4/Cujj02Ww8SeS17Gt/HIlxHJDKWVkc7WC93TLDK/eIY5zwQzxVdRSaXq1rEZEnjma8kCnPllseXEpJ5LSOMcZCoxxkEARFWKSbbOD0izS6u7KyOwXF48duswT/j33MgSXIABz84C5wd3sTVHWvD02ma3PpUUiG6hJWcEgqSvocfe5HHYnBrZuYho9leQ3Ep8toE8+OJj82fmjkX0K/KMdQTnua0GsvKthDftK/iEuski7lYIWG5XDgnIcMS3fdx/DTOJRu7M8ymjkhiRoJgyA9R8pXBPX3612EGuR3+nwtKy+edsN0FO0ypuU7hxjkY+jKT0NZt9pUkmrSQyBY5JwduFOzzB0H4kAf8CrEt2Nsy+ZwrZUr0KZ6E007ozcXCVmexeF75La/a0uroxmQmSBzwobOWQn37H2x2rorVJ3thcWDwgktHNA5xGGDYJBz+7P3W4G055HU15xpVwupRQQAu8iFF+UZOT0AI9zweuGHpiuy8OXTeeILsr5t5GrxT8eU5KgBWP8LZDDnqRSaO6lUXU6tNbiF+WvLW4siAqur5C7+QCHUEY56HGa1dKvdOiub0rextKrxMqqCQw2kH3Odoz26+1YmnS77+SMyMnlJGhSSEHkyFTuU9cbuO3zdegq6G8jUYmeKKMhPsjbcYVScgnuMELzwTkjvWdjrTS2Om3TTXfkW0LJtGDM4BKk8hShOegPP860bO1jDxQxSzgK26CSZw56gkk/Unr0z7VmQRxwOGkd42lzGxHCluN2M9CTzt9eh6V0ojXMzWISFQRtXdk9OeRk8gHPcmly2D2hVDAW6oFPlrJtkRMA98498ZqvqFpcXMLWUrXChVZQIh5ZA9SAc5Ax64xV+5AUMG81gVJVmwSwHfj8PwqrJNDbO8ty58q2lVm8x1Zc9fqflXPWpRqn1RBpXlb9Cfa/2i8n3N5ZBcSCCQsMD33ZrQuEECvEwLKmASpyCdx6HqeD+HvXKaS7FfC3MgdoLq/lCrkwxsoIOe/wDrunvXRSzxyqZbaFEaRFKLGWG3v0PfsfU0dBtNyv8A1uO1COaG43urKrIGXcQWAOTljnjgdaUsfNeSRwApaMNG+CoVsDqMleTk96p6ifKEwEhR1BLFsjDDOc57jkU+CWS43RySBcIIneRgzH6eg9MetQVbRFsmI6eDu8uOR2Yq8m4IOuNvqdvUd6qXMBu5op5o2jjyW2OxweSQzY6ck9yetWn864UpsTcyjdPsJZRj7gOeeB9ACRVqQkxxiMuwkiWQbiBt255xxn2zjpTJUuXVbla3gLSBAmd6EhI13clgA3PQk8Hp05qOc3BjTcscryA7iJSCI1J6jHHOeepBx6VejTLxosUcI3cFcruHfJ7elV5WaOXKRZZXO3d935j7cnGPrgCncSbbMiaKd45ZRIqjarMIl6gYGeeee5xx9aZcPK08zxsGVcCNmGGCd/YnoM/zqxqEEkcMZ3L5s4YB1bIX5scjGOo9+D64qnLbqVIupWmkwioXzuTrztGOOB+eKLGymTywrbXkjopOCHYY3eacDGScdu2B24onuIZJHjBKyYPMoJC4zz6DqM+496rpJFGg+eVpjkHJLMpB6nOfWm3RQRsrzuqk5Lkjjnr04Jzj8qBW11JRvV2QMZ2XcHO8fNkfeHvgjH+OTVW6IMcjP5rI5VmYtwTjGR3HBz+gqCT5naGyud8zKvlh23bsEHkD9T61n3Ut/NK8cNncRcBBJkOi9cMvTPQ9R0zVoymupFOzO2XlKzFijkg4HTB9l96oaw5OmudrbtuxV3bTk42/kdv+cU+/0XVjGZIb+KaUDbK8qtGsbdCBtBGeD6VzuopqtlE39oRTLaxMFMluvmqoBGenOTxjgY/WtEzinZlLxn4ftzaQyNIqmA+WjOwVQeFAc9h057HPauHv0QSKyKyC2cJKB1yeGxjrj2r0q3uLO/sWV5UMbqfMRkyTnjv6d/0rjtWsHsxLZxYwExFnltoG5RnqcdKp9zilFp2NnwZpMOq/bZYoxNGlvlAqfu5QOCD3Dfr3rS0jV7fQ4Rpl9NPLosjh7a7UlZLMZ5inX0B6MO36XfDQmsp7TU9M8uGSe282aNl+ScYyVx6479ev0p15FZ65qckDotrctGXiCtkSZ/gU9GHOcHp0oewLR2NXxY2mT2kNv4akj89WLSXaybo4Uwdz5zgn0HrVnww0Wn6Hb21km5TEba3VVxk55J/Dr9a5Kz8E3+nXENpLcGOKRlP2ZsbZRnnaexA6rXottp0iarJlFhith5UEQbhc9WPqajoba3sab3ksl5ukKvLCVxtOcDuK6iBheQJcRDOecHp7/Wsuw061s9jHLSkZPHLZrQ0GVVmureP7sbblz1wag022N+wyYRgYOOfeqU0Pn3gQkEL1was7HVd8fHtVVJjHe7sghj0/pQSurLd5EsUXyk4A6Zrmbu1lExmVSEzyAOgrpbmNpZV3E7c5pmqALYvGo5Ix+NDKhK2hj6NciYlIjkjjr3rZt7by3OTya57SrYWrhl4Zj09DXQrLuKsCdvtTQT3LMz7F9BWHrV4bi3eOFQx578Vo6lM0sRjhG045YjIrIaGNLOR9w3YyeaoiK6s4iPVcXDW8jASj5Qc9PSpLmJ74+TcPI0QB4bv6/Sk0u0tkur29mGWDY+bk49a0NNkt7+CadI+7AHrntQbJLqeIWtqdReC40mDN3AGTbb/uYEVl+UeYpAD4U8jcSRggipPD7393p2naZHc2waSaS4a3dWgdAilt3mqDvX5l+4V56iult5bm50nR7iyEgnkAilCoAocBlAHoNwbp6msTTrVL/wAUavZTQxOu9Y4izbSroSWWM/wnJAyOcL7VbVgjT5vIr6bC+nqWjgFtG7SN5sKefhdxQk5G/A/GtTxDrn2rSIbtNTuLm4tJM2VxHtxFKmMEcHAUHkdTwOlZLO8UhsItRms2M08Mv2sLIETliQSMg9AOeS3vWwmjXt9p1xe3MFleTJHtS4gvGtJ0XG0LtZWQjttzSvpoaNa2ktEb2gzadaae1t4pha21Iq0kN2yBob3J3FkkPIb27ZA4JAPOxaaLe4e5tE8uMygJpr8GRnwZPKJyI2VSOT8vXO3rUlxr1xpmhtovi3THfT7gRFTNGGXbFJh87C+zO9V3r9AO1P8ADEeqWM0d8sF5/pyJbRyX0flwWvmOStuZJcyGIhgN4By+0HIKkJ7BCfLJ82tvwJtY0W0vfDU+p2V6VNsd0lpOpE9menl7+CrnPZec/KdvLeYW9tbTavIl5G0L2s6i5SIbmKkkNgEFcIC2R69ODkegeNWvtWvbWK51eys7yciCEaXaOgaEMGaaWR3LmMYOwEDcw3ADrXK+IRFbWNrp1tbxQ+ROHh8rLRu2CCVJOSxyu4HnpyQM0ttSJwdT/P8Ar+vvMjxJbSJdrDvhmbznbljsAHG7qRhsjpjpxxWrb3EN3ZWpMgt9XtFxDayRELPhhlDJk7w3BDfwkdAOar6PoDzXotVaU3TpuDLuyxB6ZB9OfxFbVt4dt7bWZ4dRURqVjkE5mkQxnJG7eCNpPHXI96dyfYu7ez2/r/M1LxLLUPDkWuRSR+bplwsx084E0SqcTRup5Lbec4/hGOtcd8QdBiinFxamJ0mOS0R3LIhG5XH1XP4g11eo6Pren3N5clLq5RYDG0lwGZwhXq4TDcLkbjkAdVA6ctrE+oSqPIt7dLFpDKRbRgpGzD5kU88HO7Yem444Ip3TRjODUveOP0e+ewuowOXizgMTiRP7hx+OD9PQV2LXkclpcR2RlkgZTPbpj51fK74zg4yAzH8Se9YWraDdGCG/SzkS0lUgS/eViM7sED/OD6VV0bUDHIkLyBY/MViSOhGQGH4HB9R7gYL3MbOB61pV0sV2q2d+8yTIYwZwSyMDkAMBnkYzwe4Hatma91G90tLeW3soQzHbcMWdy/QjGFGeR34znmvOYr9oHT7SZpIGXzUMb7W+cnIDDnBOMdgSc8murtNTWa2tf9LuIyI1ZX8wSxyMA3BVlJUbWIJ3dQenGCx0wq3PS9ImhVLi+u53upizSeZLwSm7B27cKh7kKBx9K7CxdWLTyMofJYcA9ccdehy1eO2V891pEtv9rtFZl2lZbdlZCeCch+gJx0xg12ej6xq8tlaxzW9hOQNrNDc7XypIbIZcZBz/ABYNJo6YR54nU3bRQTCbaxdS2S5O3awxke/9TmuS1+4e409dJtJ3NxqTC2WBcboYgMyuePm+TgH1ZcZq/q+vWtrBB9tgulLH5YVi3l2Cliqsu4duSTgDJrnre5RvP8S3j4uBExjKKQiJGWJjzwSvXnqWOeBgDOxtBpbmtZTxtr+uXxeG3s7OGG0iYnBjVAJXOcckExjbjnbjHWt0O9rND5olikIZZFADYOegOfvfyrmLBYrDRB/wkDwK03765a7fYPtDuZZMdCSG4AHXA6g1Ytri5uLxLrTQWSRPL+03cTxoAVyZBESGc4I5baPlzyMglmVzIu61K0EEg8oO8qnyEVhzkgEn0AOMkj25OKtW1v8AZ5TbTs9zLvc8jjzMkHjuT9O3FYap51y9ta3EspDiW8vLnazSbOVUn1Bwdo4CjjrWxbOFURxqyyTkOpzuIXHXjo3UfjUNGl3Y1VzIxjkXyju2OgYHYmMYC88/j3qSFZmCNOF3Sy5BG0NlRwTjHHp64NUkJgmyphjmLD5sFthHb0yc989KtWkhMayTbBCV+Ta244BII56Hp/nNOxm9tC6XCxH5Gm5+TqAR2PP1qB4pLh5HlkYyHnKAnYCOn1OSPzpGM0s32jABUBAy47nHOcc46delPBSSeGPBjhZfMkOcnAPAOe9CV3Yle7qZt5K0ZA/doI1I2hMc4xk/5NYMlyIxCpmhTymxvOMZx0HHXgjmul8U3Gm2cTrFJGpzuVSwZtuOpNcFp17ExQywhZCg27zjaONoGDgEgY+hNU42ZpF3hz2NtbwhZJWjcxbjl0IOSAMj1z93Jxx9ary3lvvSQgOAN+7qBjGMjp0zz74qjPcx+W5tlkwzk7Y1LBnJ57Dn8s1QurpZ5G+zlEmGSyXDmMZA6HvnoM4xgZz3osLnSNyG8Se2eN26kska4GFGM/ie4+vNStcNFzvIbO0luvHHI6f56c1xV74hWCG3lRCGlbJt42xKFAwcgkDb1xyen41QtvEl5cbEtrO++zpKGkEFoXx7HcApPI75ORii1jNu53d1eFxukxGcAqoXHGc/Mc557dfaoWkCxM0Mp8yQZAf5l7Dt3PT2rk1vtMmumGqvcadcu3CXYe3eQHgjBwuOcccjOavLYyQTK9rLGYVBKea5l525wM5+X0yapeRhO2z0HatpEUjS3I/dOTl3AAB75PPPYcH8a5rXbeW3vtM1Fw0lsj/Z2AOXzk9RyCOD1rtRNMlxFBc2k4uJMbFlCkMCckg5IOTn6Zrm/GDzWGlvLZosVuz7y6MMxkcBvqeBx0rRPQ46sGmmjI8LaiLiOGAtOTDGYoigxkbjtPPTkYJrprKxEU/mznbFMPNIz8yyDHzL9ORj296xPAt7aW8VrPFAZXKSKEwMhdu8DJ68r+tbd6L+UGeaOGGO5lEiEDJDen4j+VFzNR6mjda/Nqt1Z2T+WNStpRPaTYylztHIHoxB5FdZZsnkNcNICZX8zJOfw/nXA+JNMPl6XvfE9uftJERwW2sMFfQ8V0vh3Vba9ub1nCRgzeakZ42hh0x2Oe1Q9tDam7y1Ou0yR5rwPvUAD5QwJI+vNacc0UuqFImCXca/vFU53KejD2PP61x4v5o5pHZOSSI0Xgt6fhXReHdPktbmC9vf+Pq8jkicL0AGGXj25H41KNZHRC+TywoPPTNVYRu1FdzZznH1oayeYF41KnrkVm3b3Fvtk6PFzj1pCS7HUaq4itlZfvdBiqnno6IJDiQjjnisjR9Rn1uHzCCgXoO/FWZHKAu64K5w3TFMlR0sLqLrbsQmTn09cdqr6NfPPGySEIVxx3B71l7nv9RO2YrEO386zryOSz1FNsuPNIAAo2NeW6OzuruJYtkS5c+nc+tc2lxLOJrdwVHTB7/Wt/ToTb2waaMk46msi441TzAcKei+uaZEUtjMW0CW8yEffB5xVfSY4rDTZR5gwpLEf0q9qzpbwzO7hSDgZ71glfKkQs+VuGyFHcUGu6OJg1K50zwtcgQ3FzqGn3XmQSGF2RHyxKsybl4CtIykL/Fyazx9ne8a20sBojCPmdxIWH8TMUJ+ZiN3YgnIqewivVN/P5cUdwjOxjdjhsxRiSBe7SMXUfgCOMmrmhR/2no+nNeQfaJpHW1Fx5IYbYwFRlOOAqKoI68MDzmtL9C6cfP+kc1eeXbatdTXCzzWYRY3dl3SRMp+UtgDcM9T1456Guxlf+xLU3BlimtZXWC2SCdZGuZcj92wQkAEhjgZI2nrgCsiCXTbiz1K61B0s32CSZYt6x3KNndgAgg4bG3/ABqtYwww2EL3d9cWWpQyeXbWcssirGrKqEpgkszAYkGN2QACAOZW5UlNLT/hir4hvLganHcXFvBDeQA3s73B3NPu+WKMRZG3aMsqEnouRkkm7DcR6boMUc+oXt7pLW43aLNILWW4DKSxyo3JAMrhWPPYrkK2XFNZ2tldXF1oM4kmCTy3SyfLHG+WUFm3Mo8vYoBP481Vs9ZgvoI0CXU12Z4UjRAoEm0qeZSdueOOTgdqm+o1TjJauz+ZPoEKzmKPU5RBK7ytOQgjaWQHaoJ74BPvyx7mrviS5stUOm6Xp0UN5Z2szyho/l83y0Y4Ur0Rdz7pOeQAv3TUnhTRxqSRJqbv9ileSWa2j+4kYcufMY8vgbsLwCQoIPSpdZgkeK3uNM09LRJZxFDBG21U+0tIqrjvjaOcepppFyuqaS2Wv9fcOOj3Omaba3K3JmmLkx3KtjOGIBcdlbGNw4G7BxwSkVyt1rgupnnNqhWKOJhuJAVifxAJCjGMDjmu319lsdDnsoGWd0jW3jXZhv3hCbSOmQG5rjGtBp5uNJvHWK2nVZluFbMkca5+ZT0yNojOcclW7mm/I0UVFK/Q68+JrSy0a+tYr4KltA063qJ5rSqQcCIYwQrAgyE4HAGTzXKeEfC9zqNhaQlf7OlRZInuFXdJNtcq4cHhsHn5skdiK5zUJHis3tmVDPerGJE2bML58exVHQLgn5R6V6BoWqJr+papZ2xMX2yVmdlIBigLF3wepLblAI9/ShPQxlSXNZmLa6Jew2k1va6c93bbBKfszBkuU3ELKsR+eJ/lOSu9T3ABBrym40tp5bq50qOPbAGMiSbW+ViRt2HngHr1BwRzg19L+LMaf4fuLi0mFtLbwlbSSMZCu+E8o+gbI+hAI6VwniTwdp994V+0adAI7/R4Rbyo4Cy7sDCMe7FmBVujbvyFqctSikmeLQTRo0UbTPDlCI3bosmcbX7YIyNw65Ukda3NI18WyIhQzI7blj3gqG/iAyD14PbOeelLq+n2+kTyRX2nGeGGRo3ktbqS2uA3PBZg6D8Uzx1rHvprQxzzW2oa1Fbu4jSO7QSqp4IVpEYHOMkfJzjgdcUjineDs0dm+rwyQG0jeSFxl0B2/LKeucN6YKkEfdKkc5rc0rxpdrGsb29uHkK+d58LOGYKFJBTbyVVep7DPevN7TWC0CxExTGNfLEgQhZBnGOgOcYPIzwfardnciSQvEfILrtfJkRZDjO0jbg+2fWh+RvSrOO+x6pDdX15P5ceshp3iOZpLFdwVSCIxljhc8kdPlyc1Ue+XUdQeJ77XL6OAM14LaUiGY7uBtjVQAGIJOeuAAOa5XTLtJriJVmFtMmCHWVZH2nPKkEBMY5HLZxjbmu10fULaONLCwuYUNr5jeQXCOUJVtwQsOTnpycDOeAaVjoVeMuhJp39mxXvnW6XtlcSHEdzPMZGYf7RdWbHTjPOfSti+iaSPfda4Z33kAP5ah2HTJj6d8devFUYNStrEM15OilwREGQmQE4JKgE564xjPHtUrTJfCILYbWcgtcTgIBj5QAv3ipyDggelRym/OlqjdsriOWImCFfIAI+WPeC2fmbPXrjr7nvV+Eo0aeUjLvUbHdMA8nlOMZ9uc5rmHu75tTltkl4gQlhbxhUBZgOSSccfzFbiNcQCSW8uDNuVWYZYFl2hgCASF6np6UmjSM7l9gzTIqRCEffI2kqo6nuehz9eO9WJbmKNVVGc78Z3/KGHXoOQM55HY81knVHdUC4MQz8j5Vs8kAMOpPvSwXcZA2yKxmyOMrtb+7gd849qk1u+poz3ayW58gwj5Rja3y4XIJznryf61n6rfXEY32MoZ33DaQf3mD1XHPTGR2qv5v228e3uPLKRDzXXCnzCemcdfX14+tX/NEjyR2KZ3AKfKOwAdSVyAV+7yM8kelFilLlOYu9K1bVrtDf2JIkcFll+RFHHL9/fb+dXXsp008g3kmACWjWLDBuvckcA9cdelbcMsc15tRjIxYOpDZBJIIU+vU5yabNKxCy+Q7SMrCGNkYYc8E49gO/15qtjOpUnUav0MaWza2uYLe3mWGIAmWR8yqg68dGJ/HrWeNIW4miuJbmU3R+b7SwyqknO0qOD3x16100Vt5UdwyopGUEZYZKrjJHHQksD+FUSFe4XzLnyzK4jcxDhJOx6crx+nvVGNmwh0+xjSVpUjuLiQqkz3CDAQHKhAPuDjG0fU+tbFrFeNaxmRYhKv3j5h+XGR9Dxx/+uq2mQxmMDyothYYdvvmT6jjr2HtWtFOrwSbiizFtj4+XzJO5647jjHbt3htjUUtChf2hnQzXEVu6hCB5yqwRtvOAQcZ55GPwrnbvwzBHcCS3ubmz3qCUWRtkX0B6D1+g78V1t6zPEu0pGzx8Ky4wR79++P6Uy1uI5fPQuT8yKdwxhfl/Q89PUe9CYOmraHNHQ7W8jidr2+WdE/dqtxtAk9cjruGQB0xisXW7B47V7PUik9i4Mazo20oCcfOPUEkAjjOK7KaJInkAgiXe20bRx14GO/8ATrWFr8csqyxv+8kLFMcYkU4yCffOBWid2cdWDSseU6XDNBcra20ihlDfOB97aDj8TXcTmW50RFe5ICAOpzk7hyDWF/oWn2MtwZGZpHKx3C/8syG449P6Gl/tGS8jE1uAtq+ElGeImPb2B/nVNaWOWL1vY6nwlEdTsn1K7YSSSKIVXoI8N0H0xXRaVp1rZ+IblJ4yZJ0V1PY44rlfDesAtdWsWxFhMYiUAAgHO7Przk5966rTL4yeIriS4bdPBbrwO4POQKTNIJ2O103TLZXWUrmQnPzfw/Sr986C/tQh+5FI3pjO0VFaSRvACMA4HPr9azBKbrXZ4l6RJGmfc5J5/KsjZp9TpLG6MacgYJxmuQ8fX5jZPsy5YnLAeldVdv8AZLTbgnA6gVz9zbpPp8lxN8zk/KueabCFr3IPARMTsj/cYA/Wuk1hPtEBjhABPJzWF4ehMLpKRtUjn0roLoB1Z4XA+Xpmmybe8c7phjTV1gfjHc8Z9as6tbJJ4gswi5Xnms8Wt28k0y/fUtg9M49ao6Xf3bamJLlsrF8pyc+5NC1LldHod5JHDFtOOOg61xup3ONQgjCgEnOcdq1b3XLJITcBWmkx8qZCgn6np9a4TxDqUmoX4W1coh6FOMjPc9f5U7EQLev3ca3Lqf3mz58LyAe2av6fpqz2STSht20hTkg9OoI71UtNPWG1SBT5rO2SevP+f5V2dukaaYA64KLnNI0crHzj4R8ZaVcX0S65FLbQzM73jSwmaMysrbnBHHHC7ccYXB4zSWfii10oamLXVHnglsWnjijRmxOGCEup28lDgyAjjk5PXmYbuTTLpXspJpYZXYxm2kRmMgY7XaMggNgDpz05p9mC+ofuriydXDRjz5MQbHHITeBwCD1yfmHFVf7xpS+G5t6jenxFfafJFqFjp9nJtjhgtYWmubiVBiNjErMV5J2Fjk4BKjIrKntrmXVbudNSu1yJEhvLwSbnAXJAjUBkVmAGeAOciujvPFI1XSktZZLTzERlZ2mZmdQNoRcAjcccEcn1FZytFp8UtrqMk01/DARCWilhO8rlUfKE78svAHOeSOtJnTGnC15yM+2sLxLePUJ7+11FVeFVsZpC7SkoMYiwNxCnbkEEYrXvdUs7ua1k1PTJrKKSWBme1VbkO6sisGccAED/AFbg/MmM4YgyeH9Kk2yQW+k6hcajPcEW901ntD7AwdNruoGVTdjGeG54qPU5pBFKt9o9yguF/wBJi2rtmAx+8xu+VhgZzwe5zg0tUWqcZRav/X9f0y1DcvpWpzWIeW7VgzWbPbSxNIQWX5VPRwSwwflJA7g1NeTyapdW6MpEMS+dFEr9NkE7JnHRsq429ifWsK21Laiq0c15YxoTCWgaQwOo3KmTyY8kqwPZ2K5ztq/pN+k99b3WlR3s91O73Yg+zOzOAF8ohsY3hNw3EEZVs9c076EJ3Xs36nfeIZo4tFS4QNJE8lpN5wH/ACyM6SZI+mcVT8f21rJdaZPp8zyxJdz2oBQ5G9S2PY5j6VT025l1bQbrw/aaZIlzBE0GdTuVgIG5hFhF3sWAAGMAZHXBqLVba7vINLnfU0lGot9qkgtrf7OkTLHkhjkuQCyqTuHWlub8yl7yvc5bUIlvGhi8iaaxMlmk9xCxbyV2I7IpPVgEf5eq84zjjp/D+m3uq2j3kUyRXTTNcSTIFSTbIA0ZJ7/KQo4HTHNZWpQW1sJbCO2MUkypbw2zv8sU8rbVU4/ulpCrd1YcnNd9daBqEGoNceHZo4kRVQ25TeJ0zyCOA7cH5shvr0qgpxSk/wCvuOW8R32pnT7XT9ZgSZTdQs0yyOQduXIbk9cfh60mq3Gn6rPYwXMy21xcOnmyxxypIkMWXYFh97LKmOCPnzwa0ta1Szl8Sad9tdBp9gZJHe0DEeayYJ8o4OclV2hieG4qoSuoTX9zqRuIdWWQnypbZlZIFwVRgFwWIOWIJySOuORXJcYSdtvX+v1JtW8CWms2kl/pd9Nezqih55nMrng8Mp6fTFeT3/h+50q8v7GeSLc0WyWHdxNHkMp/AjI9CBivZotEfUBLdaFJdrb26BbiW2nAJcgEKVBBAwRnjvj1rj/EFreXrXA8i3kjs2G5mgVfLz1RioH5kdxmjQ5qtDmu1ZnickbxNvSQBegUggDA6Z9eav2uotLGI5CVkHdCQw9M54YZJ9xz1roLiKM2QaaESQ3ECQTRS8sGTADxMfuuCCAPQkEEHFcfd2OJlKBhFIQULHPyk464pnmShKJ0NnctJayJMBIFUsqgqGTH8QJGGGD0ByCK6XTRYXVpGbpJJo12qwkUt164YnpnBH/6xXn13dz2urXex96pNIuPQbiOOxHsat6fq3kRloiY1YfwsQo9Rtz68/yp2QQqtM9OsoFsiDa3M0cC9I5BvRSBzlSAQOhIB4Dd8VqyeJJ7eAeZCkVwBvR2G6KQZ+Yp35xnnA+XqeK4PSdbsWb/AEh1Wc7ShlBaNTghi3tjGOp689K3ZpvtUPl3TyqrDdbhn3KeBuYZwcnAxntikl2OhVU0dxoNz/o/2hyfLclWV2PK4HzOGA5PXHWtVbuIy+Zbuvnp8oG7YD2APHJ6EA9+MCvJ7HXbq1BAk86DAUOTkx8DGPX5cYHTGOldRLq5Wd0mklkF4A0bOpk8zI4IPHQcijRmkaljsrucyNHamUiFmOQ6AFVA5GRyOcDHvUk12sVqUEsNvNPld23p2PQk/wAPfrXP6XerFbtJd+UkpBjZ42BTCkgDB65x9PmFZOt6lK93B5JO65cRJtOR7sQex5NRY2VQ6zQJljsImtI1kJd3aQHADYwS27kcA9M98VpyXCQuCEYgYJW3BKyHODg49OBnn2HblYroWrQ2toUu7gBsKZAm1SfvH68cj1xWnFJd3Mrh5EhtY9qSIh3STtjoDnGM9/8ACixrz33NfTon1CZrgxwrGsuIRI2cdy5C5wfTngDmtaEC286SKfa82SWlXC8ZJCKDnGcZycEmsKbUBaEQFGCBRGMKpwMEjp14/n7VTW+Vnjje2jS5yPLW4OwxkdCue3OeOOaLFX5jpUlt54JJCPtDoN0yROMo2evTn14wKd5SEyMlrDKYwpfbtAIPPK+lVdrwwR3DxK7xucGNMeYhA4I53ZGcg1ZE1uYXZGihndAVG8DPpuPAGBxz+lIrQsoHYyCZhJ5hO3c2Cw4A4H8Qx2Poc9cqn+k4tp3VUZhhnYZyMHBycZJ/i+nc1Wh1KI20MrNG5kABkUgjn24PB56d+PWmyzRKTKXUhWwGHDFieoB4HQc0Ejr23MssoilmRoSCxI3hgR0A49+QfSsqHzomt4JZmEjSOzSQKM8DAjBPTsc+5xV9rvZKghUSxyyeVnp13FSOcjp259vWvK0NrdJJHNCEBwd6grsJIIbd16nr6L7U1ETm4oct9DPFGhdQzo2fmB3Yx1x9B9CKxtdvRLZzP5pfzPLUYXg/MSD+GBjHrUmo6ek1ncSWF1LZzSYdQ3zIxblMr94fh03Z5zXH2Wo3Ml7Pa3ccont5GSd5MKYjnGMnhh33DI6YNWl0OapNNXMO0jLagIZ/+Pdn+Rc8DPJFdDe6emnw3rgLCNqh/wDnlMp5x9ar60hszbRpCzxzbmtiwwTt9T26g49CKrWseoarqLw3oNwVVSgAwkQ9dv8AWmzgV72INBuJ4PEFxfRWbJsTCwyHkqOd31/wrr/CF3/aM9xdsXW/mLALtwNvpWI+m3tzeaxbW3z3MccUinuMZGB+oz6V2nh+1huP7ISzfbCUDsR1zxkH8Qalm0LbnX6RIba2xdy7QEyfwFb+kWYi09ppCouZiZWI7Z6D8BgVz95CPtlnBNEzBmLvtOAFUZ5/HFdGJESLzIySpHT3qDWV9kQXV6RZPHIR5hyq5qukMcNgsbHfIecHuaydXvQ8bXAAUxtuIznOKuadNHOUmkmUkDBBppg4mkB5YjLJhScVoXcSSQRLF1PWsy9vo5NkUY34GcgVNbyyMdoGFGPm6CkFna5LcwLY28kkRySp49TXGWOm3lzJczPJ5KFuF46e1diyNId0zZA4AOazrLy3aeJjg5x6d6PQE9NSnpyW7Ruk6KxHGeOcd6wJZI7hrhIcDY/AUAcY6etbyWJ3P5Dbi2c+3NZAs4dNd2Ybbic4xngUylZamz4csxFaK0uXm68npXStAQQzkhQDlQOMH1pNDtEt7MEqN5Gf/r0+cm4XrgqSVJzgHBGffrQZN3Z8g6jbRS22LcTzog84SwW+EJwCUkA+VcdQ44I57irek3s7NbqFZpCzSAFsowIAZwvYkYBOccLxkVt3FjLYLNLpEsttbJh8ISWt8Hkd98XJxxuXpnbkVzEunXJEkUQh2sj3SxRO5EiAEukZHbGQRxwcZpvTY63GUd90dtozazLGy6RpkdrBc3SzwvJdrIqfKB8gPBI2bucgbwcc1v6rbk2pjvbecx8yJatuuI2kOd07ynmRzyckAAnhehrBsLJ55LAR29vMVVn8xWZh2wSAeMrngdQQa7CfV7m68I3Vs09nYSWySJ5MVm7yElfukkhQcEc4OQc9KrpY6IPVSWpy/h9XtUijCNdadgSPbSIR5BYbiYnByuCOM5HOflqxqk8k07QzSwCUxfKuoKYroJu4AdMqxOeWwPu4JrW1vSb6OCIvqkkTLCxKGyjCmKLG4kge2Ccjk471matLPNfDVNTutMNlJFu84WT4iQrwjxiQYIJ5xn5ic9qWyLt76a2Ryeq6X5/lwxQLIsX76cbth8nIVv3ijOC23GQcHJGOQc3TNUfTtel1HcrQTSmMuQVRZ1JXJxwu8OzYzg5J712OpaPqssEzT22nW2oXjFjDbRsXSMRkEL+8PyqOfTc3euG1SBrSS9gaVJZiohlj8ndFGq7fKMhyQD1Hr8vTnNTsRVbb9ps16fp+J6rrJ0e8sItRvr+xs5I1YQXkJMpI4+VkH30PAx1Bxgg4rndJ1v8Asa/uzqtrKmI9ggwwa2hLEsFYr8p3sSUkHAZAWO3NYOgafHJp8s8V5a2t4WNo9q4YDC4ICsgO8EhThxwQOnStyaa5026tAdCj025DY+0W00qxPhRvQISo3H5TjcOcYz0qvMIuc3dr9SnrN9FrV1pFslwkFos7Xf2iR1dodo8uMcdFyd2AxBxk120U9zdCC11zxBqkWGVDcyQwrbXCj7pQ+VxIeBl/lH3tzHg8xc6dm9hvvDukzxSvhppLm4jC3RJLMxG8jcR+hxjFaFw01xIkMmgxQNIiXFpIZo1VIj824SEsu0jr19NvWgHFXtJWffy+46ibwtDBq2lTO11NLHMY0O7dkMjcDGFVfUqo5+tQNoUY1KGKG6mVr0B4VklbAcDayrjBGVCkc9jXO3Nvr1npjE2MkUEQDJFp986ICDuyIgvzEjI6Ec56Gtvfb3dlEF123uftSrNFAL2Iuw7MpEIZW46EAgjpSRsqiivLoUPD1vfHSZY7aaY3xuJbaKQyA+SpmfbISV3FRh/l3YJB45NPv7c6ZFLaWmowiJRtjka2LspPLJJJGxy56kkc5PANUrVrxLl4riXUry3jmminhW3SPakkjMpeXcpY/vA2CnRskDNWpdUhmDW1+sukBSTLHNJNIFAH3lVdqHGDznFCfQwiov3mrfejj5dEWSBhbnToZjl5I7m4AjfnkhWVcHGD35rhb2zS3upo5bVYnM37sLMRjnkrnrkjpmvcptM0PUrXzrGC+1VIndJXgCQQbs42+YuwZxjglv61xF1GNJubma0toI7aeF7XZvWVlIwwLep6jO7nnmrRw1431R5Pq1lHcXt1NbhiPMLuqIfkySe/Pr9KwpSoYg/I3cqOvv8AX3r2TxFdRXP2bzzcOFzH5u3YSmc7SAcHDAHBz061wmq2KqjyTRxTty3mRryuehZeh96DjqUmjPWaLULZpG2Wt/Hzv5W3mGBjGB+7fOT12HPRcc2LLUp7aQWmpStHEG3PFI/zIevA55P9aw7vfdLGedkUeGcAkZyeSB93rjoOgqH7UxjWG4HmImNrA5dF9AfT2P6VRgm0dxqN/HeItyDE3XcZPkD4PBHJwe+CPXFS2moTNZAQupJDbN0oICj5mXAHA7iuROnpuf7HfLKg6iSIq6Dn7yjJ4HUruHvUdlqj2bsm7fFnICs20N2YDik13LVTsek2erTb5I5omMdwQWUSLtxjqAQM5A9fftT2vPtetWEF0rxWeWdfMkGRtX5W3enIGPf0rg7TUiflzmMk7TnAXPPbpznir93qgE1ncJNGhQ4LDkoCCOh7ZPIx0pWNHU0PW5tUs7SGeK0YKzJkIwY5GMYDZORuA65PNXTdSWFqyz3aPOwCyyNwhA44wcYx3JFee6DfzjWdmoaeXUQtJHGGYpgcF1zk4GR7gV0sUsssU87eW1rG+wW6OHkL44IA6+wOT3oaN4Vi05nmkjt7aRYnYGWRolLpGhP3iSeBk4HB5NdR4dtzawzuBJq1mwBlMuwfMMYGOOAcYIGMn2zXn2ifPql+Y/Ktp0iRQVJLmRiSC6g4YY2jGCOa62y1FrbS4Dp72zTlTGyeYELEkFlIJyDy3Y/qKLGsajlc7O/8q1jjktWNu4bLNK4bcp4Csuc7c9yQR2xXB+IPGOnQxoovkC7jHJNCAd/XoBnIwMg4781lQ+GYfGOpPcXR/s6ON/3ixSEAjPIwTgcDjA9SemK6Zfhp4bghna3tC7OG8tZXYsuATuHAwMevXHvRyMTxHL1PMYvG0UFzciS4lijnYPujDSKv95cHoTjOQOp9hXUfD/xW96ZhmRbNZHEdxduZWbCj5fwBB69OecGsXxP4FN1bebo9pb2yWsxtVAZiblhgu5JJHHYD39qz5/CmteHEW4hjM9pKv2hwELRMEO0Mw6HBJGfcijl5dWjONepJ2uesW97bvdwGI/JGDNLJ2bJ2htu71YdOQPpVXXL2VdMaTzF3zKAPMI2lQeSQCT17nGcd68/0fxR5cYMhlu9UbiOJIwix8ngH0wRyemOK0LmaWS0W2u54pplZZJvs+dqr12k+pJwAKej2LdZrc6qxuJLiIxpNLLettiJJRkgDdBx1bHPy9hxWXdXrzayrxQLM1uQ8pU5K46hWPQ59eh96v6FaRQ2zyMrnZlZPKjG2Fep+YDG5vXnA/KrfhmwnmvFjjiO+ONpJ5GG1Y/M+RQcdeASR9e5qktTOdS6Kt7B/b2rWEXmlSpLvG5+ZV4PX3HX6V3GmQ2trp09/BH5szys7J1IjPCj6AAH8a4STT47LUp44IoUt5QYvlOWj3H5jx0GFAzWlq8cc9obi8uWsrEKQsPIecY6yY/Rfz9Kh2MNebQraX5a+JNbniaR5p7CSKBklACy7hjPqApNbXhZpdP1O4YKXClFlVRzEcY349Oefrn1rgvA1vFL9tkvGdzJLGEKgpsC5yOPYiu88OWEV5qF0ixTF5RsllSQqIwc9T3OO3bNI2iej6PdG4uryWWPKJi3jbGQ2OWIPpk1engid1AcqMcjNVN0Gl2McMK+ZBEgRB3UD19afGI57QSOMKxyCDjioNUmjP1WK3SBslcZ7mm6WkJj2CMnvwe/SjVIreRFA3+WMZNR2NnKAXtm2LjoeM1KNN1qXIo/MvgsQxGvJ9TW0yuzIiDAHLE1R0S3a2DyTsGyeSK0fNS7kxG4AU84HWmkRKWo9wuWHXFYN9Fstp5o+HAx9frXRyyW8UDDdubHp1rJYB7N1I6n0oFFkXhwr9mHmkb65/wARQyXviS0RPlVSScV0dskdtCgJGT0PpWVZRSp4rkklkUptyuT0FA1o2zqVka3tcckbadbY+yqzHk5JzVe/leQrFGAGzzj0qO8ux5OxkaIKp5xx9aZmeN6zp1xaK8iMzmLcwO3DAD09cg5I9c15/qULi288xvbXgdpWkB+XJI2gr0x83PThiO1d1Hrkt7cJaXEto7u3myTMGQSc5VuScE9CBxkVn+JboC7SaJ9NZ5ojFIkM29XBBIJ+XrkdKuSPTi7r31/XUyfB+q3+mXWovHb288nCT26uhG5flYgsT0A4YZGOoI5HR6pq63trJd6bBPHKI2hZHQ/vOCFQlSSGHO1uhBI+6eOOsSpv7eW1VlnuW2rDDH/rGJz5YZs4Z+qsBw3GMGtCe3t3DXi+ckaLvM8qsZCu7DJIB/qyCTxxzSu7F0oWuv6+R0d3rum3pFzJPMIUTPky2syoj7txZwFOSPkIGcZI61Pc64+nxXGpJpV8LCOMH/iZOIIpiBzJuk5L7gpQKpI69enn1vPNaviO8n0+SPJhiR3kZhu3KoH8WCSAQMr1yMV0wtw5kvmuNO0/U7baUtpb03FwysOJVbJEmSCMoflPBGeaLhGTl7kmtWRNeyFLx5NSWSVvuW1rKY9qNyqF/vlBmQkIIwTk85FUdWXTYvDy6Vpn2u7iRX/5YMiszHnKgDJ4zznoPQVY0vTrjVZpZA7SQeXhS0pRU2ry5yMgdXxycH3rUuIBb2sE0dysF20bsFhuGabdgKm9ByDtKngc81OrRtGlBW5mcr4bhluID9iutl/InlvbSgMtywPGCxG1sE+pyPRjt6XTNJt715LQyzQ3O4RNDIAgLnjY3OF7cnj0JqqNKtXt7qbRZLq5MLIgjW3kb5fLVQysE4KgL1AJxz6nYivtP1KGJ3uIrWRFVFkEMjBWJJ8sswJXP907lweBmqSFRqOEVH+k/wDIqPbT6Mnn2l7cPpoJARwHa3H3SxOCWXp1+YZ4zya6Cze4bR7O61kre6fc4nivMtIFz3JGQFByOwGfY1Wsr+3Ry0E0U8cTGOSCKQM7Nz84GQSOSMLjjGepFN0myAvbiHQNTl0zVGQssUSFrS4PyiRXhboRk5YbWwwJzmpNJN2Tj8u68jbXRhehpbO+ZSrs0D+WqyKeg8p9u3GDzkEEZHpWRqsNl4bjeO+sFms2LvE/lqGQtg+USB84Lng4OAecAcSSrqmnQMt/pggSEEs9sgvLNh3KKMSxHnkFW9c1BZapYavHFOb5biyRGUC5lRPKPV3UDAQ8deWxwSc4oMbpu8dPwMqDT7y18yGxklYXMMZme1mZYmlJ2/wko/3lXHHCr71sXkGpotzDe266hcBiBFqacgAj54imCpzjJGT78Gsryk06B0SGeKKT94kmZIWQBScMFwG+UFlJAYHnnFbGooBpwu7i6vNUISS4ImviqBQMfKFwMZxgHk/XihIUppStbT5/15nIapeqNZCa1Hc2qzlYZZYHBnA2ZzvXHmD7vDg8Y9KytT1PTjYCznCrIhUwXaoA7gH5g8QJ2uAcgD5WAyACCK6dNCsUW0guUtxBJHM0klvCAgypZvnfOQqjgkDp61xPi17SOO0SwWaC5kjjmeEr5bbgCUYnCkZOCMAHBGOuatXRxYhqKdv+HJ7ib7UsH2qGK2YSkIW2JLcDpuWN2Ugltoxz9446Guf1yK2JgS71I3DEn9xbwOUXB6M7BFbGcZGR168Vpxyx/abiW5s7eGWW3aFFVEaOENwVy5yrHBG49M8dcmPTLae/NwktmsjxsYFdWWMYGcZB6dOtP0OJ80viehzL6XZ3rF7W2nM4XcYIbhVeTuWUbD9dvPfFZd28cUSW62sTfNv33LlzjrwQBjpzXodtpLXDWeyE22owsrq0UmDJ1KMrDlSDjkHt2rC16xikfyjE8WoRkR3BGWSc5+8QclZM8sM7W6jaeC+hhKGpxM1wLibMr+XHngoBgfgMf40+6jYJHPKn2m1ckLKp2uSOoJ9R7irdzpLQ3DoWADDCHHBPaqkBNjcN51tFcIQVeKTODkEZBB4I6g0XM+VoqKqiVTby4PYSfL+vQ06Z5oXKuCPr/jTrqHy8OrebCcYkxgj2b3qDayk7fujn2pE7GvbtPLbx3FrdeZNC53WwZhIgx95exU5/hOR3GOa7nw94lT+x7JFQ2rIfJeWOJHIAPLbup5I6/rXmHmtvDEDcpBDKNpB+oq9b6xdRXHnsRLKTkvJ95vUMw+8D0Oc0xqVj1O4S1U6ZNbX97Cl072st7NLlCXbK56EJkfMSeMg9OB0IuLh0Sz1K0+zlIhHvhlBRVAA65JyQAB2NcLqviSHyTEkUcmnyRC4s45lLEK3BG7Iy6sGQnGMqSOoq/oP2CWOO3h1OOexIEirKwtpVz1STHzOOOinHOR3Bpo3pVLHqGgyWNxCbbTrCE2yOuZVXIZ/Uk5LHAIxn16V0et+IbHS7eXd5k1wVJWJYyzHAxz6YOOTgD3zXm8F1a3TQQ6StzZK/35TFI6wjByGXO3vgY56Z99W+ttrpb6daXs0blZrk3Ug8yUcbY92BgN1x2XPc0bnQ+XqdZ4WtTNYrazTJOLSEyzToMCaaQklh+O4/l0q/e2SXmm3dgCDEFE8a4+YM2RlRnlNyjPuQas6f59tGVuLtJ7iVgzNFlCzvhs4PVR0GcdO1Zt9qFvby/ugY7NI5TI7AFVyMYyOCMjOQeCuKGx8keXQ5tfCela3NHJqVvm5mbYZYm8txtVgSNvGM7evXHauJ1jwz/wAIxftcQR3d7aCXak24yPCDnAEY6sMY39OfU16dDrVvZ+GX1JURpZoxGmxcs3PJyefvEc/XFNvHnOjzXEsUZuV8qUiOQNtTcMEnJLMT2HTFCSbIqKyuedT+L7VJlshHeWKxxlVE9uVZz0ZQpHX3POa6HSYp0ilu9WivLO0uQZI7SKZUeQDAXzH5OeGyAM1sa/qUMu25vGlvbVWUqLtAyl1YHAwMg8kH2YivO/F/iOz+1eTo6QW9zLuJWIExxA8YIbILdTkdzQ3bcmySXQ6fT9ZknOotZQiMMVj3vlcICTtQHknkDPoPxrK1y/nkiKXcDm7GERCM4z6e+KxtAnuo0ADmWSE/KHP3v8aL7UrmTXhPdFZbhVOxEP3W55NQ3chK/vFzwtqAtrQq7ZnG4RnP8TNyf0/SvWfBaix0+CEuHdyXcluWY+teLaTJGJkfymKoP4QcBu9eufD25F5MytA6QwAYkJzuJ/mOlTuarQ7iC3lnBGRs9jnFbNrHFHYOGxu6lagaNYYVMWAT68VLAoMm1+c5NQat3RBawrKreZGu0njjvVp7cJbbl+VfTGKbG/ly+WeAWwCavaht+zpHH3xTtpqS20zDFjdXK/un2p3A/lV7SbfyZHEiE/Xt7VtwQCO3TA5Aqrb4a+cYGKVhc90xzxRtgrEMk96oA7rlomjAXtW1NHhCSeay5oD/AKwMQc4zTFGVzKvEdGeLaBgZU1yrTyicSE/vSSnPc5rptZDTMnlsd47+1c/4jjMFrbM0eHDA7v8Aaz3pWNotW1Oj0K7LW7GUjzPU+lWtRu1ksthHytyTWLaDzbVY4zhs/ex1+v0ov7fyhEst1znnPHHU59KaM3ueNaBrSJc+aIzPcu2bm2VQZJFxzjsGGM56HGeh4v3GoabcabNLaQlQtpOYmKtCZWCtt2E85DDsc1yz6IQzGylCXCqC0cgAEwbAX/gYO4dfTB5xVe8ia0s7ma5toU3odxgiEiqQQCxAOUPzZyQAckelaX01O1Ll0ubtrJY3ubOa9sURIwIxcFIxJEqLtyeBvAxu4GWUsDzTWS3utRnNxql7c2SES3P2aZT5Uz5AlGW3FBtQsA3v60Jax2I2/brEpLEk9u6bSAoORgjlWByM+jehqtYQx6lay3pmhuAZ3mmQRMzqWOFViB8oYKACTjP40ndGsVGaUebbY1r/AEyw0vUd+gGS0vIUYwu5O8urBWSbnJVww568A9uY7+UXmmr5QizI6bo3H+lQP/FsZevPy8dd2MdcVraOf+1tKsriKS3i3SJGZ3NwyIw5UBCMbSo/iIOVODmmXFu3/CRXC6hcXE9m7RG4lt1DKZAoEJKr8/V2QjAwXQ88ZW5UanJ7tuuvY3NMniMqQa5LMdCDeXPcWqbQpLZ8ufaBvzgBtnygDkdSOg1C6vNPY2oM0MEPyQmOAEheRtO04GAOAewrn44bS7tikcetqyNhIvsEhA54T7oU5GTzgda0Yry+sYBvsWtNx8pLy6m4C7sFRGm5j97oSCPXtS9TeMEnzR97y6lHw7fG31nVSuo29rJ5ENy8sjcZDPHtA7EjHU9qbc6c895JFpW57HUSFlubyN0jmJGSoThmOehG0E4wcipIJf8AiroftySapN9jlhguMJhTuBTYh27BhZO5Ykdea1LkWN556XFleG2Dvufyn2MRxkbOoGDn6fU0ty4vVp6fK/mZNobueKD+05729WAE20rDhzgHOFAR+AQc5JzkjPBz9U0fSY5ZIL/T2sSY91vIFZmUqflbY57lWBwB1x066N75uiXwt7HT5mkb99axXcJwq55kTfxzgcYIPfoTXP3Uc2x42kMZkdso/wAxV8qTGkgBHm/MMoFAXIOT0LaM3yRbTXuvyf4P/g/fudLFq8cqi3066uI7qNlBjtLl3hJOCH2SiQKhGMfxdQAMGrGp6FJqHkTX3i3Rmu2ZBGyQCHGPl3kxyDeRn+IHqe1cAkTadeG9infTryMnykmYzKxJJddxzk8AbgDzjnFbSateIge3vrLyAS2GZbeRAR/EgGdwzyFU+2aVzF003Z/1+Wpp6tc6haRvZG90PUJlD7fs5ntm3Y/1jAN5ZHy9cDOMY9eYtgjmOTUJ7uwgkXz7iTzc7ZMdCDL0yN+ApY8YHNaN9eaqtkdQaKNzIqKqG5hBJ/gBQgNkEjHA4asHTLjUtNtpLhbYm+imURTsU3wzKwK+Vk99o5I6cZxTv3JlBL4Gvx/yIdWkT7KkcdlqU+wmSO4vrl4VwyklUV2xtbB24UE5xzxmvpa3FxqltALi1kt7RZZoFh2IhkcrukXIIdsswB6gLxgAVc1i61XWr+P+1jO01zdOtxEWUY8sbnQnJPAWIDOMY4qotnPqWpNMykmJI1cxHkMOd3oMDHXNHMc3snKfNf8Arcm1nRb63jeSYuTGpkyk8L5iON+Qrdvp2rX0WyvI9SuiltexXjxNIkaxq6SruB2gAZU8Eh+RkbSMHIguUheLLxeUZt2TLM+ct/ER6DP5dq0dP8NPrOjLdxyRiWL/AFgiRRsZccD8e3vnvVrR3RlKLfuysivNHctMJ20+aCWIGMxyWzw7huyAQchWHpisZcX10rKsjTTy7XhnAXc+Plw2MdiMfTinW6rsDyF0vBwkyjjCsQdwPUAflVy6ge20+Qt9yTDEkeZDPgg/Kx5Q8fjTuYuD6mFruiXUClGgMgySsWCWBxk+59x1rFn0CTCuoAEi7kOdwb1GfUf55FddJNaBo5rSGQL91C0e0xjn5T0LZ4wx6dOeMWNU0qPR5S+oSXNhaSr5scqRs8M745V0BO3OPvLyOMihq5FrbnmlxpktswwjIxOGVuhH8iKoXNnEJFVMQuc5QtlSR3B7fQ/nXoV7a3NxFFdXoe005/mha7XaJOfuLIBtY+5A+lc1fwxSXPkWUO+OV1QHrtY8Y3d6m1iZRUldHIywPEf3i7T6GmiJ9wxgrnrXQ3OlyQQZUlFB2vHnkEccg1kzRLC4MkZ2g87OMj8cihMxnTcSI3DtYLE7sGt3LxA9g2Nw/MA49zWv4S1eLTr8yy+YowMFVEnlHOS21vvDjkZB7g8VSnt7eWN5rNskL88LHDDI7D0+maoFCXCxkAoOmcGqM9j3rw/4g/tXTdiXdrFBKuwzeYEkibuCf4xxkdM9sHIqW8vF0+4QaXLqN99nczXFy91vaNugbYzAbz0KjB254PBrwzzNR0sR+Z59us6eYqkkLIpOM8diR29Pauw07xxp+nafElhpQtrraBK+fMVzgAnOQff+eaq/c1VTQ7pdeu9VvBNeQXMKBW+yW6SjEvPzO43AEZB4AI7H1rX06OLXryaTW9Rlvoo4z5FkgAQOMH5gP4QC34jpXlQ8ds/nRyJBcWLuGW1uoN5B77XH3c5PrjNQ3Hi97iP7PHFHZW8RLtbQbwje7tnLdhjpS0Roqzatex6f4jkuCvlaS0W3S4Fu7qN5siTJAjjU4PzgNuYeg554p+neI5dQuV0uS2MUnmBbl3JQInUqO5JAwCOOc5ryeXxky6abSxtnj84lp5ZJctI3r7DrVS+8W6neqM/Z4JAc+bChDgegJJx+FO4nWvoz0jxX4nj0nUpLK3lW4kRd48uTIjPUB2yfm7Z74GcGuQtZY7mZrmVV+0SsWOONuen+NcjbAzXZebMjsxZmbkknqSfWuns5YIEZJbdHZ2DLKCyunsADgg+4zx1qG7sXNKSNaKB7SIyRu6yHJPoB7VtWOhJc28bb5EuZgM88k+lULJQ/FwHZAQzEc7VHbHua6/wdqFn9uklvJUWJBlVc7Sx/Gkio6q7Niw0C202xuIULvGpDOvcnHTNdd4EUraqABuZi/AxgGmwWQullJKuJzvdVPRcdDWn4cCDVMj5FI6E0nvY3jtc3NXMnlIicEds9Kt6VN5rMX5ZOuagvTuuy0WSPaqOlyvHqIt1wxlJJ9gKz6mtrxNqd/MhZowd6dPel069+0WpaUESIcGtCG0C4UDjH65rK1aFreYPBjBPIpshWehtxXYeAbvwz60sK7ELEYLc1kpLHc7UQ7dvp/WrbtcRx5Ygx9u9BPLYma6ebciA8HH1qnqd2YbEhQS28A+1WLWQGJig2n0xWRHcpcalPFOh+X7vofSncaSNGKDfFGzDLMASfWuL8S3KxXSRsS9vFJ85B6dMV1Mt3JDkSkKinAx6VzGqCK5t54AmPMOSO9MFroai2cctks1jcDLYIweg9KxtXx9nlnvZc+WpAUZNa2gab5GnqYHIKKRg9sVgpYT3s1490shRSDH/dbr09Txz+FA4pPc4fXIkvLTzo7VlfyWjDRAE5xlWXHPBVT07Ed6ybxkuvIuLmeWGyuIYy9ykJLkSJkrt6ZAJYAkbghAIOK3RcfYbYQb+IYxEYsZaIo24FCOcYPT249KzPDF3bvp1havJEFjnaPzi3yRlJZCiyL3jZjFhj905B4IrRrU6eZxV2Uit5YXGY7xLKTYtwskDF4psDJKqeqk7WwMfxfQaEl7FFo+nXkmnSQXIjEGJXU27huq+b/A2eQGxgjIzk5XxhFb6bD9kRxbafdjzLZ7g7m0y5BJK57IzZDDoM7vXNvRr5dO1K8tpdLMc8axmWyMJuLdgVwzBxztY5OfwNJdiuZNprT9TntVk1q4S0l0+x+zmO4ja3eVxJcJKpIC7RnaSMjDZBwDg4BrWmsYo/CrNYwNcw32JnnLl5ZC2CHB4O4ksSD1K47DFi3gsIbiNrT7LazqQzFCeVbplc7QATghcHmrU8D6bfxpbyxWkeoAtFtG6KK4OS0ThuVSQbnUHJDK+ByKXKbuUW1zf12J9NlsdQ0iwvDeLGcyR3MD3B+STK5ypO7qewxhsmup0vUtJubX7NcaWY50jJzHCY9/A53cEkYzn2561xVokTeJori1ubazupoGt5IUPmRG4iIGGUYzHIgJDDkFCK1LW7tbiR1vtIaKdITKRbEMmQufNH8WMDJGDxn6Ukjde8nzN6f1/TMvWLe0j1TWpRtt2tUiFplXTMq5lKlumCXUE571swWwn05L+C8ENqAHAmuZGBXAZxhechck8+prC0xoL+yEsjbJ7l/tUrRggjzZkG3G7n5XVeR0FTTSC3tToUMMZvxqRRYIgQ80LKJSH7BFyIyeCOcZ6FpJFus4JNO7HLai9vryC3UC+uDFHDsYYs7ZVDM7Hu5aTGOPnB6hTVGXTYLOe4tbbzp1tQvlBFIJuOCS5zysat94YYtIOuDT9P1N4rfUtRvJ7ZdQM0t7czyQhTIqMVXyt3ZVA425HXqc1d01ZLLQ082JBqdwVnnkvFbf5rks3lp97q3JbaDtHOMUtHqNXfuy1v03f/AAChqi3Nrftc6vqc2rQSo0zTKI2kHGD5ilWCj5vvdO2B1rndtxC0dtZvDtkTcsqvvEik/wCrLL1AyT688Guyt9HWRR5OrTR3GMsQ23zSMnkR4649T2HtXM6x4dVYdSu0uEjvYZ9z2kcYCldufMjbOAQNxx0JU9DzSd+hnUg4rW2nyKG+WMyvJJBHFC2fKljEiSdt6HHzDI4zg/LzVa2Mr3KymRZYEHneb5ROxuAQTnt8mT68diauppsstq9zZrtNq4he4tXXzIXbgxGEkM33cZG5cAkH0dDqo03XUK4tJoGMp+x5geIEYcjPTAGcEEgg8HNI55VNLmXqF0sHijdezQt9nj/fNHGTiTylDkfMQRkhCVyDtB6Crfhm5eH7QJzJBNqfL/J/EzcoeCfugdMd/Ss+RLa58T2IWVBayRFYoriPeqkMFRWxsOPutn5cdcYGK3LyTVNLSLTZ1hlniH2+KfLRuREGLAq4PzJxnnDD15pre5yqejU+/wCLNbVfKvXaZIcvtU3A/wBZubBGRwMAnBxirdnIi2CW2n2ssTSACeTftVx2b2Pv3FJczXNxbfak0K4hZXKgQ3cThXU4PzFhwDkY5xjmqt34htILF2l0zUbO8ZPL+TyzFMp6ghZMgkdxWjQnUjy2sY89jPa6bb3JiDyrLl1LYwN3IIx05qvdT3Nnp8sEbN9kuRvWFjnAPDL+BzV3U/EFtBZyQx2+oQziHyRDNaspRhjac8/KRx+ArnJb6I3OyORi0MbtiZGQ5C5kGCOuAx5pehjKa3Z0ts1jc6NHYTtHI7qGglJG5UA5DZPBBwAe/wCFVLWTFxpkzztJBMz77Eys0OxOFbn+Mtkg9sDFVrT+z47dJhqNnI5j3SLC6sQMcYGcnAPNOs9OE0caxhUZSVVVyMoQCD/31u59qLtGigpbu5s+ILy0vBLb20cSwmUSF7hd0gY/xliOcdM1lXWn2vlHKO833h5fJEinOfoCAfyrRjtprSCVvMFyCvzK3zKfb2NV7UzaNqY+0wNCl0gwoIID9lznpii/U1cFHTozEuLO41a41fWLwRCVruWe5iJCmPe/LKO6hmwQORkHp0xL/Q4BaiS4ikSGYlFCYLKQOOP1P1rttVeGS/vDKiSRXKLdx7l+XzFAV+cA9QpwPXvVDQ9LfVtQhlu5XtxKxS1kkfbub0Pvxx69OtPRnLKFlboecTaEY8F/uLyWHpWZcwlLlJLiEyJIu8fMVJ7fe9j65r1HxRpbwXQt1G6CIZ+9vLMAAWPA4znAHT361xt/bB22K7MkSkgY4XJ5HtzU7GM6V0cuLeGQJ5brE+1iwcnt/U+3H0pskMcIHmTBlb0RuPx6U+4j+dsqVpWaS0ePyJW+6GPHQntg9aaZyuNiCG4WCZJYkLMnQsfbr/Wm52W+P4pDk884HT8z/KtRLi1urbyL6yhjkjDObqDckh6cMmdhA9gp96zp49r/AD8hwCrJ0Ye3+FNkjEB3oM8+lADsoYhjj0FPSPDfKVPBzzz0prIVj5ypFAGpo+marfySf2bp15cmNfMk8qItsX1PoK0LdmJC7TvBwc9jWHaz3GCqTzorDDhZGGR74re0iJmMcUEZdnYIqqMliTgYpSt0NaV7m3ppdsoztvPXPf0rpNNtGN1FHLHJJI5wsezggc5yag0HRriHUpIriMrNCfmVh936/nXqWkeHWubyGS6zmJN+1SflJ6D8qm3c6I2eiLWh+HWXTzPa2tr8/wA0isgZ1H+zj0o0LR7K11uW5RXknQA+cxPHqAM4Fb1rbSaNE0sLOY+jK3UCqGoo8enzX8OPMuCFwOnJzuov1NFG2h3GkES2j3GRhlyBWbpEZXULmV+GYgIfaofNlsraGCAgu4G5eyrjnNQapqsUZj8klPKHUdDU2K5uh1Ul0VjUuSDnGB1NSQxC7kHnLlRzg81zui6vDfocxnevAB9fWtq3v/Ll2nIfHFANWV0Utos9XZo1zE3BHp9a6XckkO5SuT2JrL8l5JUfHLVNewyRoWTgAUkKXvMmvo1ht96KFbGcelYV5dJb7ZGAJJyeOlMNxPdSKGkMaqck4qtf2cck27ezJjA5/rQVGPRlHVbyPz/OmZo424C/1rJS4ZdWjuYwZojHtbA4zmti4jVY8SrwvCqwrjdTv5tMvA8IXJbGw9MZ71SYpRaWh28OrNFpcrIoPm8Lntk960bYGKxXzSFZuQo7mvNtX1NWubZ7YtHHkSYPQn39Oa7Twxf/ANoKZpT5vl4Cfp1/GnYR5Ppuux25xeppkcvyPazRSMwd1bowOSMq55IOdoFYNtb3VwjX8MdraKxnX52yJw8rsQeMMQCF7cYqe++xIZpNPZmmjywVUZYzjoWY4x245rZ0PTra1EdtNb3OI7aF1MkbNG6umQeCSA+C2fftiq30Z1xXLJMw7k3c1o9rd3BNkEC5AjbAz0lG7JUDo2cgcE4qM29xY3scT20izxRLIbj7Q9zBJAD8u4x5dVwQMpgEY4yM12EegQXXyx3zRHJKuo3DGPQcj61gPozWepwwSvc28UkjK8Krx8wALDGMArk4UjJXpUu+5vKnFrR/15Ezatb3mneTZOby+XKR2TuLktuJX5WKEsuSh6A4yCAeaTT9ZhTT/sV9aXM6z/LPE5O6Vt2C2ThkcMoIzgrgEHGKwdYtWt75U1KSO6ghJEVxGvmJK38Tj+JcDC5453DqKfLfBZpoLOWVre9xI8H23cFkABxvkI4wBw2RwKOYlQstXdf10Lep+IbyCSN0uZ53hmF1azvatHOrBsHzPkwwbBUspweSV611N3rthrthDY21xYFdQYR5ZgHtoyAZS+4cMASmD/EwI6VzEPii5NtHstd7x/K85Qb0Vhj5miwCMg4yc89TWPaxodT8+5jmvnnYi7FiDbkDaSGjZsFmIBJBJ35PAIFFxudtY/PT+n+Z3evSr5TWlvEZbiFWCqjCRBs+YZJyVQY6DqRgCsm1nePxXI1lcmd7mHyGnkUpvbHmfKCCUUKRhRycd+tZqWkVrAlxp98QseGEDW8ZmA2liSq52EBedzBs54GM1T+2TafDpwH9ly3cu/Y00Z2gsrgs+84JDEYyMZHPANJlqvF++7/1/Xc6dIP7UsbXTcnfdag0bNvG5ow7SyYdumFjAxx94euD1mmXjT3Ekcboboj94LgqCQw6hSRnJzxnhhj0rlvDOg6rbLFJZ3mnwpBbtaxR3Ebu8iMQZJMNgqzlR17dhnjSudjyvJd3t/eXqBo3TeILc4AzEfLIZ8gAY3HBAyO1NG8G0n7pvarqMFkUtbtoLu+wMW8EYmmUdckDO38SB71yHi7fqetQK6C1tZWjjNp9p8xgjOq4kcZC5AY7OffIrZuNWitbS3S3u9M0/wCY/u7GxUBRtyHIBOTjpnnJ9q5++N3cG8vIlVY7WJJUV0ZFVIx5xZsE/M/PHf2FJhUTcfeEt/sUjWk1/NO9y1qIYXs59rAnbnaewGWyrfJ8x4FZfji1vYrBPtxtZo/LPlfZGjCrg5LbVOHPABK4HP3RmtH7WIbDRZvKX5LQSuzfPNcMojGwLngAggDAHXrgmq/ii3QaXe3ccUSXM4CqFk+VVcjEfqfr3oe1jmlZpuxxM0zSSyiafzwFMqGXCOxUksrBupOG4zz0710DeJF8oQTSRzLbQXCW7TqWcF8bUJPRh8wDcEgnOeQVsbCayuNQtjMAtlNHNI8inYqKqswK5+bl8Y9/Tms24BttOnnndVgvVFzGUclo0EhIyOi5I3AdQHFJaHLU7f1p/X5HX+HPErzaTZ6arW0MMES2shdSdzAbmYHpk53df4qrTT2V5ZvqLQbU+aNS+5IkkDsqqvHXapOOT1rC0e8tlih3wvcQvbqtzApK7ynGVzjLAbWX1Bx1PGiZLVWubRZJL2zEqy2tyPljAlQMQUzhSSD8wxk9cHitUzLm2iinqUsV6JoJblrqaNo0tmiU7clwM+oGAcVnXMrOkbIYxNJcE/ImxWGF3LgejcY6c+9T3dkoIZ91vJJcwxQ4fJAG4yMO+BlOvc1X1VZI7aQo4kgE7tAyLtdVwFLfQgfmRmpbEo+8aGmmG9heyuo4I7RGLwLJEpMmPvojEZAU54z3/Gtbw3p0F7Iv2a8lgkeFxGT86PIhBwVPqpPTGMZ7VQWF7nTFkSACOFlb93x/DgEfVf8APFGmXraRfPFHC90gkint5Eb5irfIVI9SCV9jRfubKLidxZWaTQRGRPKIXZMxG1S4b7uDzkdfcVneJNMa5haaKX90DtR24Vm9h1xVNNZthrcbWNvePC6O/luOdw4yQemBx+FSXUl48yST2rRISTD84Ib1FDaOiKund3OfW3d54rq48w6fFKImdznbuGGBP90HHPqOa7PTbS1n0c6fJarPFyoOcjAbII9PrWHrBnsdBvpYJYXa7CxSWZUkuxONyejY69jik0LUb7T9KUm3lnsEG0ugyYvXpyR7HkURaRDjZtMgvLaSLWX0+5nlMhX/AER5PmLoCcqx/vL+o5rA1zSHSQTuFMR+XfypOOf5V1kpgvZom85HhY7JJgw3RscFGT0IYDmq+vpcQpFa6lCj3EYV0mH3JR1PH8LY6qfwps55LeKPONX08RymOJFkQjI/vH/GqKaQWxKjIcL93J3L+Fd/rWmLFZSyhvLkiIcKyY+TGRj+VVLPSru60C4vGjjeCIp5rbeU3dDntQkcsonD2Wl+Vo2v3k1zGk0EcUUcbLlpS7YO30wBWSiEjymAZAMgnqh9RXbXtrGNFntfs9wZnullNwJMqFUEbMdzk5zXNXVrcvcCRYX2j+ILgAVUtkjlcbNmZc2clsxEoUqwBVk6MD3FRENgFS2Md62IY/NjaKU/Io+Rv7v4elZrh1lZMoqqMHmkKxJZKHJGACw5IrqvCzGz1O2nL7Gt3EiNjuOn61z2kCJGO4nHr610docyxzxpkRdR6j0qdnc0itD0jwhK+oa7c3N4+S5+0Tv3PfH+favWdDMkNm13dBR5rbsdcDsK8U0C4IlTJGZmEkpU/cj9Pf8A/VXtUOpaQNJSV7hcBQCN1HQ0jZMfquo26WVxMT8oQlgTXMaTrkF/pDXUqZtrdisKg5809uOuKzvFWrafremDS9LEgupW+dhkBV7n6YrS0PSIdPt7W0tclPvZODhvr/SklY1u5bG5pVjf3WnxveOYlkI3E/eA7A1sto1pNHEtun3eNx7/AOIpEvTZQrFdfM3ADjvWno3lpGZEz5ajAXGcfSk3ctLl1MBoH0nVIyABG3Xjt61vyRtcSI5B244981HrqLcwNIAfQHFGgXyXEKwSD94gGR6CpXYqT6mjppkleTL7iOmar393cFXgSItjjOaad1rK8iNyeuRiq88sziT94CW5GByKGJLUja4KmO3SDfnqccH8ajlY2Tj7RHlWI2r3zmoDfyxMscC4m6FiMHHpWNqtzcyX1skr5dpM5PQfWqRTi7G/rNnLdxxzMQjDkKDjNeb+INNnvdYaHztuFJLZ9+OPavUTZz3BVpn+RcBQRx9cVQ13QAwSaD5Zx95+9ARlY810PTCmtrFdFmgxwG5wfrXXeGfJXWb1bIELw23+AH6/0qhqsT6bcOsKGR5FJYY5BxT/AAwktraiOCctdTks7Y4XP+FNClrotjz9Li4vrSEFPtts3Cu+FYfUngGo9MuzZeJYUM8yQW0IRVkxIm3duEWQemCx46ZpPBsY/ta3XdIFlRHdd7YYkEnIzitrxJDCb1SIYk2bWUIgUA7j2FXvqdMZXun6lia6Z7hmgiRZjjypfNIULkYDnuPQHB468VU1oT3lhC0ktzcTibyoY42EcbM4ITbtAJw3zHJOAD6Vn6OBLcSrL84ltmnfdzlwwG7nvV25QJf6eELKosjdbVYgeb5yJux67XYfiaLXVzbmS9SnoM8mnwG3ee4srtCwmzGJI5v+mq+5JO7rnOfaqPjW309lt2s3jlnkba+XUK8uNwVD12KBlj1GQvU11viP9xo8F7CAl1FZvNHKowyOp+Uj0rzmeR49fuCjFfItVWPH8IZSWH49/Woeisxu7fuaFu204hZZ5LzMaMR5j/Myt/ECo5HPpxUV3DA94A12kkUqiJ54EKbjksrZIyW5PPXj2rWiY2jW9zbExzzxfvHXqflH5fhUus2lubu1UxLjYX9yw6Envjt6UcmlzX2klGz2/plDUUhvk0+xv03Si6RZHS3Cu0ADlpEZvm27V+7nAJI9KxtDkifUYL8xbi7PLFbSoZNsRACsFbIIO9sDsdx70njTUbxNav7cXEhit4ZUiDncVDIQQCeeQB+Qp3hhfP1uASM/y4hG1yuEAC7Rjtjj3pddDldSLfNbb+v8zuILoJaRw2UhsHn4eYyYZVH3swnODyAGBHLdeKsSzXiQyQLNDd2CL5aNaW6ZQDgAI3PbqCelYlrcSz3WpPK5LwbIon6Mi5bgEc9hUmjXdwdUtoWld4nkLsrncC2cZ57470N7I9CnCVnNEti8jXRhjneCayjIK+Su9cscblCgjAIHP51S1iS5k0PVmimmWKZ5MRysu0s5ERbhRk7snjoAB71JHK41p3BAdLu4KsFAIwvGD+Aq1JIx0HwbdEgzz6jK8jEcMVaRhx04IHHtTTJrJpJPqiibq8W13hLd45La3iDshiYq5ZlC+g+UEnrgZ5rD1XVXubdI2mieGGVQfn2BmJwACc5KqCcnu1Ubm9uU0WPE8nztbWrZbP7oxYK+wwoH046E1fv7aGLQrWdI18/7QVEh5YKEbAyece1K9zhnUuvkVHvby7k1OyhMgsZX3yPGdp2bEA3Aj7p2gdt2ew4Lr9Et8rNHI83lhn3jLdwVUDhRg46Vl2h22N4o6SziJ/8AaURqQPz5p4ke4nsJJ5Hd5mAkLMfm/dk8/jzRc55JWd/61ImkXTr2eC3ZnjuEC243KTE2VIyDnIOCo98YJAxW/wCFIIrjWpUkuJI4XQPiVgFZldg4APGMMGKnjrWVaWlvfXLrdxJIrWiggjGcu3p34HNZFvf3UVpKUnYGa1jEh67syAn88Dn2qttzG7WiOm16/me4+320RNntKwROAWijViyjI/vHJ55xgZwK1vDkEd6stxbPHJALeGPc3P3gSw/M4/CsXxWzW2jRywHZIyHLDryKveE2a31fVYoWKR+bE2wHjLA54o6lp8rVjS8PWt2Z00uylidbjekSmRV3mNmwELcFiwGB334qjriRW1xez2zSrNHIVa3nHkuAR3U9GV1HHv261SuxjQ7W5H+uF63zfVmzTtTZtRsJzfO07QwSlHkYlsqCBlupxgdc9KadypNwT7C294TfteXcs5jZmaQgckY+8M9cd/Wtg3QjvI2tozcROwEb3EmyMH+91zj6DmovBSq0cTkZPmH6HJUHjp3NSXztYtfW9ofJghv5Io0UYCrxwPbk1Nram8NdEWJxFJeNc+b9pMWczgEInrtAyAOw7mremXFumlpLEzrOrliQPlbP8Ljv9evNZmpTSQeH8RMVEs2x8dwFBA/Op7FQkDRqMIQMiqWjOjk9o3F9BZDLp9vfTXGmw/2RcqUZWAcQMf41/iH0HTrWPbXm2NrO4vBNG42CWaTcuR/C27ocdK19Vupm0e8maQmSO18xT6MEyD+dQaLDEZrOyMSG1kaWF4yoIZVQMufUhiTnryae7scc48jbMC91KWOBLd7jzrSHjYy7sKeMbvT60y0vWj8xQtzHBcJ5bIkgCvjkZHcVdsxu065Dc7ZmUZ9AeBTbu2hbwzLKY18wMVDe3pST6nNKF3buYV1cXMlltikfywzHLMCdx68CsS6h/fuGZ9qrudsciujuAINKhWIBQ2S2B16Vh6mzC7vUBO0qoI/Gg55KxV0ySG3lSS6DeQT8xA59h+eKzL2SNru4AGY1c+Wx647Zq5OcwID044/Gm2UavcSb1B+c0+hj1J9IVInWSdSU7ADrXY2Qt5GUIwy/AUGqug20LaNJI0YLg4BPYc1oRW8VvYIYY1Qk8kdaTRpFm14aS2srmUXrYbO5RjP/AAE1q3UbwXIvbWMvbtn91n3rkcfv4253YznPfivSdKAms/3qq2AMZFJGsSpb7LXT5riWNRdzHAI6Ae1dB4Zvo5tkVzN8x4JI/WuR1KV/tyR7jsDnAr0fw/p1oVgYwJu2bs+9SdSTsbz2Di3LLIsijkZ5q/osamMxr8pyc4GRRIixwsEGBjpUfhd2+3XC5+UN0pWJb0LGqs9tFtbaUPHI6+9Y/hoTDWZpNpaNgANo71ta4BJNEjjK7ulU9B+TUJFXhQBxS6jv7po6jA7Mpb5UbqMVHYWib3XadwGTmrevOywLtOOKi0wnyg2fmIPP407akpuxUvtPijTewAfJ5FQX2n26LbPx5jPkHHetHUTu8sHkHkis25Ytc2qscgFsD8aew02zYMgUxxsM/wBKuzxoQGbGQKpW6grk5yGHOfcUupOyMdpxwKLkNanl/iqaWHxeVjOQ8TDbn0//AF1Vv9Vg+xRQaY+Lgn5yvH+RSeKPm8USOfvLBwfTJ5rO8Kov26Q7RnrTfY1h3P/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Characteristic dome-shaped, shiny, waxy papules are present on the penis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_29_11734=[""].join("\n");
var outline_f11_29_11734=null;
var title_f11_29_11735="Classification of lower extremity chronic venous disorders";
var content_f11_29_11735=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Classification of lower extremity chronic venous disorders",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/29/11735/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/29/11735/contributors\">",
"     Greg Moneta, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/29/11735/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/29/11735/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/29/11735/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/29/11735/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/29/11735/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/29/11735/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lower extremity chronic venous disorders encompass an entire spectrum of morphologic and functional abnormalities of the venous system. They can present in childhood as congenital lesions or early onset acquired disorders which by adulthood are quite common. Vein-related problems may or may not be symptomatic and include a wide range of clinical signs varying from minimal superficial venous dilation to chronic skin changes with ulceration.",
"   </p>",
"   <p>",
"    An overview of the Clinical-Etiology-Anatomy-Pathophysiology (CEAP) classification of lower extremity chronic venous disorders will be presented here. An overview of the clinical evaluation and management of lower extremity chronic venous disease is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34521?source=see_link\">",
"     \"Overview and management of lower extremity chronic venous disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard definitions for venous diagnosis have been adopted by international consensus [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11735/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Chronic venous disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;This term includes the full spectrum of morphological and functional abnormalities of the venous system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Chronic venous disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term chronic venous disease is used when morphological or functional abnormalities (venous valvular incompetence) are present of long duration and manifested as symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    signs indicating the need for treatment",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    further investigation. Venous valvular incompetence is identified by duplex ultrasound as retrograde venous flow of abnormal duration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/43/33462?source=see_link\">",
"     \"Diagnostic evaluation of chronic venous insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptoms may include but are not limited to lower extremity tingling, burning, aching, pain, tightness, skin irritation, heaviness, swelling, fatigue or muscle cramps.",
"   </p>",
"   <p>",
"    Venous signs include dilated veins (eg, telangiectasia, varicose veins), leg edema, skin changes, or ulceration.",
"   </p>",
"   <p>",
"    The severity of both symptoms and signs of venous disease tends to correlate with the degree of underlying venous valvular dysfunction. However, minimal visible evidence of venous disease may be associated with venous valvular incompetence, especially if the patient reports symptoms of limb aching, heaviness and swelling (",
"    <a class=\"graphic graphic_picture graphicRef70438 \" href=\"UTD.htm?33/60/34766\">",
"     picture 2B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11735/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43365?source=see_link\">",
"     \"Pathophysiology of chronic venous disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Chronic venous insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnosis of chronic venous insufficiency is made in patients with chronic venous disease who display more advanced clinical signs, such as significant edema, skin changes or ulceration (",
"    <a class=\"graphic graphic_picture graphicRef56758 graphicRef71020 \" href=\"UTD.htm?36/39/37492\">",
"     picture 1A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/43/33462?source=see_link\">",
"     \"Diagnostic evaluation of chronic venous insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CEAP CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An international consensus conference initiated the Clinical-Etiology-Anatomy-Pathophysiology (CEAP) classification to categorize chronic venous disorders to facilitate communication between practitioners and serve as a basis for standardized reporting during scientific analysis of management alternatives (",
"    <a class=\"graphic graphic_table graphicRef52388 \" href=\"UTD.htm?10/45/10973\">",
"     table 1",
"    </a>",
"    ). The classification continues to be updated and refined [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11735/abstract/1,3-6\">",
"     1,3-6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Clinical signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical spectrum of chronic venous disorders is wide. Some individuals with minimally dilated veins (",
"    <a class=\"graphic graphic_picture graphicRef62119 \" href=\"UTD.htm?17/58/18351\">",
"     picture 2A",
"    </a>",
"    ) or even varicosities do not have significant complaints and may not find the appearance of their veins concerning (",
"    <a class=\"graphic graphic_picture graphicRef56463 \" href=\"UTD.htm?21/63/22514\">",
"     picture 3A",
"    </a>",
"    ). Others find even the smallest dilated veins cosmetically troublesome even in the absence of symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13592?source=see_link\">",
"     \"Clinical evaluation of lower extremity chronic venous disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The visible signs of chronic venous disorders are categorized as C0 to C6 depending on appearance. Additionally, patients are classified as asymptomatic (a) or symptomatic (s) depending on the presence of lower extremity symptoms such as aching, pain, tightness, skin irritation, heaviness or muscle cramps. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13592?source=see_link\">",
"     \"Clinical evaluation of lower extremity chronic venous disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     No visible or palpable signs of venous disease (C0)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of symptoms, patients without significant visible evidence of venous disease are unlikely to have venous pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11735/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Telangiectasias/reticular veins (C1)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Telangiectasias are a confluence of dilated intradermal venules &lt;1 mm in diameter (",
"    <a class=\"graphic graphic_picture graphicRef62119 graphicRef70438 \" href=\"UTD.htm?37/62/38881\">",
"     picture 2A-B",
"    </a>",
"    ). Synonyms include: spider veins, hyphen webs and thread veins. Telangiectatic matting consists of typically fine, red vessels (&lt;0.2 mm) that can develop following any venous treatment (eg, laser therapy, surgical stripping, sclerotherapy).",
"   </p>",
"   <p>",
"    Reticular veins are dilated bluish subdermal veins, 1 to 3 mm in diameter (",
"    <a class=\"graphic graphic_picture graphicRef62119 graphicRef70438 \" href=\"UTD.htm?37/62/38881\">",
"     picture 2A-B",
"    </a>",
"    ). They are usually tortuous. Excluded are normal visible veins in persons with thin, transparent skin. Synonyms include: blue veins and subdermal varices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Varicose veins (C2)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varicose veins are subcutaneous dilated veins 3 mm or greater in size (",
"    <a class=\"graphic graphic_picture graphicRef56463 graphicRef68551 \" href=\"UTD.htm?15/19/15669\">",
"     picture 3A-B",
"    </a>",
"    ). They may involve the saphenous veins, saphenous tributaries, or non-saphenous superficial leg veins. Synonyms include varix, varices and varicosities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Edema (C3)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The edema associated with chronic venous disease is due to an increase in the volume of fluid in the skin and subcutaneous tissues and will indent when pressure is applied (",
"    <a class=\"graphic graphic_picture graphicRef70438 \" href=\"UTD.htm?33/60/34766\">",
"     picture 2B",
"    </a>",
"    ). Lower extremity swelling due to lymphedema is often confused with that due to venous origin. Venous edema usually occurs at the ankle, and may extend to the leg but less commonly extends to the foot and toes, distinguishing it from lymphedema. The evaluation and management of lymphedema is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=see_link\">",
"     \"Clinical manifestations and diagnosis of lymphedema\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33817?source=see_link\">",
"     \"Prevention and treatment of lymphedema\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Pigmentation or eczema (C4a)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pigmentation is a characteristic brownish darkening of the skin due to hemosiderin deposition as a consequence of extravasated red blood cells (",
"    <a class=\"graphic graphic_picture graphicRef56758 \" href=\"UTD.htm?3/63/4080\">",
"     picture 1A",
"    </a>",
"    ). It usually occurs in the ankle region but may extend to the leg or foot.",
"   </p>",
"   <p>",
"    Eczema is an erythematous dermatitis, which may progress to blistering, weeping or scaling eruption of skin of the leg (",
"    <a class=\"graphic graphic_picture graphicRef51553 \" href=\"UTD.htm?41/25/42399\">",
"     picture 4",
"    </a>",
"    ). It is most often located near varicose veins but may be located anywhere on the leg.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Lipodermatosclerosis (C4b)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipodermatosclerosis (LDS) is localized chronic inflammation and fibrosis of the skin and subcutaneous tissues of the lower leg (",
"    <a class=\"graphic graphic_picture graphicRef65447 \" href=\"UTD.htm?11/14/11490\">",
"     picture 5",
"    </a>",
"    ), sometimes associated with scarring or contracture of the Achilles tendon (",
"    <a class=\"graphic graphic_picture graphicRef76901 \" href=\"UTD.htm?25/57/26527\">",
"     picture 6",
"    </a>",
"    ). It is sometimes preceded by diffuse inflammatory edema of the skin which may be painful and which is often referred to as hypodermatitis. The differential diagnosis includes: lymphangitis, erysipelas, or cellulitis.",
"   </p>",
"   <p>",
"    Atrophie blanche (white atrophy) is localized, circular or stellate ivory depressed region of abnormal skin surrounded by dilated capillaries and sometimes hyperpigmentation (",
"    <a class=\"graphic graphic_picture graphicRef67105 \" href=\"UTD.htm?28/43/29360\">",
"     picture 7",
"    </a>",
"    ). It is a sign of severe chronic venous disease that arises spontaneously and should not to be confused with a healed ulcer scar (patient history of ulceration is lacking).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Healed venous ulcer (C5)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Healed venous ulcerations may also exhibit atrophic skin with pigmentary changes (",
"    <a class=\"graphic graphic_picture graphicRef56758 \" href=\"UTD.htm?3/63/4080\">",
"     picture 1A",
"    </a>",
"    ). These are distinguishable by history of ulceration and appearance from atrophie blanche.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Active venous ulcer (C6)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venous ulcers are full thickness defects of the skin, most frequently in the ankle region, that fail to heal spontaneously (",
"    <a class=\"graphic graphic_picture graphicRef71020 \" href=\"UTD.htm?13/14/13536\">",
"     picture 1B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;From an etiologic viewpoint, venous disorders are considered to be one of the following:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Congenital (Ec)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital venous disorders present at birth or develop in childhood (eg, Klippel Trenaunay syndrome). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30038?source=see_link\">",
"     \"Vascular lesions in the newborn\"",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Primary (Ep)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary venous disorders develop independent of other disease and account for the vast majority of cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Secondary (Es)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary venous disorders develop as a consequence of another pathology, such as following venous thrombosis or trauma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23127?source=see_link\">",
"     \"Post-thrombotic (postphlebitic) syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Etiology not specified (En)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In clinical studies, if an origin of venous disease is not identified, En is assigned.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The venous system of the lower extremity is divided into the superficial and deep systems. Veins that traverse between the same system (superficial to superficial or deep to deep) are termed communicating veins, whereas veins that connect the superficial to the deep system are called perforating veins. The nomenclature of the venous anatomy of the lower extremity is standardized to eliminate confusing terminology [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11735/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Eighteen named venous segments are used as locators of pathology and classified anatomically as superficial veins (As), deep veins (Ad), perforating veins (Ap) or venous location not specified (An) (",
"    <a class=\"graphic graphic_table graphicRef77469 \" href=\"UTD.htm?24/54/25451\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Superficial venous system (As)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The superficial veins are contained in the subcutaneous tissue of the lower extremity within a superficial space that is bounded deeply by the muscular fascia and superficially by the dermis. The major superficial veins of the lower extremity include the great and small saphenous veins. Other lower extremity superficial veins with more variant anatomy include the anterior, posterior and superficial accessories of the great saphenous vein, the superficial accessory of the small saphenous vein, intersaphenous veins (communicating veins between the great and small saphenous veins) and the lateral venous system.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The great saphenous vein originates from the dorsal venous network of the foot and courses medially in the lower leg and thigh (",
"      <a class=\"graphic graphic_figure graphicRef55019 \" href=\"UTD.htm?35/46/36579\">",
"       figure 1",
"      </a>",
"      ). It drains into the common femoral vein at the confluence of the superficial inguinal veins via the saphenofemoral junction. The great saphenous vein also drains into the deep venous system through both calf and thigh perforating veins.",
"     </li>",
"     <li>",
"      The small saphenous vein originates from the lateral foot and courses posteriorly along the midline of the calf overlying the fascia between the heads of the gastrocnemius muscle (",
"      <a class=\"graphic graphic_figure graphicRef52340 \" href=\"UTD.htm?41/42/42671\">",
"       figure 2",
"      </a>",
"      ). It usually joins the deep system at the level of the popliteal veins as the saphenopopliteal junction. The anatomy of the proximal small saphenous vein is, however, highly variable and it may join the femoral vein in the thigh or it may be a tributary of the great saphenous vein. A cranial extension of the small saphenous vein may course up the posterior thigh.",
"     </li>",
"     <li>",
"      The accessory saphenous veins can become more prominent after saphenous ablation procedures and are a potential source of recurrent varicose veins.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Perforating veins (Ap)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perforating veins are those veins that traverse the muscular fascia to connect superficial veins with deep veins. They are located anteriorly, posteriorly, laterally and medially in both the thigh and calf.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Deep venous system (Ad)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The deep veins of the lower extremity are contained within the deep muscle compartments bounded by the muscle fascia (",
"    <a class=\"graphic graphic_figure graphicRef75219 \" href=\"UTD.htm?42/56/43906\">",
"     figure 3",
"    </a>",
"    ). The deep veins of the lower extremity are classified as intramuscular (within the muscle) or intermuscular (between muscle groups). The intermuscular veins are more important in the development of chronic venous disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11735/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Leg &ndash; The intermuscular veins of the leg include the popliteal veins and crural veins (paired anterior tibial, posterior tibial and peroneal veins) (",
"      <a class=\"graphic graphic_figure graphicRef75219 \" href=\"UTD.htm?42/56/43906\">",
"       figure 3",
"      </a>",
"      ). The intramuscular veins include the gastrocnemial and soleal veins.",
"      <br/>",
"      <br/>",
"      The three paired crural veins are named after the artery they accompany. The posterior tibial veins originate from the medial foot at the medial malleolus, the anterior tibial veins from the dorsum of the foot and the peroneal veins from venous collaterals originating between the distal tibia and fibula. The popliteal veins originate in the popliteal space as the confluence of the crural veins. The popliteal veins transition to be renamed the femoral veins at the level of the adductor canal in the thigh.",
"     </li>",
"     <li>",
"      Thigh &ndash; The intermuscular veins of the thigh include the femoral vein, deep femoral vein and common femoral vein. The femoral vein is joined just below the saphenofemoral junction by the deep femoral vein to form the common femoral vein (",
"      <a class=\"graphic graphic_figure graphicRef75219 \" href=\"UTD.htm?42/56/43906\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Pelvis &ndash; The pelvic veins draining blood away from the lower extremities can contribute significantly to the development of chronic venous disease. The main collecting veins of the pelvis include the external iliac veins, internal iliac veins, and common iliac veins.",
"      <br/>",
"      <br/>",
"      After passing beneath the inguinal ligament, the common femoral vein becomes the external iliac vein, which is joined by the internal iliac veins to form the common iliac veins. The common iliac veins merge at the level of the umbilicus to form the inferior vena cava. Because the inferior vena cava is usually located to the right of the spine, the left common iliac vein is longer with a less vertical path to the cava (",
"      <a class=\"graphic graphic_figure graphicRef75219 \" href=\"UTD.htm?42/56/43906\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Anatomy not specified (An)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In clinical studies, if an anatomic location is not identified, An is assigned.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiologic element of the CEAP classification designates the presence or absence of venous reflux",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    obstruction.",
"   </p>",
"   <p>",
"    The venous valves and \"venous pump\" (effect of leg muscle contraction on venous flow) are the two major determinants of venous flow [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11735/abstract/6\">",
"     6",
"    </a>",
"    ]. Blood is directed from the superficial system (draining the skin and subcutaneous tissues) to the deep venous system by muscular contractions and prevented from flowing in the opposite direction by passive closure of one-way venous valves.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Venous reflux (Pr)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Damage to the vein valves from trauma or prior venous thrombosis causes varying degrees of retrograde flow (&gt; .5 seconds) in the venous system termed reflux. Reflux may be present in isolated segments or throughout the entire course of the superficial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    deep venous systems. Deep venous reflux is associated with the most severe clinical symptoms and signs [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11735/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43365?source=see_link\">",
"     \"Pathophysiology of chronic venous disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/43/33462?source=see_link\">",
"     \"Diagnostic evaluation of chronic venous insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Venous obstruction (Po)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Superficial or deep venous thrombosis causes obstruction and impedes flow in the venous system. Superficial veins become more prominent as flow is re-routed around a venous obstruction. Over time thrombus within the vein often degrades and is resorbed, however, the vein segment and its valves may become permanently damaged. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35305?source=see_link\">",
"     \"Approach to the diagnosis and therapy of lower extremity deep vein thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23127?source=see_link\">",
"     \"Post-thrombotic (postphlebitic) syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Venous reflux and obstruction (Pr,o)",
"    </span>",
"    &nbsp;&mdash;&nbsp;When both reflux and obstruction are identified (Pr,o) is designated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Reflux not specified (Pn)",
"    </span>",
"    &nbsp;&mdash;&nbsp;When neither reflux nor obstruction are identified or in clinical studies, if the presence of reflux or obstruction is not identified, Pn is assigned.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     MEASURES OF CLINICAL SEVERITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measures of clinical severity are important tools that help to objectively follow patient response to clinical management and for documentation for insurance purposes. These measures are also useful for clinical research to define patient populations, quantify outcomes and to compare different management strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11735/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Venous clinical severity scale",
"    </span>",
"    &nbsp;&mdash;&nbsp;The venous clinical severity score (VCSS) is complementary to the CEAP classification [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11735/abstract/8\">",
"     8",
"    </a>",
"    ]. Ten clinical parameters (pain, varicose veins, edema, hyperpigmentation, inflammation, induration, number of ulcers, durations of ulcers, size of ulcers, and compliance with compression therapy) are graded from zero to three depending on severity (None = 0, Mild = 1, Moderate = 2, Severe = 3) (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?34/0/34818?source=see_link\">",
"     calculator 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Venous disability score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The venous disability score (VDS) quantifies physical limitations due to chronic venous disease. Patients are considered [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11735/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Score = 0; asymptomatic",
"     </li>",
"     <li>",
"      Score = 1; symptomatic, but able to carry out usual activities without compression therapy",
"     </li>",
"     <li>",
"      Score = 2; symptomatic, but carry out usual activities only with compression therapy or limb elevation",
"     </li>",
"     <li>",
"      Score = 3; symptomatic, but unable to carry out usual activities even with compression therapy or limb elevation",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Venous segmental disease score (VSDS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The venous segmental disease score (VSDS) combines the anatomic and physiologic components of CEAP [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11735/abstract/8\">",
"     8",
"    </a>",
"    ]. Major venous segments are evaluated for the presence of reflux",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    obstruction. The relative importance of each anatomic segment is weighted, with a maximum score of 20, 10 for reflux (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?31/44/32448?source=see_link\">",
"     calculator 2",
"    </a>",
"    ) and 10 for obstruction (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?26/62/27616?source=see_link\">",
"     calculator 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Villalta scale",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Villalta scale is a clinical measure for post-thrombotic syndrome that helps in identifying and treating patients earlier in the course of developing the syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11735/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The symptoms and signs associated with post-thrombotic syndrome are the same as in other chronic venous diseases; however, following acute deep venous thrombosis, these symptoms and signs develop over a shorter interval [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11735/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23127?source=see_link\">",
"     \"Post-thrombotic (postphlebitic) syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Five symptoms (pain, cramps, heaviness, paresthesias and pruritus) and six clinical signs (skin edema, skin induration, hyperpigmentation, redness, venous ectasia, pain on calf compression) of venous disease are assigned points depending on their severity (none = 0, mild = 1, moderate = 2, severe = 3) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11735/abstract/9\">",
"     9",
"    </a>",
"    ]. The sum of these points determines the severity of post-thrombotic syndrome (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?12/63/13299?source=see_link\">",
"     calculator 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The diagnosis and severity of PTS is based upon the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      PTS not present: 0 to 4",
"     </li>",
"     <li>",
"      Mild PTS: 5 to 9",
"     </li>",
"     <li>",
"      Moderate PTS: 10 to 14",
"     </li>",
"     <li>",
"      Severe PTS: &gt;15",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lower extremity chronic venous disorders encompass a spectrum of morphologic and functional abnormalities of the venous system. Several classification systems are used to categorize these disorders and determine disease severity for the purpose of providing an accurate record of the patient's disease status, facilitating communication between practitioners, and serving as a basis for standardized reporting. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Clinical-Etiology-Anatomy-Pathophysiology (CEAP) criteria, developed by international consensus, classifies lower extremity venous disease based upon clinical signs, etiology, anatomic location, and pathophysiologic abnormality. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'CEAP classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Measures of lower extremity venous clinical severity augment the CEAP criteria and assign point values to various clinical, anatomic, activity, and lifestyle-related parameters. Higher scores indicate more severe debilitation due to chronic venous disease. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Measures of clinical severity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Villalta scale is a clinical scale used to identify patients who have developed post-thrombotic syndrome following lower extremity deep vein thrombosis and to grade the severity of the post-thrombotic syndrome. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Villalta scale'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11735/abstract/1\">",
"      Eklof B, Perrin M, Delis KT, et al. Updated terminology of chronic venous disorders: the VEIN-TERM transatlantic interdisciplinary consensus document. J Vasc Surg 2009; 49:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11735/abstract/2\">",
"      Langer RD, Ho E, Denenberg JO, et al. Relationships between symptoms and venous disease: the San Diego population study. Arch Intern Med 2005; 165:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11735/abstract/3\">",
"      Caggiati A, Bergan JJ, Gloviczki P, et al. Nomenclature of the veins of the lower limbs: an international interdisciplinary consensus statement. J Vasc Surg 2002; 36:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11735/abstract/4\">",
"      Caggiati A, Bergan JJ, Gloviczki P, et al. Nomenclature of the veins of the lower limb: extensions, refinements, and clinical application. J Vasc Surg 2005; 41:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11735/abstract/5\">",
"      Ekl&ouml;f B, Rutherford RB, Bergan JJ, et al. Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg 2004; 40:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11735/abstract/6\">",
"      CRANLEY JJ, KRAUSE RJ, STRASSER ES. Chronic venous insufficiency of the lower extremity. Surgery 1961; 49:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11735/abstract/7\">",
"      Kakkos SK, Rivera MA, Matsagas MI, et al. Validation of the new venous severity scoring system in varicose vein surgery. J Vasc Surg 2003; 38:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11735/abstract/8\">",
"      Rutherford RB, Padberg FT Jr, Comerota AJ, et al. Venous severity scoring: An adjunct to venous outcome assessment. J Vasc Surg 2000; 31:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11735/abstract/9\">",
"      Kahn SR, Partsch H, Vedantham S, et al. Definition of post-thrombotic syndrome of the leg for use in clinical investigations: a recommendation for standardization. J Thromb Haemost 2009; 7:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11735/abstract/10\">",
"      Kahn SR. Measurement properties of the Villalta scale to define and classify the severity of the post-thrombotic syndrome. J Thromb Haemost 2009; 7:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11735/abstract/11\">",
"      Labropoulos N, Gasparis AP, Pefanis D, et al. Secondary chronic venous disease progresses faster than primary. J Vasc Surg 2009; 49:704.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8177 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-DA858D2583-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_29_11735=[""].join("\n");
var outline_f11_29_11735=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H36\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Chronic venous disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Chronic venous insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CEAP CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Clinical signs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - No visible or palpable signs of venous disease (C0)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Telangiectasias/reticular veins (C1)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Varicose veins (C2)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Edema (C3)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Pigmentation or eczema (C4a)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Lipodermatosclerosis (C4b)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Healed venous ulcer (C5)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Active venous ulcer (C6)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Etiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Congenital (Ec)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Primary (Ep)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Secondary (Es)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Etiology not specified (En)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Anatomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Superficial venous system (As)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Perforating veins (Ap)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Deep venous system (Ad)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Anatomy not specified (An)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Venous reflux (Pr)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Venous obstruction (Po)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Venous reflux and obstruction (Pr,o)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Reflux not specified (Pn)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      MEASURES OF CLINICAL SEVERITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Venous clinical severity scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Venous disability score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Venous segmental disease score (VSDS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Villalta scale",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/8177\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8177|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/46/36579\" title=\"figure 1\">",
"      Superficial veins of leg anterior view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/42/42671\" title=\"figure 2\">",
"      Superficial veins of lower leg posterior view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/56/43906\" title=\"figure 3\">",
"      Deep veins of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8177|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/63/4080\" title=\"picture 1A\">",
"      Skin changes of chronic venous insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/14/13536\" title=\"picture 1B\">",
"      Venous stasis ulcer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/58/18351\" title=\"picture 2A\">",
"      Telangiectasia of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/60/34766\" title=\"picture 2B\">",
"      Telangiectasia reticular veins and mild ankle edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/63/22514\" title=\"picture 3A\">",
"      Varicose veins of the thigh and calf",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/36/40526\" title=\"picture 3B\">",
"      Severe varicose veins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/25/42399\" title=\"picture 4\">",
"      Autoeczematous reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/14/11490\" title=\"picture 5\">",
"      Stasis dermatitis sclerotic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/57/26527\" title=\"picture 6\">",
"      Lipodermatosclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/43/29360\" title=\"picture 7\">",
"      Atrophie blanche lipodermatosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8177|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/45/10973\" title=\"table 1\">",
"      CEAP classification for chronic venous disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/54/25451\" title=\"table 2\">",
"      Lower extremity vein list",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?34/0/34818?source=related_link\" title=\"calculator 1\">",
"      Calculator: Venous clinical severity score",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?31/44/32448?source=related_link\" title=\"calculator 2\">",
"      Calculator: Venous segmental disease score for reflux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?26/62/27616?source=related_link\" title=\"calculator 3\">",
"      Calculator: Venous segmental disease score for obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?12/63/13299?source=related_link\" title=\"calculator 4\">",
"      Calculator: Villalta score for severity of post-thrombotic syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35305?source=related_link\">",
"      Approach to the diagnosis and therapy of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13592?source=related_link\">",
"      Clinical evaluation of lower extremity chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=related_link\">",
"      Clinical manifestations and diagnosis of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/43/33462?source=related_link\">",
"      Diagnostic evaluation of chronic venous insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34521?source=related_link\">",
"      Overview and management of lower extremity chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43365?source=related_link\">",
"      Pathophysiology of chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23127?source=related_link\">",
"      Post-thrombotic (postphlebitic) syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33817?source=related_link\">",
"      Prevention and treatment of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30038?source=related_link\">",
"      Vascular lesions in the newborn",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_29_11736="Infants with antenatal exposure to serotonin reuptake inhibitors";
var content_f11_29_11736=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Infants with antenatal exposure to serotonin reuptake inhibitors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/29/11736/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/29/11736/contributors\">",
"     Shari I Lusskin, MD, FAPA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/29/11736/contributors\">",
"     Shaila Misri, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/29/11736/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/29/11736/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/29/11736/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/29/11736/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/29/11736/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depression and anxiety disorders can be seen in a significant number of pregnant women. Untreated depression and anxiety have been shown to have both short and long-term deleterious effects on the mother, the child, and the family. Psychotherapy may be effective as the initial treatment for women with mild depression who have never required medication. However, pregnant women with a history of medication-responsive depression and those with chronic relapsing and more severe illness will often require pharmacotherapy as the primary treatment, with psychotherapy as an adjunct.",
"   </p>",
"   <p>",
"    Since their introduction in 1988, maternal use of selective serotonin reuptake inhibitors (SSRIs) during pregnancy and breastfeeding has steadily increased, and is considered the treatment of choice for moderate to severe maternal depression. With the rise in maternal use of SSRIs, there has been a growing awareness of potential adverse effects of SSRI exposure in the offspring. Concerns about SSRIs have also extended to the serotonin-norepinephrine reuptake inhibitor class of antidepressants (SNRI).",
"   </p>",
"   <p>",
"    The management of pregnant women with depression and their offspring requires coordination of care among the family physician, obstetrician, psychiatrist, and pediatrician. Close collaboration is required to optimize care for both the mother and child and to minimize risks associated with maternal mental illness and the effects of neonatal drug exposure when pharmacotherapy is required.",
"   </p>",
"   <p>",
"    The effects of antenatal serotonin reuptake inhibitor (SRI) exposure, particularly SSRIs, on the infant will be reviewed here. General issues related to the treatment of depression during pregnancy, including the need for and selection of pharmacologic therapy for individual patients, and the use of SSRI in breastfeeding mothers are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29735?source=see_link\">",
"     \"Depression in pregnant women: Clinical features and consequences\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=see_link\">",
"     \"Depression in pregnant women: Management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38745?source=see_link\">",
"     \"Use of psychotropic medications in breastfeeding women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reported adverse effects of antenatal exposure in the offspring of women who required SSRI therapy have included possible teratogenicity and an increased risk of neonatal complications. Although adverse effects of neonatal SSRI exposure upon neurodevelopmental outcome have also been a concern, currently available data does not demonstrate any short or long-term effects on neurodevelopment. The teratogenicity of SSRIs and other antidepressants in pregnancy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=see_link&amp;anchor=H9#H9\">",
"     \"Depression in pregnant women: Management\", section on 'Teratogenicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data on both the teratogenic and neonatal complications associated with SSRI exposure in utero are based upon case reports, case series, and epidemiologic studies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11736/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In these reports, the following limitations make it uncertain whether or not antenatal SSRI exposure has a direct, causal and independent negative effect on offspring [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11736/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Confounding variables &mdash; Variables, which have been poorly controlled for (if at all) in these reports, include: severity of maternal depression, comorbid psychiatric disorders, exposure to tobacco, alcohol, and illicit drugs, exposure to maternal use of other prescription and nonprescription medications, the gestational age, and the presence of delivery complications. The severity of maternal anxiety and depression has been shown in many studies (albeit imperfectly controlled themselves) to have deleterious effects upon the fetus and the neonate. However, pharmacologic studies have rarely controlled for these factors [",
"      <a class=\"abstract\" href=\"UTD.htm?11/29/11736/abstract/2\">",
"       2",
"      </a>",
"      ]. The comorbidities associated with antenatal depression (eg, substance abuse, tobacco use,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      poor compliance with prenatal care) may exacerbate or mediate some of these effects [",
"      <a class=\"abstract\" href=\"UTD.htm?11/29/11736/abstract/3\">",
"       3",
"      </a>",
"      ]. Increasing severity of these factors also increases the risk of fetal and neonatal adverse effects. In general, pregnant women who require psychopharmacologic therapy have more severe depression associated with comorbid anxiety disorders. [",
"      <a class=\"abstract\" href=\"UTD.htm?11/29/11736/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Role of antenatal depression'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29735?source=see_link\">",
"       \"Depression in pregnant women: Clinical features and consequences\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28746?source=see_link\">",
"       \"Infants of mothers with substance abuse\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Different SSRIs and SNRIs agents &mdash; Most studies report results based upon pooled data from mothers treated with a variety of SSRIs, each of which may have different effects on the exposed infant. These drugs vary in potency, receptor selectivity, and pharmacokinetic properties (such as half-life and the presence of active and nonactive metabolites), which alter their impact. The limited data on the neonatal effects of individual SSRI are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=see_link&amp;anchor=H7#H7\">",
"       \"Depression in pregnant women: Management\", section on 'SSRIs and SNRIs'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Concerns about SSRIs have also extended to the serotonin-norepinephrine reuptake inhibitor class of antidepressants (SNRI), specifically",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/18/19752?source=see_link\">",
"       venlafaxine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      . Although data are limited, it does not appear that venlafaxine increases the risk of birth defects. Case reports have associated symptoms of neonatal behavior syndrome with both venlafaxine and duloxetine [",
"      <a class=\"abstract\" href=\"UTD.htm?11/29/11736/abstract/4\">",
"       4",
"      </a>",
"      ]. The evidence, however, is insufficient to draw any conclusions about whether SNRIs are any different from SSRIs in the risk of neonatal complications following prenatal exposure (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=see_link&amp;anchor=H7#H7\">",
"       \"Depression in pregnant women: Management\", section on 'SSRIs and SNRIs'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Poor study design &mdash; Many of the reports are limited by lack of validation of fetal exposure, non-standardized or incomplete neonatal assessment, non-standardized or lack of diagnostic criteria, and small sample size.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Support for adverse neonatal effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the above limitations, the similarity of symptoms observed in neonates with antenatal SSRI exposure to those observed in adults with SSRI discontinuation syndrome, and SSRI toxicity or side effects has lent plausibility to the hypothesis that in utero SSRI exposure can adversely affect the newborn infant [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11736/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In adults with SSRI discontinuation syndrome, the abrupt withdrawal of SSRI is proposed to decrease serotonin concentrations at neuronal synapses and produce cholinergic overactivity resulting in the characteristic symptoms of dizziness, nausea, diarrhea and emesis, fatigue, muscle aches, chills, anxiety, insomnia, irritability, and hyperactivity. These symptoms overlap with those seen in neonates born to mothers treated with SSRIs during the third trimester of pregnancy (diarrhea, emesis, insomnia, irritability, tremors, jitteriness, and changes in muscular tone) (",
"    <a class=\"graphic graphic_table graphicRef81736 \" href=\"UTD.htm?9/34/9771\">",
"     table 1",
"    </a>",
"    ). In addition, some symptoms are similar to those seen as side effects of SSRIs or of SSRI toxicity. Thus, it remains uncertain whether neonatal symptoms are due to SSRI withdrawal or directly due to SSRI toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11736/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/33/26135?source=see_link&amp;anchor=H12#H12\">",
"     \"Antidepressant medication in adults: Switching and discontinuing medication\", section on 'Discontinuation of antidepressants'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other findings that have been attributed to antenatal SSRI exposure, such as persistent pulmonary hypertension of the newborn and small for gestational age, would not, however, be explained by this proposed pathogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11736/abstract/2,5\">",
"     2,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TERATOGENICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A majority of published data suggest that there is no increased risk of teratogenicity with the use of SSRIs during pregnancy. This evidence is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=see_link&amp;anchor=H9#H9\">",
"     \"Depression in pregnant women: Management\", section on 'Teratogenicity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     NEONATAL EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neonatal complications that have been noted in the setting of in-utero exposure to SSRIs include effects on weight, size, pulmonary function, and a constellation of symptoms in newborn infants referred to as the neonatal behavioral syndrome or poor neonatal adaptation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11736/abstract/1,2,6,7\">",
"     1,2,6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Neonatal behavioral syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The terms neonatal behavioral syndrome and poor neonatal adaptation have been used to describe a variety of symptoms exhibited by newborn infants who have been exposed to SSRIs during the third trimester of pregnancy. In 2004, the United States Food and Drug Administration (FDA) issued a safety alert that neonates exposed to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/18/19752?source=see_link\">",
"     venlafaxine",
"    </a>",
"    (SNRI) late in the third trimester of pregnancy are at risk for behavioral and respiratory symptoms that required prolonged hospitalization, respiratory support, and tube feeding [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11736/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The symptoms, which can occur as a single entity or in combination with one or more other symptoms, include (",
"    <a class=\"graphic graphic_table graphicRef81736 \" href=\"UTD.htm?9/34/9771\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11736/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Jitteriness, tremors",
"     </li>",
"     <li>",
"      Diarrhea and emesis",
"     </li>",
"     <li>",
"      Irritability or agitation",
"     </li>",
"     <li>",
"      Hypoglycemia",
"     </li>",
"     <li>",
"      Hypothermia",
"     </li>",
"     <li>",
"      Hyperreflexia",
"     </li>",
"     <li>",
"      Hypotonia or hypertonia",
"     </li>",
"     <li>",
"      Respiratory distress",
"     </li>",
"     <li>",
"      Excessive crying",
"     </li>",
"     <li>",
"      Difficulty in feeding (eg, desaturation during feeds)",
"     </li>",
"     <li>",
"      Sleep disturbances",
"     </li>",
"     <li>",
"      Seizures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The true incidence and prevalence of neonatal behavioral syndrome related to SSRI and SNRI exposure has not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11736/abstract/10-21\">",
"     10-21",
"    </a>",
"    ]. In addition, the mechanisms that may account for these complications have yet to be fully elucidated. The pathogenesis is likely to be multifactorial, with the severity of maternal mental illness also playing a role [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11736/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Role of antenatal depression'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A comprehensive review of the literature that included nine cohort studies and 13 case reports or series concluded that in utero exposure to SSRIs during the last trimester of pregnancy results in an increased risk of neonatal behavioral syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11736/abstract/1\">",
"     1",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Late pregnancy SSRI exposure (primarily",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/59/18361?source=see_link\">",
"       paroxetine",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/63/33785?source=see_link\">",
"       fluoxetine",
"      </a>",
"      ) was associated with an increased risk of neonatal behavioral syndrome compared to no exposure or only early pregnancy exposure (30 versus 6 or 9 percent, respectively, RR 3.0 of late versus pooled early or no exposure data, 95% CI 2-4.4) (",
"      <a class=\"graphic graphic_table graphicRef81736 \" href=\"UTD.htm?9/34/9771\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Neonates with late SSRI antenatal exposure were more likely to be admitted to special care nurseries, generally for observation and often in second-level neonatal units (RR 2.6). Infants exposed to SSRIs had a longer length of hospital stay.",
"     </li>",
"     <li>",
"      Management consisted primarily of supportive care. Most symptoms resolved within two weeks without any pharmacologic therapy or intervention.",
"     </li>",
"     <li>",
"      Severe symptoms are rare and include seizures, dehydration, excessive weight loss, hyperpyrexia, and rarely respiratory difficulties requiring intubation. No deaths were associated with antenatal SSRIs exposure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    None of the cohort studies included in the above review adequately controlled for the severity of maternal depression or maternal substance abuse (tobacco, alcohol, and illicit drugs). (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Role of antenatal depression'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    It is not known whether premature infants are more susceptible to the effects of",
"    <span class=\"nowrap\">",
"     SSRIs/SNRIs",
"    </span>",
"    than term infants. This was evaluated in an observational study of 76 neonates exposed to SRIs and 91 controlled unexposed infants [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11736/abstract/21\">",
"     21",
"    </a>",
"    ]. All 21 exposed preterm infants (mean gestational age 34 weeks) developed symptoms consistent with neonatal behavioral syndrome compared to 40 of the 58 exposed term infants (69 percent). However, multivariate analyses demonstrated that prematurity itself was associated with signs of neonatal behavioral syndrome independent of SRI exposure. Although, the rate of prematurity was higher in the exposed compared to nonexposed group (27 versus 9 percent), when adjusted for confounding variables, prenatal SRI exposure was not associated with an increased risk of prematurity. In this study, there was no difference in length of hospital stay between exposed and unexposed infants. Symptoms were transient and self-limited in both exposed preterm and term infants. Further studies are required to ascertain whether preterm infants are more susceptible to antenatal SRI exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regardless of whether antenatal exposure to SSRIs plays a causal role or is itself a marker for another underlying etiology of neonatal behavioral syndrome (such as severe maternal depression), in utero exposure to SSRIs in the third trimester of pregnancy is an identifiable risk factor for poor neonatal adaptation. Clinicians need to identify affected infants and provide relevant counseling for their parents. The parents should be aware that these symptoms usually resolve spontaneously and are of short duration (usually a few days to a maximum of two weeks). During the symptomatic period, their infant may have difficulties with feeding",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sleeping, or be more irritable. Seizures and respiratory distress requiring intubation are rare events [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11736/abstract/1,19,22\">",
"     1,19,22",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    Most infants require no treatment. For infants with more pronounced symptoms, supportive care based upon management of infants with neonatal opioid withdrawal has been recommended by some authors. However, this intervention has not been evaluated in a controlled trial in newborns with neonatal complications following antenatal exposure to SSRIs [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11736/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/57/39833?source=see_link&amp;anchor=H8#H8\">",
"     \"Neonatal opioid withdrawal (Neonatal abstinence syndrome)\", section on 'Supportive care'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The regimen includes decreasing sensory stimulation (eg, quiet, low-light environment room and swaddling the infant), providing frequent small feedings to address increased caloric needs and feeding difficulties, and promoting mother-infant skin-to skin contact that improves neonatal temperature regulation, breathing regularity, weight gain, and facilitates maternal-infant bonding.",
"   </p>",
"   <p>",
"    However, there are published case reports that in infants with severe symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11736/abstract/14\">",
"     14",
"    </a>",
"    ], pharmacologic therapy cannot be recommended because of the paucity of data and the spontaneous resolution of neonatal behavioral syndrome in almost all infants without any apparent long-term significant sequelae.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Persistent pulmonary hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;SSRI exposure in the second half of pregnancy may be associated with increased risk of persistent pulmonary hypertension (PPHN).",
"   </p>",
"   <p>",
"    Three studies have observed an increased risk of PPHN in infants prenatally exposed to SSRI as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A cohort study, which compared 377 women whose infants had persistent pulmonary hypertension of the newborn (PPHN) and 836 control women with healthy infants reported an association between late third trimester exposure to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/63/33785?source=see_link\">",
"       fluoxetine",
"      </a>",
"      and PPHN [",
"      <a class=\"abstract\" href=\"UTD.htm?11/29/11736/abstract/5\">",
"       5",
"      </a>",
"      ]. In this case control study, PPHN occurred in 14 infants who were exposed to fluoxetine,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/59/18361?source=see_link\">",
"       paroxetine",
"      </a>",
"      , or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/18/7465?source=see_link\">",
"       sertraline",
"      </a>",
"      after the 20th week of gestation compared with six infants in the control group (adjusted OR, 6.1 95% CI 2.2-16.8).",
"     </li>",
"     <li>",
"      A retrospective study using the Swedish Medical Birth Registry found a lower risk of PPHN [",
"      <a class=\"abstract\" href=\"UTD.htm?11/29/11736/abstract/23\">",
"       23",
"      </a>",
"      ]. This study used first trimester maternal interviews and prescriptions written by antenatal care clinics during the rest of the pregnancy to estimate antenatal exposure prospectively. Of the 504 infants with PPHN, 11 had first trimester exposure to an SSRI (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/63/33785?source=see_link\">",
"       fluoxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/16/38152?source=see_link\">",
"       citalopram",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/18/7465?source=see_link\">",
"       sertraline",
"      </a>",
"      , or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/59/18361?source=see_link\">",
"       paroxetine",
"      </a>",
"      ) and five had third trimester exposure. For infants born after 34 weeks of gestation with first trimester exposure and third trimester exposure, the adjusted relative risk [RR] of developing PPHN was 3.6 [95%CI, 1.2-8.3].",
"     </li>",
"     <li>",
"      In a population-based study that included more than 1.6 million live births from five Nordic countries, infants whose mothers filled a prescription for SSRI later than the 20",
"      <sup>",
"       th",
"      </sup>",
"      week of gestation had an increased risk of PPHN compared with control infants (adjusted RR 2.1, 95% CI 1.5-3) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/29/11736/abstract/24\">",
"       24",
"      </a>",
"      ]. For the 11,014 prenatally exposed infants, the absolute risk of PPHN was 2.9 per 1000 live births compared with the absolute risk of 1.2 per 1000 live births for nonexposed infants.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, the following studies found no association between prenatal SSRI exposure and PPHN:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective analysis of several health insurance databases in the United States found no increased risk of PPHN between 1104 neonates exposed to SSRIs in the third trimester and 1104 unexposed neonates [",
"      <a class=\"abstract\" href=\"UTD.htm?11/29/11736/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a case-controlled study of 11,923 infants born at a single center from 2003 through 2009, in which 5 percent of the cohort was exposed to late prenatal SSRI, none of the 20 cases of PPHN were associated with late prenatal SSRI exposure [",
"      <a class=\"abstract\" href=\"UTD.htm?11/29/11736/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A similar finding was noted in a retrospective cohort study of 25,214 newborns (prenatal SSRI exposure in 3 percent), in which none of the 16 cases of PPHN were exposed to prenatal SSRI [",
"      <a class=\"abstract\" href=\"UTD.htm?11/29/11736/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several other factors are associated with PPHN including, among others, maternal obesity, smoking, diabetes, asthma, late preterm or postterm birth, and cesarean section [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11736/abstract/26,28\">",
"     26,28",
"    </a>",
"    ], so that an independent association of SSRIs and PPHN needs to be confirmed by eliminating confounding variables before any change in the management recommendations for the treatment of maternal depression is considered.",
"   </p>",
"   <p>",
"    In 2006, the FDA issued an initial public health advisory on the possibility of an increased risk of PPHN in infants exposed to antenatal SSRIs in the second half of pregnancy based on a single study [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11736/abstract/29\">",
"     29",
"    </a>",
"    ]. In a 2011 review, the FDA reported subsequent studies yielded conflicting results and that \"it is premature to reach any conclusions about a possible link between SSRI use in pregnancy and PPHN\" [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11736/abstract/30\">",
"     30",
"    </a>",
"    ]. As a result, the FDA recommended health care professionals should not alter their clinical management of depression during pregnancy based on this concern of PPHN. In practice, this means not lowering or discontinuing an effective SSRI during the third trimester.",
"   </p>",
"   <p>",
"    Because the Nordic study was published subsequently, it was not included in the 2011 FDA report. However, results from this study showed the absolute risk of PPHN would only increase from a general incidence of 0.1 to 0.3 percent of live-births with late prenatal SSRI exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11736/abstract/24\">",
"     24",
"    </a>",
"    ]. As a result, we continue to concur with the 2011 FDA advisory that effective SSRI administration not be altered during pregnancy based on a concern of PPHN in the offspring as the available literature demonstrates a favorable benefit to risk profile, and favors continued maternal administration of SSRI,.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Role of antenatal depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted previously, maternal depression and anxiety have been shown to have deleterious effects upon the offspring. However, interpretation of published data is difficult because of study limitations including but not limited to the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Variable definitions of maternal illness",
"     </li>",
"     <li>",
"      Variations in rating scales used and timing of assessment,",
"     </li>",
"     <li>",
"      Inadequate control of confounding variables factors such as socioeconomic status, licit and illicit substance use, exposure to partner mental illness, and the impact of maternal depression",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This was illustrated in a population based study that compared infants of depressed mothers who took SSRIs, infants of depressed mothers who did not take SSRIs, and control infants of healthy mothers who were not diagnosed with depression and did not take SSRIs [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11736/abstract/2\">",
"     2",
"    </a>",
"    ]. This study reported that infants of depressed mothers who received SSRI therapy compared to infants of depressed mothers without SSRI therapy and control infants had slightly lower birth weights, and were more likely to have respiratory distress, increased duration of neonatal hospital stay, feeding problems, and jaundice.",
"   </p>",
"   <p>",
"    A prospective Danish cohort study compared the outcome of neonates born to mothers treated with SSRIs (n=329) to those with either a history of psychiatric illness but no SSRI treatment during pregnancy (n=4902) or no history of psychiatric illness (n=51,770) based upon maternal reporting from 1989 to 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11736/abstract/31\">",
"     31",
"    </a>",
"    ]. Adjustment for confounding maternal factors (prepregnancy body mass index, and age, tobacco and alcohol use, and parity) was performed by multivariate linear and logistic analysis. There were no differences in birth weight and head circumference among the three groups. Infants with antenatal exposure to SSRI were born 3.8 and 4.5 days earlier than those born to mothers with a history of psychiatric illness and no SSRI treatment and those with no history of psychiatric illness, respectively. SSRI-exposed infants were more likely than either comparison group to have five-minute Apgar scores &le;7 and to be admitted to the NICU even after adjusting for the Apgar score.",
"   </p>",
"   <p>",
"    Several limitations of this study included the inability to determine actual medication exposure, approximation of the severity of maternal depression, which was based upon diagnostic codes or maternal self-report, and inability to determine illicit drug, tobacco, and alcohol use and use of nonprescription medications. Nevertheless, despite these limitations, these results suggest that antenatal SSRI exposure may have a direct effect on offspring independent of the severity of maternal depression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     NEURODEVELOPMENTAL OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data on the long-term neurodevelopment of SSRI-exposed infants, but the available evidence suggests that these drugs do not affect neurodevelopment in exposed offspring:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, which included 55 who were exposed in utero to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/63/33785?source=see_link\">",
"       fluoxetine",
"      </a>",
"      (37 only in the first trimester), there were no differences in global IQ scores, language development, or behavioral development between children exposed to fluoxetine compared to nonexposed children at 16 and 86 months of age [",
"      <a class=\"abstract\" href=\"UTD.htm?11/29/11736/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a subsequent report of 40 infants exposed to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/63/33785?source=see_link\">",
"       fluoxetine",
"      </a>",
"      throughout pregnancy, there were no differences in global IQ scores, language development, behavioral development or temperament between children with in utero fluoxetine exposure and nonexposed children of healthy mothers [",
"      <a class=\"abstract\" href=\"UTD.htm?11/29/11736/abstract/33\">",
"       33",
"      </a>",
"      ]. However, multivariate analysis suggested that the duration of maternal depression and the number of depressive episodes following delivery correlated with lower IQ scores and poorer language development.",
"     </li>",
"     <li>",
"      Neurodevelopmental outcome of children exposed at least during the third trimester to an SSRI (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/59/18361?source=see_link\">",
"       paroxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/63/33785?source=see_link\">",
"       fluoxetine",
"      </a>",
"      , or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/18/7465?source=see_link\">",
"       sertraline",
"      </a>",
"      ) or to paroxetine plus",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/7/11383?source=see_link\">",
"       clonazepam",
"      </a>",
"      was prospectively studied in a cohort of 46 mother-child pairs and 23 healthy, nonmedicated control pairs [",
"      <a class=\"abstract\" href=\"UTD.htm?11/29/11736/abstract/19\">",
"       19",
"      </a>",
"      ]. While transient neonatal symptoms occurred in 30 percent of the exposed group compared to 9 percent in the control group, there were no differences in developmental outcomes between the symptomatic and asymptomatic infants or between the exposed and unexposed infants. Some of the infants were also exposed postnatally through breastfeeding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Internalizing and externalizing behaviors were evaluated in a prospective longitudinal study of prenatally exposed children at ages 4 to 5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11736/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. All of the mothers remained on medication, but due to attrition, the study groups were reduced to 22 exposed and 14 unexposed mother-child pairs.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rates of internalizing behaviors (emotional reactivity, withdrawal, irritability, depression, or anxiety) were not different between the groups when using parent, teacher, or clinician ratings [",
"      <a class=\"abstract\" href=\"UTD.htm?11/29/11736/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Externalizing behavior (activity, attention, and impulsivity) did not differ between the exposed and control groups when controlling for maternal mood depression based upon parent, teacher, or clinician ratings [",
"      <a class=\"abstract\" href=\"UTD.htm?11/29/11736/abstract/35\">",
"       35",
"      </a>",
"      ]. Maternal depression and anxiety, however, were associated with increased reports of externalizing behavior.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, a subsequent report from the same prospective longitudinal study group reported prenatal exposure to SSRI in combination with current maternal anxiety were associated with an increased rate of internalizing behavior at three years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11736/abstract/36\">",
"     36",
"    </a>",
"    ]. Externalizing behavior was associated with current maternal mood but not antenatal SSRI exposure.",
"   </p>",
"   <p>",
"    Further studies with a larger number of patients are needed to determine with certainty the long-term effects of SSRI exposure on offspring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of pregnant women with depression, and their offspring, requires coordination of care among the obstetrician, psychiatrist, and pediatrician. Close collaboration is required to optimize care for both the mother and child by minimizing risks associated with maternal mental illness and the effects of neonatal drug exposure when pharmacotherapy is required. Evaluation must include review of concomitant medication as well as substance abuse.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Since their introduction in 1988, selective serotonin reuptake inhibitors (SSRIs) have been the treatment of choice in moderate to severe maternal depression during pregnancy. This has been associated with an increased awareness of potential adverse effects of antenatal SSRIs exposure in the offspring. General issues related to the treatment of depression during pregnancy, include the need and selection of pharmacologic therapy with individualization of treatment for every patient. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29735?source=see_link\">",
"       \"Depression in pregnant women: Clinical features and consequences\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=see_link&amp;anchor=H7#H7\">",
"       \"Depression in pregnant women: Management\", section on 'SSRIs and SNRIs'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A majority of published data suggest that there is no increased risk of teratogenicity with the use of SSRIs during pregnancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=see_link&amp;anchor=H9#H9\">",
"       \"Depression in pregnant women: Management\", section on 'Teratogenicity'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antenatal SSRI exposure has been associated, in some studies but not in others, with slightly lower birth weight, shorter gestation, and an increased risk of transient neonatal complications. A causal relationship has not been established and it is difficult to separate the impact of maternal depression and anxiety, other drug use, comorbid conditions such as obesity, on pregnancy outcome. These factors must be considered when assessing the risks and benefits of SSRI treatment. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Role of antenatal depression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neonatal behavioral syndrome and poor neonatal adaptation have been used to describe a variety of symptoms exhibited by newborn infants who have been exposed to SSRIs during the third trimester of pregnancy (",
"      <a class=\"graphic graphic_table graphicRef81736 \" href=\"UTD.htm?9/34/9771\">",
"       table 1",
"      </a>",
"      ). During the symptomatic period the infant may have difficulties with feeding, sleeping, or irritability. Clinicians need to identify affected infants and provide parental counseling. Parents should be aware that these symptoms will resolve spontaneously and are of short duration (usually a few days to two weeks). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Neonatal behavioral syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most infants with neonatal behavioral syndrome do not need any treatment beyond what is routinely provided in the normal newborn nursery setting. We suggest that more symptomatic infants receive supportive care (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Supportive care includes providing respiratory support, decreasing sensory stimulation, providing small frequent feedings, and promoting mother-infant skin-to skin contact. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It remains uncertain whether there is an increased risk of persistent pulmonary hypertension with SSRI exposure in the second half of pregnancy. If there is an increased risk, the absolute risk remains small (ie, risk of PPHN in 3 infants in 1000 livebirths with late prenatal SSRI exposure compared with a background incidence of 1 in 1000 livebirths). Based on the available literature, we suggest clinical management of pregnant women with depression not be altered based on a concern for increased risk of neonatal PPHN (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Persistent pulmonary hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although data are limited, available evidence suggests that antenatal SSRIs exposure does not affect neurodevelopmental outcome in exposed offspring. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Neurodevelopmental outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11736/abstract/1\">",
"      Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005; 293:2372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11736/abstract/2\">",
"      Oberlander TF, Warburton W, Misri S, et al. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006; 63:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11736/abstract/3\">",
"      Law KL, Stroud LR, LaGasse LL, et al. Smoking during pregnancy and newborn neurobehavior. Pediatrics 2003; 111:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11736/abstract/4\">",
"      Eyal R, Yaeger D. Poor neonatal adaptation after in utero exposure to duloxetine. Am J Psychiatry 2008; 165:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11736/abstract/5\">",
"      Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006; 354:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11736/abstract/6\">",
"      Suri R, Altshuler L, Hellemann G, et al. Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am J Psychiatry 2007; 164:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11736/abstract/7\">",
"      El Marroun H, Jaddoe VW, Hudziak JJ, et al. Maternal use of selective serotonin reuptake inhibitors, fetal growth, and risk of adverse birth outcomes. Arch Gen Psychiatry 2012; 69:706.",
"     </a>",
"    </li>",
"    <li>",
"     2004 Safety alerts for drugs, biologics, medical devices, and dietary supplements www.fda.gov/medwatch/SAFETY/2004/safety04.htm#effexor (Accessed on April 17, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11736/abstract/9\">",
"      Chambers CD, Johnson KA, Dick LM, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996; 335:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11736/abstract/10\">",
"      Misri S, Oberlander TF, Fairbrother N, et al. Relation between prenatal maternal mood and anxiety and neonatal health. Can J Psychiatry 2004; 49:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11736/abstract/11\">",
"      Stiskal JA, Kulin N, Koren G, et al. Neonatal paroxetine withdrawal syndrome. Arch Dis Child Fetal Neonatal Ed 2001; 84:F134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11736/abstract/12\">",
"      Costei AM, Kozer E, Ho T, et al. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002; 156:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11736/abstract/13\">",
"      Nordeng H, Lindemann R, Perminov KV, Reikvam A. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr 2001; 90:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11736/abstract/14\">",
"      Laine K, Heikkinen T, Ekblad U, Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 2003; 60:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11736/abstract/15\">",
"      Cohen LS, Heller VL, Bailey JW, et al. Birth outcomes following prenatal exposure to fluoxetine. Biol Psychiatry 2000; 48:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11736/abstract/16\">",
"      Casper RC, Fleisher BE, Lee-Ancajas JC, et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 2003; 142:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11736/abstract/17\">",
"      Zeskind PS, Stephens LE. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 2004; 113:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11736/abstract/18\">",
"      Oberlander TF, Misri S, Fitzgerald CE, et al. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry 2004; 65:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11736/abstract/19\">",
"      Sanz EJ, De-las-Cuevas C, Kiuru A, et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 2005; 365:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11736/abstract/20\">",
"      Levinson-Castiel R, Merlob P, Linder N, et al. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 2006; 160:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11736/abstract/21\">",
"      Ferreira E, Carceller AM, Agogu&eacute; C, et al. Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. Pediatrics 2007; 119:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11736/abstract/22\">",
"      Nordeng H, Spigset O. Treatment with selective serotonin reuptake inhibitors in the third trimester of pregnancy: effects on the infant. Drug Saf 2005; 28:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11736/abstract/23\">",
"      K&auml;ll&eacute;n B, Olausson PO. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2008; 17:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11736/abstract/24\">",
"      Kieler H, Artama M, Engeland A, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ 2012; 344:d8012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11736/abstract/25\">",
"      Andrade SE, McPhillips H, Loren D, et al. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2009; 18:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11736/abstract/26\">",
"      Wilson KL, Zelig CM, Harvey JP, et al. Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors. Am J Perinatol 2011; 28:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11736/abstract/27\">",
"      Wichman CL, Moore KM, Lang TR, et al. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin Proc 2009; 84:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11736/abstract/28\">",
"      Hern&aacute;ndez-D&iacute;az S, Van Marter LJ, Werler MM, et al. Risk factors for persistent pulmonary hypertension of the newborn. Pediatrics 2007; 120:e272.",
"     </a>",
"    </li>",
"    <li>",
"     Treatment challenges of depression in pregnancy and the possibility of persistent pulmonary hypertension in newborns www.fda.gov/CDER/DruG/advisory/SSRI_PPHN200607.htm (Accessed on April 17, 2007).",
"    </li>",
"    <li>",
"     FDA safety alert. Selective serotonin reuptake inhibitor (SSRI) antidepressants: Drug safety communication - Use during pregnancy and potential risk of persistent pulmonary hypertension of the newborn file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm283696.htm (Accessed on December 29, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11736/abstract/31\">",
"      Lund N, Pedersen LH, Henriksen TB. Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Arch Pediatr Adolesc Med 2009; 163:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11736/abstract/32\">",
"      Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997; 336:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11736/abstract/33\">",
"      Nulman I, Rovet J, Stewart DE, et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 2002; 159:1889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11736/abstract/34\">",
"      Misri S, Reebye P, Kendrick K, et al. Internalizing behaviors in 4-year-old children exposed in utero to psychotropic medications. Am J Psychiatry 2006; 163:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11736/abstract/35\">",
"      Oberlander TF, Reebye P, Misri S, et al. Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy. Arch Pediatr Adolesc Med 2007; 161:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11736/abstract/36\">",
"      Oberlander TF, Papsdorf M, Brain UM, et al. Prenatal effects of selective serotonin reuptake inhibitor antidepressants, serotonin transporter promoter genotype (SLC6A4), and maternal mood on child behavior at 3 years of age. Arch Pediatr Adolesc Med 2010; 164:444.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5007 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-F656983DA9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_29_11736=[""].join("\n");
var outline_f11_29_11736=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Support for adverse neonatal effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TERATOGENICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      NEONATAL EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Neonatal behavioral syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Persistent pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Role of antenatal depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      NEURODEVELOPMENTAL OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5007\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5007|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/34/9771\" title=\"table 1\">",
"      Neonatal behavioral syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/33/26135?source=related_link\">",
"      Antidepressant medication in adults: Switching and discontinuing medication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29735?source=related_link\">",
"      Depression in pregnant women: Clinical features and consequences",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=related_link\">",
"      Depression in pregnant women: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28746?source=related_link\">",
"      Infants of mothers with substance abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/57/39833?source=related_link\">",
"      Neonatal opioid withdrawal (Neonatal abstinence syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38745?source=related_link\">",
"      Use of psychotropic medications in breastfeeding women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_29_11737="Actinic keratosis - dorsal hand";
var content_f11_29_11737=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F50949%7EONC%2F53177&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F50949%7EONC%2F53177&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Actinic keratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Actinic keratosis. Scale overlies erythematous macules.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Actinic keratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Actinic keratoses present as rough, erythematous, scaly macules on chronically sun exposed skin. They are usually easier felt than seen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Fitzpatrick TB, Johnson RA, Wolff K, Suurmond D. Color Atlas and Synopsis of Clinical Dermatology. Common and Serious Diseases. (4th Ed), McGraw-Hill, New York 2001. p.220.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_29_11737=[""].join("\n");
var outline_f11_29_11737=null;
var title_f11_29_11738="Care of the neonatal intensive care unit graduate";
var content_f11_29_11738=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Care of the neonatal intensive care unit graduate",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/29/11738/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/29/11738/contributors\">",
"     Jane Stewart, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/29/11738/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/29/11738/contributors\">",
"     Steven A Abrams, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/29/11738/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/29/11738/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/29/11738/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advances in neonatal intensive care have improved the survival of high-risk preterm and critically ill term infants [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. &nbsp;Infants who are discharged from the neonatal intensive care unit (NICU) require continued comprehensive clinical care. Thus, the primary care provider needs to identify, understand, and manage their ongoing medical needs [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The primary care clinician plays a key role in providing optimal continuity of treatment by coordinating transition of care from the neonatologist, providing direct medical care, and facilitating ongoing care of the infant by subspecialists and other health professionals.",
"   </p>",
"   <p>",
"    This topic will review the care of the infant who is discharged from the NICU. The discussion primarily focuses on preterm infants who represent the majority of NICU graduates, especially the issues in the care of the very low birth weight (VLBW) infant (birth weight &le;1500 g). Criteria for discharge and planning for discharge are discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/7/27765?source=see_link\">",
"     \"Discharge planning for high-risk newborns\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of the approximate four million births that occur in the United States each year, about 1.92 percent of the infants will be born &lt;32 weeks gestational age (GA) and 11.7 percent &lt;37 weeks GA [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/2\">",
"     2",
"    </a>",
"    ]. The number of late preterm infants delivered between 34 and 36 weeks gestation has increased 25 percent since 1990, and accounts for about 8.28 percent of all births. Although over the past five years the preterm birth rate has fallen slightly, with the advances in neonatal care, the number of preterm infants and critically ill term infants who survive and are discharged from the NICU continues to increase [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Although most NICU graduates are discharged from the NICU when their adjusted gestational age is near or at term, they differ greatly in their medical needs compared to healthy term infants. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22713?source=see_link\">",
"     \"Late preterm infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the need to provide optimal care to the NICU graduates and address their specific medical issues, the American Academy of Pediatrics (AAP) has developed guidelines for the primary care provider in the management of the high-risk infant [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/6\">",
"     6",
"    </a>",
"    ]. These guidelines highlight the shared responsibility of the care of the infant between the primary care provider and the neonatologist, the need for effective communication with the family and other professionals involved in the care of the infant, the importance of continuity of care at the time of discharge from the NICU, and the role of the primary care provider to identify and care for the problems associated with these infants. Specific quality-of-care indicators for the neurodevelopmental follow-up care of very low birth weight children have also been developed by an AAP expert panel and serve as a useful guide for primary care providers [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon the AAP guidelines, the role of the primary care clinician in the care of the NICU graduate includes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Communication with the neonatologist and family (if possible) during the NICU course of the infant. Ongoing communication facilitates the transfer of medical information (patient's medical history, medications, and technologic needs); allows collaborative arrangements for follow-up with primary, subspecialty, and neurodevelopmental care; and determines the appropriate timing of transfer. For the family, contact with both the neonatologist and primary care provider decreases confusion and uncertainty regarding transfer of care. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/7/27765?source=see_link\">",
"       \"Discharge planning for high-risk newborns\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Primary medical care responsibility when the infant no longer requires intensive care treatment. The primary care clinician provides care to the infant either as an outpatient upon discharge to home or as an inpatient upon transfer back to the referring hospital.",
"     </li>",
"     <li>",
"      Knowledge of existing medical problems and the ability to detect new problems that are commonly seen in the neonate after discharge from the NICU. As examples, preterm infants are at increased risk for hearing loss, retinopathy of prematurity, and developmental delay, and they require hearing screening, retinal examination, and neurodevelopmental evaluation.",
"     </li>",
"     <li>",
"      Ongoing coordination of care among subspecialists and other health care professionals. The primary care provider should be aware of and be able to utilize community services for both the patient and the family as needed.",
"     </li>",
"     <li>",
"      Consistent care that provides continuity of information and psychosocial support to the family [",
"      <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OUTPATIENT MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ambulatory management of NICU graduates includes evaluation of growth, vision, hearing, and development, and immunization. In addition, many infants will also have multiple ongoing medical problems for which the primary care provider can either assume primary responsibility or share responsibility with specialists and other medical professionals for their management. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Common medical problems'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Initial visit",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial visit is scheduled within a few days to a week after discharge from the hospital depending on the patient's gestational age, weight, and medical problems [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/9\">",
"     9",
"    </a>",
"    ]. The visit includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Review of the infant's NICU course, current medications, and medical equipment. This should include information on growth parameters (head circumference, length, and weight, and the growth curve during the birth hospitalization), vital signs (respiratory and heart rate, percent oxygen saturation on room air, and blood pressure), nutrition (type of feeding, and volume and frequency of feeds), immunization record, neonatal screening (metabolic, cranial imaging, hearing, ophthalmologic), and other specific problems related to individual patients.",
"     </li>",
"     <li>",
"      Evaluation of the infant's progress since discharge, including growth and assessment of the patient's specific medical problems.",
"     </li>",
"     <li>",
"      Time to listen and address the family's concerns [",
"      <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/6\">",
"       6",
"      </a>",
"      ]. The primary care provider should ensure that the family understands the infant's medical diagnoses, and any medications (including administration and schedule) and equipment required in",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      care.",
"     </li>",
"     <li>",
"      Review the patient's future appointments with subspecialty services and the schedule of subsequent primary care visits and hearing and vision screening. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Screening'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Subsequent visits",
"    </span>",
"    &nbsp;&mdash;&nbsp;The schedule for subsequent visits will depend on the patient's medical condition. In general, primary care visits will be more frequent in the beginning (eg, every one to two weeks) to monitor and establish adequate growth. Visits will focus on routine primary care (eg, immunization), general care directed towards the NICU graduate (ie, hearing, vision and development screening), and specific medical problems of the individual patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Growth",
"    </span>",
"    &nbsp;&mdash;&nbsp;NICU graduates are at risk for inadequate growth due to their increased caloric and nutrient requirements and poor feeding. After discharge from the hospital, these patients require frequent monitoring of their growth and overall nutrition. Optimal growth is still not clearly defined [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Monitoring the growth and nutritional management of the premature NICU graduate are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23912?source=see_link\">",
"     \"Growth management in preterm infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Immunization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preterm infants are at increased risk for vaccine preventable infections. Immunization in the premature infant results in a protective antibody response [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/11-17\">",
"     11-17",
"    </a>",
"    ]. As a result, the American Academy of Pediatrics (AAP) recommends that medically stable preterm infants should receive full immunization based upon their chronological age consistent with the schedule and dose recommended for normal full-term infants (",
"    <a class=\"graphic graphic_figure graphicRef82617 \" href=\"UTD.htm?24/55/25463\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=see_link&amp;anchor=H2#H2\">",
"     \"Standard immunizations for children and adolescents\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immunizations may have been started in NICU. However, delays in immunization are common, especially in unstable infants. Thus, the clinician should obtain complete detailed records of any immunizations given in the NICU.",
"   </p>",
"   <p>",
"    There are specific issues with some immunizations in the preterm infant that are highlighted below.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatitis B (HBV) &mdash; The AAP and Advisory Committee on Immunization Practices (ACIP) recommend that HBV immunization be administered to premature infants according to the HBsAg status of the mother and the birth weight of the infant prior to discharge. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/63/37881?source=see_link&amp;anchor=H12#H12\">",
"       \"Hepatitis viruses and the newborn: Clinical manifestations and treatment\", section on 'Hepatitis B vaccine and premature infants'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Influenza &mdash; Premature infants are at high risk for complications from seasonal influenza virus infection and should receive influenza vaccine after six months of age [",
"      <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/18\">",
"       18",
"      </a>",
"      ]. Influenza vaccination is recommended for all children older than six months. In infants, whether they are preterm or term infants, two intramuscular doses of the",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/21/20824?source=see_link\">",
"       inactivated influenza vaccine",
"      </a>",
"      should be given one month apart from each other starting at a chronological age of six months [",
"      <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/18\">",
"       18",
"      </a>",
"      ]. Family members and household contacts of infants younger than six months of age, especially those at risk for respiratory illness, should be immunized with the influenza vaccine. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=see_link&amp;anchor=H7#H7\">",
"       \"Seasonal influenza vaccination in children\", section on 'Indications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Respiratory syncytial virus (RSV) &mdash; Preterm infants, especially those with chronic lung disease, are at increased risk for significant morbidity and mortality from RSV infection. The prophylactic administration of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/0/40964?source=see_link\">",
"       Palivizumab",
"      </a>",
"      , a humanized monoclonal antibody against RSV, has been shown to prevent severe RSV in high-risk infants who are premature or have chronic lung disease, congenital heart disease, airway abnormalities, or neuromuscular disease [",
"      <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/19\">",
"       19",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      As a result, the AAP recommends prophylactic treatment with palivizumab for these high-risk infants. Immunoprophylaxis should be given based on gestational age as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Infants &le;28 weeks of gestation until they are 1 year of age",
"     </li>",
"     <li>",
"      Infants between 29 and 32 weeks of gestations until they are 6 months of age",
"     </li>",
"     <li>",
"      Infants between 32 and 35 weeks of gestation with one of the following risk factors: daycare attendance or a sibling younger than five years of age until they are three months of age.",
"      <br/>",
"      <br/>",
"      The indications, efficacy, administration (including dose and schedule), and adverse effects of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/0/40964?source=see_link\">",
"       Palivizumab",
"      </a>",
"      therapy are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/17/15640?source=see_link&amp;anchor=H104278856#H104278856\">",
"       \"Respiratory syncytial virus infection: Prevention\", section on 'Immunoprophylaxis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pertussis &mdash; All adults older than 19 years of age should receive a single pertussis booster, especially if they are in close contact with an infant. The pertussis booster vaccine is given in combination with vaccines for diphtheria and tetanus (ie, Tdap). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=see_link&amp;anchor=H5#H5\">",
"       \"Tetanus-diphtheria toxoid vaccination in adults\", section on 'Indications for Td or Tdap vaccination'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rotavirus &mdash; The AAP recommends initial vaccination of preterm infants at or following discharge from the hospital if they are clinically stable and at least 6 weeks, but fewer than 15 weeks, of age. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40937?source=see_link&amp;anchor=H6#H6\">",
"       \"Rotavirus vaccines\", section on 'Schedule'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;In premature infants, the site for administering intramuscular vaccines is the anterolateral thigh. The length of the needle is based upon the muscle mass of the infant and may be less than the standard",
"    <span class=\"nowrap\">",
"     7/8",
"    </span>",
"    to 1 inch length normally used for term infants [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;NICU graduates are at increased risk for hearing, vision, and neurodevelopmental problems. These conditions may have been identified in the NICU or may only be recognized after discharge. As a result, these infants require screening for these potential problems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Hearing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The estimated prevalence of bilateral sensorineural hearing loss (SNHL) is one to two per 1000 newborns in the United States but is 10 to 20 times higher among infants admitted to the NICU than in healthy term neonates. Because of the increased risk for SNHL in patients admitted to the NICU, the Joint Committee on Infant Hearing, which encompasses seven national organizations, recommends automated auditory brainstem response as the screening test for hearing. Screening the newborn for hearing loss, including infants admitted to the NICU and their follow-up after discharge, is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/13/27865?source=see_link&amp;anchor=H14#H14\">",
"     \"Screening the newborn for hearing loss\", section on 'NICU admissions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Vision",
"    </span>",
"    &nbsp;&mdash;&nbsp;NICU graduates, especially VLBW and extremely low birth weight (ELBW) infants (birth weight &lt;1500 g and &lt;1000 g, respectively), are at increased risk for long-term ophthalmologic abnormalities, including retinopathy of prematurity (ROP). ROP, a developmental vascular proliferative retinal disorder, is seen in VLBW and ELBW infants. ROP typically presents at approximately 32 weeks gestation, peaks at 38 to 40 weeks, and begins to regress by 46 weeks.",
"   </p>",
"   <p>",
"    Initial retinal screening by an ophthalmologist should be performed four to six weeks after birth with additional examinations at intervals of one to three weeks until the retinal vessels have fully matured.",
"   </p>",
"   <p>",
"    Screening is indicated for patients that are at increased risk for ROP:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      All infants with birth weights &le;1500 g or a gestational age (GA) of less than 31 weeks",
"     </li>",
"     <li>",
"      Infants with birth weights between 1500 g and 2000 g or a GA &gt;31 weeks whose clinical course places them at increased risk",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Compliance with screening is imperative, as ROP is the second most common cause of childhood blindness, and treatment can reduce the morbidity of this condition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10762?source=see_link\">",
"     \"Retinopathy of prematurity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    VLBW survivors are also at increased risk for other ophthalmologic disorders, such as strabismus, myopia, and amblyopia. They should undergo examination by an ophthalmologist at 9 to 12 months of age. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Ophthalmologic conditions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Neurodevelopment",
"    </span>",
"    &nbsp;&mdash;&nbsp;NICU graduates are at increased risk for developmental delays and disabilities compared to term infants. The risk is increased with the decreasing gestational age. The primary care provider plays a crucial role in identifying and referring at risk-infants for further evaluation and early intervention services. States vary in their eligibility criteria for services. Primary care clinicians should be familiar with their state's requirements and refer eligible patients as soon as possible after discharge home. The long-term neurodevelopment outcome of premature infants and their follow-up care are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34922?source=see_link\">",
"     \"Long-term neurodevelopmental outcome of premature infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Psychosocial issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bringing home a NICU graduate can be very challenging to parents because of social, financial, and psychological stresses [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The clinician should be attentive to these stresses and provide care and assistance to these parents. Support services, such as home health nursing visits, early child interventions services, and support groups, should be offered to parents of the NICU graduate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Vulnerable child syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Features of this syndrome include parents being overprotective of the NICU graduate, abnormal separation difficulties, overindulgence, sleep problems, and long-term problems (eg, behavioral issues, poor peer relationships, and poorer developmental outcome) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/22\">",
"     22",
"    </a>",
"    ]. Such behavior from parents can lead to conflicts within the family, as other siblings and spouses may feel neglected. Clinicians should monitor for this situation and help reduce its occurrence by providing parents with frequent reassurance and monitoring of the infant in question.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Daycare",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some NICU graduates may be too unstable initially to be placed in formal daycare. When choosing a daycare, parents should make sure the patient is stable on room",
"    <span class=\"nowrap\">",
"     air/oxygen",
"    </span>",
"    and feeding is on a routine schedule. Licensed daycare personnel should be trained in cardiopulmonary resuscitation. Patients should be kept out of daycare if they are at high risk for infection, especially if they are being discharged to home in the fall or winter months when seasonal viruses are more prevalent. NICU graduates with BPD are at increased risk for respiratory morbidities with an increased risk of emergency room visits and use of systemic corticosteroids and antibiotics, and experience more days with trouble breathing [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Car seats",
"    </span>",
"    &nbsp;&mdash;&nbsp;All fifty states in the United States require the use of car safety seats for infants to prevent morbidity and mortality caused by motor vehicle accidents. However, premature infants are at increased risk for cardiopulmonary compromise while in car seats. Compared to term infants, premature infants have greater decreases in oxygen saturation and more frequent episodes of desaturation, bradycardia, and apnea while restrained in car seats or beds [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/24-26\">",
"     24-26",
"    </a>",
"    ], with the risk being greatest with infants with predischarge weights &le;2000 g [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     AAP guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of these observations, guidelines were developed by the American Academy of Pediatrics (AAP) in 1996 to minimize the risk of cardiopulmonary compromise [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/28\">",
"     28",
"    </a>",
"    ], which were revised in 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/29\">",
"     29",
"    </a>",
"    ]. They include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Observation of all infants &lt;37 weeks gestation in their car seats before discharge to evaluate for possible apnea, bradycardia, or oxygen desaturation. In addition, infants greater than 37 weeks who are at risk for obstructive apnea, bradycardia, or oxygen desaturation should also be evaluated. These include infants with hypotonia (eg, Down syndrome), those who have undergone cardiac surgery, or have micrognathia (eg, Pierre Robin sequence).",
"      <br/>",
"      <br/>",
"      The duration of observation varies among institutions, but a period of 90 to 120 minutes or the duration of travel, whichever is longer, is suggested. During this trial, the infant's heart and respiratory rate, and oxygen saturation should be monitored. Infants \"fail\" the screen if they have: oxygen desaturation below 90 or 93 percent for more than 10 seconds, apnea greater than or equal to 20 seconds, or bradycardia less than or equal to 80 beats per minute [",
"      <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/30\">",
"       30",
"      </a>",
"      ]. If the infant fails the car seat test, use of a car bed can be considered. A similar period of cardiorespiratory monitoring in a car bed should be performed prior to discharge to home. Discharge should be delayed, and an investigation for cardiopulmonary abnormalities should be sought in any infant who persistently fails the car seat or bed cardiopulmonary screening test. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Car beds'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Rear-facing car seats with three-point harness systems or convertible car seats with five-point harness should be chosen (",
"      <a class=\"graphic graphic_figure graphicRef74459 \" href=\"UTD.htm?11/5/11349\">",
"       figure 2",
"      </a>",
"      ). The car seat should have a distance of less than 14 cm (5.5 inches) from the crotch strap to the seat back and a distance of less than 25.4 cm (10 inches) from the lower harness to the seat bottom.",
"     </li>",
"     <li>",
"      Families should be instructed by trained hospital staff on how to position their infant properly in the car seat. The infant should be positioned with the buttocks and back flat against the back of the car safety seat (",
"      <a class=\"graphic graphic_figure graphicRef74459 \" href=\"UTD.htm?11/5/11349\">",
"       figure 2",
"      </a>",
"      ). Car inserts or padding may be placed on both sides of the infant to provide lateral support for the head and neck, if needed. The shoulder straps are adjusted into the lowest slots that ensure the infant's shoulders are above the slots. The harness must be snug and the car seat's retainer clip should be positioned at the midpoint of the infant's chest.",
"     </li>",
"     <li>",
"      The infant is placed in the rear seat in a rear-facing car safety seat, which is the safest position. The car safety seat should never be placed in the front passenger seat with a passenger-side front air bag because of the risk of death or serious injury from the impact of a deployed air bag. Whenever possible, an adult should be seated adjacent to the infant and the infant should never be left unattended while in a car seat.",
"     </li>",
"     <li>",
"      Infants with documented cardiopulmonary compromise should travel in a supine or prone position in an alternative safety device, such as a car bed.",
"     </li>",
"     <li>",
"      If the infant requires home cardiac and apnea monitoring, this equipment should also be prescribed and used during travel. This equipment should be wedged on the floor or under the vehicle seat to minimize the risk of it falling or striking the infant or other passengers in the car.",
"     </li>",
"     <li>",
"      The duration of time the infant is seated in a car seat should be minimized. Families should be advised that car safety seats should only be used for travel.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Car beds",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the use of car beds has been suggested by the AAP for infants with documented cardiopulmonary compromise in car seats [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/29\">",
"     29",
"    </a>",
"    ]. However, it is unclear whether car beds provide a safer mode of transportation than car seats.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One crossover study of 151 very low birth weight infants reported no differences between the use of car beds versus car seats in the frequency of cardiopulmonary events [",
"      <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/26\">",
"       26",
"      </a>",
"      ]. Cardiopulmonary events occurred in 15 percent of infants while in the car seat and 19 percent while in the car bed. These results suggest that cardiopulmonary events are common regardless of whether a car bed or car seat is used.",
"     </li>",
"     <li>",
"      A second crossover study of 200 term newborns (gestational age 38 to 40 weeks) reported significant oxygenation desaturations when infants were observed in both car beds and car seats as compared with hospital cribs [",
"      <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/31\">",
"       31",
"      </a>",
"      ]. The mean oxygen saturations were 97.9, 96.3, and 95.7 percent when infants were positioned in the hospital crib, car bed, and car seat, respectively. The mean minimal oxygen saturations was lower in both car bed and seat (83.7 and 83.6 percent) compared with the crib (87.4 percent). The mean time of oxygen saturation below 95 percent was higher in both the car bed and seat (17.2 and 23.9 percent) compared with the crib (6.5 percent).",
"     </li>",
"     <li>",
"      In a smaller study of 20 premature infants (median gestational age 33 weeks) evaluated by polysomnography, there was no difference in the frequency of episodes of airway obstruction [",
"      <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/32\">",
"       32",
"      </a>",
"      ]. There were fewer episodes of central apnea and arousal in infants when placed in car beds versus seats, however, premature infants exhibited significant respiratory instability in both settings.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a result of these findings, when a car bed is being considered, we agree with the AAP guidelines that the infant should also be observed for cardiopulmonary stability for 90 to 120 minutes in a car bed. The same criteria as noted above need to be met prior to discharge and transportation of the infant in a car bed [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/29\">",
"     29",
"    </a>",
"    ]. If a car bed is used initially, before transitioning to a car seat, a period of observation of the infant in their car seat for cardiopulmonary events should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'AAP guidelines'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Hospital readmissions",
"    </span>",
"    &nbsp;&mdash;&nbsp;NICU graduates, including both term and preterm infants, are at increased risk for readmissions to the hospital, with reported rates of readmission from 10 to 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. This was illustrated in a study that analyzed data from all premature infants born in nonmilitary hospitals in the state of California from 1992 to 2000. Fifteen percent of infants with a gestational age less than 36 weeks who survived to home discharge required at least one readmission to the hospital within the first year of life [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most common causes for rehospitalization include infections (especially respiratory syncytial virus infection) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/37,38\">",
"     37,38",
"    </a>",
"    ], respiratory problems [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/36,37,39\">",
"     36,37,39",
"    </a>",
"    ], feeding problems, and surgical issues. Parents should be made aware of the increased potential of readmissions for their premature infant.",
"   </p>",
"   <p>",
"    NICU graduates with significant neonatal morbidities are at increased risk for rehospitalization, as illustrated by a retrospective national register study of all very preterm infants (gestational age below 32 weeks) born alive in Finland between 2000 and 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/40\">",
"     40",
"    </a>",
"    ]. The highest rates of rehospitalization were seen in infants with seizures and obstructive airway disease. Rehospitalization rates increased with the number of morbidities at one, two, and three years of age as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      No morbidities: 40, 18, and 13 percent, respectively",
"     </li>",
"     <li>",
"      One morbidity: 65, 41, 27 percent, respectively",
"     </li>",
"     <li>",
"      Two or more morbidities: 73, 63, and 56 percent, respectively",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    NICU graduates who were extremely premature have the highest rates of hospital rehospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/36,41,42\">",
"     36,41,42",
"    </a>",
"    ]. In a large study from the National Institute of Child Health and Human Development Neonatal Research Network of 3787 extremely premature survivors (mean birth weight 787 g) born between 2002 and 2005, 45 percent of the cohort were rehospitalized by 18 to 22 months [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/42\">",
"     42",
"    </a>",
"    ]. The reasons for rehospitalization were respiratory symptoms (45 percent), surgery (21 percent), infection (16 percent), growth and nutrition issues (5 percent), central nervous system abnormalities (4 percent), and a variety of other causes (9 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     COMMON MEDICAL PROBLEMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;NICU graduates are at risk for complications in various organ systems due to their immaturity and long-term sequelae from medical problems during their NICU course. The primary care clinician should be familiar with the more common medical problems that are found in the NICU graduate and coordinate subspecialty care when needed. The most common of these problems are briefly reviewed below, and many are discussed as individual topics in greater detail elsewhere in the program.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Respiratory",
"    </span>",
"    &nbsp;&mdash;&nbsp;NICU graduates often have long-term respiratory issues even after discharge. The most common respiratory problem in premature infants is bronchopulmonary dysplasia (BPD), also referred to as chronic lung disease of prematurity. In addition, these infants are at risk for reactive airway disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/39\">",
"     39",
"    </a>",
"    ] and respiratory infections [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Bronchopulmonary dysplasia (BPD)",
"    </span>",
"    &nbsp;&mdash;&nbsp;BPD is defined as respiratory disease in infants who require supplemental oxygen at 36 weeks postmenstrual age and who have persistent abnormalities on chest radiographs [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/43\">",
"     43",
"    </a>",
"    ]. Infants with BPD often have abnormal lung function during the first year of life and require monitoring and supportive care. At discharge, cardiorespiratory parameters (including respiratory and heart rate, blood pressure, oxygen requirement, chest radiograph, and echocardiogram to assess for the presence of pulmonary hypertension) should be obtained as a baseline status of the patient. At home, these infants may continue to require supplemental oxygen, medications (eg, diuretics and bronchodilators), and increased caloric needs.",
"   </p>",
"   <p>",
"    Clinical management (in collaboration with subspecialists) is focused on monitoring the cardiorespiratory status of the patient, ensuring optimal growth, and minimizing respiratory exacerbations. Pulmonary improvement is based upon the formation of new alveoli that occurs with adequate growth. For patients on diuretic therapy, electrolytes should be monitored on a regular basis.",
"   </p>",
"   <p>",
"    In patients that require supplemental oxygen and medications and exhibit improved pulmonary function, oxygen and medications are weaned slowly, ensuring that the patient maintains adequate growth. Often, the patient is generally allowed to outgrow the diuretic dose, which is discontinued when it reaches a subtherapeutic dose.",
"   </p>",
"   <p>",
"    Patients should be monitored for morbidities related to BPD, including acute respiratory exacerbations, upper and lower respiratory infections, cardiac problems (eg, cor pulmonale and pulmonary hypertension), and growth failure [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/9\">",
"     9",
"    </a>",
"    ]. Any respiratory problems should be treated aggressively with oxygen, diuretics, bronchodilators,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    steroids [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/4\">",
"     4",
"    </a>",
"    ]. These patients often have a high readmission rate to the hospital during the first two years of life [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. After two years of age, most respiratory and nutritional problems begin to improve [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25398?source=see_link\">",
"     \"Outcome of infants with bronchopulmonary dysplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17034?source=see_link\">",
"     \"Pulmonary outcomes of bronchopulmonary dysplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Apnea of prematurity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 25 percent of premature infants develop apnea of prematurity. Most will outgrow this by the time they reach maturity at a postmenstrual age of 40 weeks, often prior to discharge from the NICU. However, some will continue to have apnea and may be discharged home on methylxanthine therapy, such as caffeine. Patients may also be discharged home on apnea monitors. Timing of when to stop caffeine or discontinue monitoring varies among physician practices and will depend on many factors, including postmenstrual age and the presence of symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/13/43223?source=see_link\">",
"     \"Management of apnea of prematurity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Sudden infant death syndrome (SIDS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;SIDS is the death of an infant less than one year of age that remains unexplained despite a thorough investigation. Preterm compared to term infants are at a greater risk for SIDS with a peak risk at 50 to 52 weeks postmenstrual age [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/4\">",
"     4",
"    </a>",
"    ]. Infants may have home apnea monitors, but there is no evidence that monitoring decreases the rate for SIDS.",
"   </p>",
"   <p>",
"    Infants born prematurely or admitted to the NICU for other reasons should follow the American Academy recommendations of supine (back) sleeping position. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37194?source=see_link&amp;anchor=H5#H5\">",
"     \"Sudden infant death syndrome: Risk factors and risk reduction strategies\", section on 'Prematurity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Gastroesophageal reflux (GER)",
"    </span>",
"    &nbsp;&mdash;&nbsp;GER is common in premature infants and those with BPD, neurological impairment, or congenital defects (eg, tracheo-esophageal fistulas or diaphragmatic hernias). Complications associated with GER in the preterm infant include poor weight gain due to decreased caloric intake, apnea and bradycardia, aspiration, choking, esophagitis, laryngospasms, and discomfort.",
"   </p>",
"   <p>",
"    The evaluation and management of GER in the preterm infants are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/6/23657?source=see_link\">",
"     \"Gastroesophageal reflux in premature infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Anemia of prematurity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preterm and low birth weight infants develop anemia that occurs earlier and is more severe than the physiologic anemia seen in term infants with appropriate and appropriate for gestational infants.",
"   </p>",
"   <p>",
"    In preterm infants, the nadir for hemoglobin level is 7 to 10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    at 4 to 8 weeks after birth compared to 11",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    at 8 to 12 weeks in term infants. In a trial of low birth weight infants (birthweight between 2000 and 2500 g), infants treated with iron supplementation (2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) compared to those who received placebo from six weeks to six months had lower rates of iron deficiency (3.8 versus 36 percent) and iron deficiency anemia (0 versus 9.9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/47\">",
"     47",
"    </a>",
"    ] .",
"   </p>",
"   <p>",
"    In our practice, all preterm infants (less than 37 weeks gestation) and low birth weight infants (birth weight less than 2500 g) who are breastfed receive iron supplementation of 2 to 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day through 12 months of age. This approach is consistent with the recommendation from the 2010 American Academy of Pediatrics Committee on Nutrition report on the diagnosis and prevention of iron deficiency and iron deficiency anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/48\">",
"     48",
"    </a>",
"    ]. Infants who receive iron-fortified formula need less additional supplementation than those who are exclusively breastfed, because for a given volume, iron-containing formula contains a higher concentration of iron than breast milk. Symptomatic infants may require red blood cell transfusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20792?source=see_link\">",
"     \"Anemia of prematurity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Ophthalmologic conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premature infants are at risk for ophthalmologic conditions, including retinopathy of prematurity (ROP), amblyopia, strabismus, significant myopia, and anisometropia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As previously discussed, ROP (a developmental vascular proliferative retinal disorder) is common in preterm infants, especially ELBW and VLBW infants, and is the second most common cause of blindness in childhood. Screening for ROP with retinal examination is imperative four to six weeks after birth, as treatment can reduce the morbidity of this condition. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Vision'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10762?source=see_link\">",
"     \"Retinopathy of prematurity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In preterm infants, there is a high prevalence of other ophthalmologic disorders, as demonstrated in a report of ELBW infants evaluated at five years old. Reduced visual acuity, strabismus, myopia, and stigmatism were present in 27, 14, 12, and 11 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/50\">",
"     50",
"    </a>",
"    ]. Thus, we recommend that all premature infants undergo examination by an ophthalmologist at 9 to 12 months of age and at two to three years of age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24505?source=see_link\">",
"     \"Visual development and vision assessment in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to ROP, other ophthalmologic conditions seen in NICU graduates include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Refractive errors &mdash; Refractive errors are more frequent in premature than term infants. Among premature infants evaluated at 4.5 years, the proportion of eyes with myopia and high myopia (5 diopters or greater) was 15.7 and 3.9 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/51\">",
"       51",
"      </a>",
"      ]. Low gestational age and severe ROP increased the risk. Vision is corrected with glasses or contact lenses. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28628?source=see_link\">",
"       \"Refractive errors in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Amblyopia &mdash; Amblyopia is reduced vision caused by lack of use of one eye during the critical age for visual development (before seven years old). In premature infants, amblyopia typically results from strabismus, anisometropia, and bilateral high refractive error (bilateral ametropia) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/49,50,52\">",
"       49,50,52",
"      </a>",
"      ]. Amblyopia can become permanent if it is not treated before 6 to 10 years of age. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8153?source=see_link&amp;anchor=H8#H8\">",
"       \"Overview of amblyopia\", section on 'Natural history and sequelae'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Strabismus &mdash; Strabismus, defined as misalignment of the eyes, occurs in approximately 13 to 25 percent of premature infants compared with 2 to 5 percent of term infants [",
"      <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/46\">",
"       46",
"      </a>",
"      ]. The most common form is esotropia (crossed eyes), although exotropia (also known as wall-eye) and hypertropia (vertical misalignment of the eyes so that one eye is higher than the other) also occur. Strabismus typically requires surgical correction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34951?source=see_link&amp;anchor=H8#H8\">",
"       \"Evaluation and management of strabismus in children\", section on 'Evaluation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anisometropia &mdash; Anisometropia, defined as a substantial difference in refractive error between the two eyes, occurs more often in premature than term infants [",
"      <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/51,53\">",
"       51,53",
"      </a>",
"      ]. Because the eyes cannot accommodate (focus) separately, the eye with the higher refractive error can develop amblyopia. Treatment for anisometropia is vision correction with glasses or contact lenses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Neurodevelopmental problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;NICU graduates are at increased risk for neurodevelopmental problems and disabilities compared to term infants. As discussed previously, screening is necessary to identify infants with neurodevelopmental problems who require early interventional services and is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34922?source=see_link&amp;anchor=H24#H24\">",
"     \"Long-term neurodevelopmental outcome of premature infants\", section on 'Follow-up care'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neurodevelopment disorders, other than sensory impairment (ie, hearing and vision loss), that occur frequently in NICU grads are listed here and are reviewed in greater detail separately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Motor impairment and cerebral palsy &mdash; Cerebral palsy is a common sequelae seen in approximately 7 to 9 percent of very low birth weight infants (birth weight below 1500 g). It is important to monitoring the motor function of NICU grads during office visits to detect those with significant motor impairment who require referral to a pediatric neurologist for further evaluation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29209?source=see_link\">",
"       \"Clinical features of cerebral palsy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41768?source=see_link\">",
"       \"Epidemiology and etiology of cerebral palsy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15962?source=see_link\">",
"       \"Management and prognosis of cerebral palsy\"",
"      </a>",
"      .) Visual motor and motor coordination problems are also more common in premature infants; early identification of these issues and implementation of occupational therapy or physical therapy are indicated.",
"     </li>",
"     <li>",
"      Learning and language delays &mdash; Developmental screening is imperative so that early identification of problems can occur and early intervention be initiated. Developmental evaluations should be based on patient's postmenstrual age and not chronological age until at least 24 months of age. Referrals to high-risk development clinics and Early Child Intervention Programs should be made for all premature infants. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34922?source=see_link\">",
"       \"Long-term neurodevelopmental outcome of premature infants\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26343?source=see_link\">",
"       \"Evaluation and treatment of speech and language disorders in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32665?source=see_link&amp;anchor=H6#H6\">",
"       \"Specific learning disabilities in children: Clinical features\", section on 'Risk factors'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Primary care clinicians can identify infants who would benefit from early intervention by screening preterm survivors using a quality developmental screening instrument [",
"      <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/54\">",
"       54",
"      </a>",
"      ]. In one retrospective study, the use of a developmental screening tool, the Ages and Stages Questionnaire, compared to clinical impression increased the identification and referral rates for preterm infants (26 versus 10 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/55\">",
"       55",
"      </a>",
"      ]. About half of the patients (56 percent) identified by the screening tool were eligible for early intervention doses.",
"     </li>",
"     <li>",
"      Psychosocial difficulties &mdash; Psychosocial difficulties are increasingly a concern in the population of premature infants. In particular, prematurity appears to be a risk factor for autism. Appropriate screening tools that the primary care physician can use to identify children at risk for autism include the Infant Toddler Checklist for toddlers less than 18 months and the Modified Checklist for Autism in Toddlers (M-CHAT) for children 18 months and older [",
"      <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hydrocephalus &mdash; Posthemorrhagic hydrocephalus occurs in approximately 35 percent of preterm infants with intraventricular hemorrhage (IVH). The risk increases with the severity of IVH (ie, grades III and IV). It can be obstructive, communicating, or both; transient or sustained; and with slow or rapid progression. In some cases, shunt replacement is required. These patients need to be monitored for shunt malfunction or infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/46/31465?source=see_link\">",
"       \"Management and complications of intraventricular hemorrhage in the newborn\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/54/5994?source=see_link\">",
"       \"Hydrocephalus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Surgical",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some NICU graduates will have had surgeries prior to being discharged from the NICU. These include surgical bowel resection secondary to necrotizing enterocolitis (NEC)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intestinal perforation, gastrostomy tube placements, fundoplications, ventriculo-peritoneal shunts, tracheotomy, and cardiac surgeries. Parents should be instructed on how to care for the surgical areas. Coordination with surgical services and post discharge follow-up should be arranged.",
"   </p>",
"   <p>",
"    Both umbilical and inguinal hernias are common in preterm infants.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Umbilical hernias &mdash; Umbilical hernias are reported to occur in up to 75 percent of preterm infants with BW between 1000 to 1500 g [",
"      <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/9\">",
"       9",
"      </a>",
"      ]. The hernia is more noticeable when the infant is crying or straining (eg, bowel movement). Most will resolve spontaneously by two years of age. Surgical closure is considered if the hernia is still present after age four, is &gt;2 cm in size,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      associated with abdominal pain [",
"      <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/57\">",
"       57",
"      </a>",
"      ]. Surgery is indicated if there are signs of incarceration.",
"     </li>",
"     <li>",
"      Inguinal hernia &mdash; Inguinal hernias are more common in preterm than term infants. The incidence of inguinal hernia varies as follows [",
"      <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/55,58\">",
"       55,58",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Birth weight 500 to 1000 g &mdash; 30 to 42 percent",
"     </li>",
"     <li>",
"      Birth weight 1000 to 1500 g &mdash; 10 percent",
"     </li>",
"     <li>",
"      Birth weight 1500 to 2000 g &mdash; 3 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other risk factors include male sex and prolonged mechanical ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/59\">",
"     59",
"    </a>",
"    ]. The rate of incarcerated hernia is greater in preterm compared to term infants [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/60\">",
"     60",
"    </a>",
"    ]. If an inguinal hernia is detected, referral to pediatric surgery should be made. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21561?source=see_link\">",
"     \"Overview of inguinal hernia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Dental",
"    </span>",
"    &nbsp;&mdash;&nbsp;In premature infants, teeth eruption may be delayed. It is based upon adjusted postmenstrual age and usually occurs between 3 to 10 months. The American Academy of Pediatric Dentistry Guideline on Infant Oral Health Care recommends a first visit to the dentist by 12 months of age. Optimal exposure to fluoride is also recommended either via water or systemically administered drops [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Premature infants and term infants who have been critically ill are at increased risk of developing dental problems. These include enamel hypoplasia with increased risk for dental caries, delayed tooth eruption, tooth discoloration, palatal groove, and tooth malalignment [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Infants with a history of prolonged intubation have v-shaped palates, posterior cross bites, deformed incisal edges, and missing teeth [",
"    <a class=\"abstract\" href=\"UTD.htm?11/29/11738/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/28/19905?source=see_link\">",
"       \"Patient information: Retinopathy of prematurity (ROP) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    Advances in neonatal intensive care have improved the survival of high-risk preterm and critically ill term infants who upon discharge continue to need comprehensive clinical care. The primary care clinician plays a key role in providing optimal continuity of these patients by coordinating transition of care from the neonatologist, providing direct medical care, and facilitating ongoing care of the infant with subspecialists and other health professionals.",
"   </p>",
"   <p>",
"    The following are important aspects of outpatient primary care management of the neonatal intensive care (NICU) graduate:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Review the infant's NICU course, current medications, and medical equipment. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Initial visit'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Continue assessment of the patient's growth. If growth is inadequate, evaluation of the infant's nutrition and initiation of corrective measures (eg, changes in the composition, volume, and caloric density of the feeds, and mode of feeding), and for contributing conditions (eg, gastroesophageal reflux or feeding disorders) are required. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Growth'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23912?source=see_link\">",
"       \"Growth management in preterm infants\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For all preterm infants, we recommend administration of childhood vaccines based upon",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      chronological age with the same schedule and dose recommended for normal term infants (",
"      <a class=\"graphic graphic_figure graphicRef82617 \" href=\"UTD.htm?24/55/25463\">",
"       figure 1",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Patients should have received hepatitis B (HBV) immunization during their NICU course (",
"      <a class=\"graphic graphic_table graphicRef55139 \" href=\"UTD.htm?27/57/28572\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Immunization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For preterm infants, infants with chronic lung disease and those with hemodynamically significant congenital heart disease, we recommend prophylactic administration of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/0/40964?source=see_link\">",
"       palivizumab",
"      </a>",
"      to prevent severe RSV infection (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Palivizumab should be administered to infants &lt;1 year of age who were born at &le;28 weeks of gestation and for infants &lt;6 months of age who were born between 29 and 32 weeks of gestation. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Immunization'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/17/15640?source=see_link&amp;anchor=H104278863#H104278863\">",
"       \"Respiratory syncytial virus infection: Prevention\", section on 'Palivizumab'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For NICU graduates, we recommend administering influenza vaccine at the chronological age of six months (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). During influenza season, family members and household contacts of at-risk infants younger than six months of age should be immunized with the influenza vaccine. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Immunization'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=see_link&amp;anchor=H7#H7\">",
"       \"Seasonal influenza vaccination in children\", section on 'Indications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend screening for hearing, vision, and neurodevelopmental problems, which have a high prevalence rate in the NICU graduate (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We recommend hearing screen at the time of discharge for all infants admitted to the NICU (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ) and suggest a repeat screen in the first year of life (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For infants at risk for retinopathy of prematurity, we recommend retinal screening by an ophthalmologist (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We recommend an additional ophthalmologic examination at 9 to 12 months of age (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ), because other vision problems are common in NICU graduates. These include reduced visual acuity, strabismus, myopia, and stigmatism. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Ophthalmologic conditions'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10762?source=see_link\">",
"       \"Retinopathy of prematurity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Primary care clinicians need to ensure the NICU graduate is evaluated for neurodevelopmental disabilities and be familiar with community resources that would be beneficial to the child. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34922?source=see_link\">",
"       \"Long-term neurodevelopmental outcome of premature infants\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Consistent care that provides continuity of information and psychosocial support to the family is important.",
"     </li>",
"     <li>",
"      Preterm infants in car safety seats are at increased risk for cardiopulmonary compromise and clinicians need to be familiar with the American Academy of Pediatrics guidelines for proper selection of car safety seats and positioning of the preterm infant to minimize their risk (",
"      <a class=\"graphic graphic_figure graphicRef74459 \" href=\"UTD.htm?11/5/11349\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Car seats'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinician should be familiar with the more common medical problems that are found in the NICU graduate and be able to coordinate subspecialty care when needed. Common medical problems include bronchopulmonary dysplasia (BPD), apnea of prematurity, sudden infant disease syndrome (SIDS), gastroesophageal reflux (GER), and anemia of prematurity. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Common medical problems'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/1\">",
"      Meadow W, Lee G, Lin K, Lantos J. Changes in mortality for extremely low birth weight infants in the 1990s: implications for treatment decisions and resource use. Pediatrics 2004; 113:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/2\">",
"      Martin JA, Hamilton BE, Sutton PD, et al. Centers for Disease Control and Prevention National Center for Health Statistics National Vital Statistics System. Births: Final Data for 2006. National Vital Statistics Reports 2009; 57:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/3\">",
"      Stoelhorst GM, Rijken M, Martens SE, et al. Changes in neonatology: comparison of two cohorts of very preterm infants (gestational age &lt;32 weeks): the Project On Preterm and Small for Gestational Age Infants 1983 and the Leiden Follow-Up Project on Prematurity 1996-1997. Pediatrics 2005; 115:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/4\">",
"      Verma RP, Sridhar S, Spitzer AR. Continuing care of NICU graduates. Clin Pediatr (Phila) 2003; 42:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/5\">",
"      American Academy of Pediatrics Committee on Fetus and Newborn. Hospital discharge of the high-risk neonate. Pediatrics 2008; 122:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/6\">",
"      The role of the primary care pediatrician in the management of high-risk newborn infants. American Academy of Pediatrics. Committee on Practice and Ambulatory Medicine and Committee on Fetus and Newborn. Pediatrics 1996; 98:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/7\">",
"      Wang CJ, McGlynn EA, Brook RH, et al. Quality-of-care indicators for the neurodevelopmental follow-up of very low birth weight children: results of an expert panel process. Pediatrics 2006; 117:2080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/8\">",
"      Berger SP, Holt-Turner I, Cupoli JM, et al. Caring for the graduate from the neonatal intensive care unit. At home, in the office, and in the community. Pediatr Clin North Am 1998; 45:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/9\">",
"      McCourt MF, Griffin CM. Comprehensive primary care follow-up for premature infants. J Pediatr Health Care 2000; 14:270.",
"     </a>",
"    </li>",
"    <li>",
"     Groh-Wargo S, Thompson M, Hovasi-Cox J, et al. Nutritional Care for High-Risk Newborns, Precept Press Inc, Chicago, IL 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/11\">",
"      Slack MH, Cade S, Schapira D, et al. DT5aP-Hib-IPV and MCC vaccines: preterm infants' response to accelerated immunisation. Arch Dis Child 2005; 90:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/12\">",
"      Kirmani KI, Lofthus G, Pichichero ME, et al. Seven-year follow-up of vaccine response in extremely premature infants. Pediatrics 2002; 109:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/13\">",
"      D'Angio CT, Maniscalco WM, Pichichero ME. Immunologic response of extremely premature infants to tetanus, Haemophilus influenzae, and polio immunizations. Pediatrics 1995; 96:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/14\">",
"      Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 19:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/15\">",
"      Ome&ntilde;aca F, Garcia-Sicilia J, Boceta R, et al. Antibody persistence and booster vaccination during the second and fifth years of life in a cohort of children who were born prematurely. Pediatr Infect Dis J 2007; 26:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/16\">",
"      R&uuml;ckinger S, van der Linden M, von Kries R. Effect of heptavalent pneumococcal conjugate vaccination on invasive pneumococcal disease in preterm born infants. BMC Infect Dis 2010; 10:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/17\">",
"      D'Angio CT, Heyne RJ, O'Shea TM, et al. Heptavalent pneumococcal conjugate vaccine immunogenicity in very-low-birth-weight, premature infants. Pediatr Infect Dis J 2010; 29:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/18\">",
"      Saari TN, American Academy of Pediatrics Committee on Infectious Diseases. Immunization of preterm and low birth weight infants. American Academy of Pediatrics Committee on Infectious Diseases. Pediatrics 2003; 112:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/19\">",
"      Committee on Infectious Diseases. From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009; 124:1694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/20\">",
"      Drotar D, Hack M, Taylor G, et al. The impact of extremely low birth weight on the families of school-aged children. Pediatrics 2006; 117:2006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/21\">",
"      Silverstein M, Feinberg E, Young R, Sauder S. Maternal depression, perceptions of children's social aptitude and reported activity restriction among former very low birthweight infants. Arch Dis Child 2010; 95:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/22\">",
"      McCormick MC, Shapiro S, Starfield B. Factors associated with maternal opinion of infant development--clues to the vulnerable child? Pediatrics 1982; 69:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/23\">",
"      McGrath-Morrow SA, Lee G, Stewart BH, et al. Day care increases the risk of respiratory morbidity in chronic lung disease of prematurity. Pediatrics 2010; 126:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/24\">",
"      Willett LD, Leuschen MP, Nelson LS, Nelson RM Jr. Risk of hypoventilation in premature infants in car seats. J Pediatr 1986; 109:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/25\">",
"      Merchant JR, Worwa C, Porter S, et al. Respiratory instability of term and near-term healthy newborn infants in car safety seats. Pediatrics 2001; 108:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/26\">",
"      Salhab WA, Khattak A, Tyson JE, et al. Car seat or car bed for very low birth weight infants at discharge home. J Pediatr 2007; 150:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/27\">",
"      Ojadi VC, Petrova A, Mehta R, Hegyi T. Risk of cardio-respiratory abnormalities in preterm infants placed in car seats: a cross-sectional study. BMC Pediatr 2005; 5:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/28\">",
"      Safe transportation of premature and low birth weight infants. American Academy of Pediatrics. Committee on Injury and Poison Prevention and Committee on Fetus and Newborn. Pediatrics 1996; 97:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/29\">",
"      Bull MJ, Engle WA, Committee on Injury, Violence, and Poison Prevention and Committee on Fetus and Newborn, American Academy of Pediatrics. Safe transportation of preterm and low birth weight infants at hospital discharge. Pediatrics 2009; 123:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/30\">",
"      Bass JL. The infant car seat challenge: determining and managing an \"abnormal\" result. Pediatrics 2010; 125:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/31\">",
"      Kornhauser Cerar L, Scirica CV, Stucin Gantar I, et al. A comparison of respiratory patterns in healthy term infants placed in car safety seats and beds. Pediatrics 2009; 124:e396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/32\">",
"      Elder DE, Russell L, Sheppard D, et al. Car seat test for preterm infants: comparison with polysomnography. Arch Dis Child Fetal Neonatal Ed 2007; 92:F468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/33\">",
"      Gray JE, McCormick MC, Richardson DK, Ringer S. Normal birth weight intensive care unit survivors: outcome assessment. Pediatrics 1996; 97:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/34\">",
"      Hack M, Taylor HG, Drotar D, et al. Chronic conditions, functional limitations, and special health care needs of school-aged children born with extremely low-birth-weight in the 1990s. JAMA 2005; 294:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/35\">",
"      Escobar GJ, McCormick MC, Zupancic JA, et al. Unstudied infants: outcomes of moderately premature infants in the neonatal intensive care unit. Arch Dis Child Fetal Neonatal Ed 2006; 91:F238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/36\">",
"      Underwood MA, Danielsen B, Gilbert WM. Cost, causes and rates of rehospitalization of preterm infants. J Perinatol 2007; 27:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/37\">",
"      McCormick J, Tubman R. Readmission with respiratory syncytial virus (RSV) infection among graduates from a neonatal intensive care unit. Pediatr Pulmonol 2002; 34:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/38\">",
"      Nachman SA, Navaie-Waliser M, Qureshi MZ. Rehospitalization with respiratory syncytial virus after neonatal intensive care unit discharge: A 3-year follow-up. Pediatrics 1997; 100:E8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/39\">",
"      Koivisto M, Marttila R, Saarela T, et al. Wheezing illness and re-hospitalization in the first two years of life after neonatal respiratory distress syndrome. J Pediatr 2005; 147:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/40\">",
"      Korvenranta E, Lehtonen L, Peltola M, et al. Morbidities and hospital resource use during the first 3 years of life among very preterm infants. Pediatrics 2009; 124:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/41\">",
"      Luu TM, Lefebvre F, Riley P, Infante-Rivard C. Continuing utilisation of specialised health services in extremely preterm infants. Arch Dis Child Fetal Neonatal Ed 2010; 95:F320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/42\">",
"      Ambalavanan N, Carlo WA, McDonald SA, et al. Identification of extremely premature infants at high risk of rehospitalization. Pediatrics 2011; 128:e1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/43\">",
"      Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001; 163:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/44\">",
"      Furman L, Baley J, Borawski-Clark E, et al. Hospitalization as a measure of morbidity among very low birth weight infants with chronic lung disease. J Pediatr 1996; 128:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/45\">",
"      Cunningham CK, McMillan JA, Gross SJ. Rehospitalization for respiratory illness in infants of less than 32 weeks' gestation. Pediatrics 1991; 88:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/46\">",
"      Bhutani VK, Abbasi S. Long-term pulmonary consequences in survivors with bronchopulmonary dysplasia. Clin Perinatol 1992; 19:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/47\">",
"      Berglund S, Westrup B, Domell&ouml;f M. Iron supplements reduce the risk of iron deficiency anemia in marginally low birth weight infants. Pediatrics 2010; 126:e874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/48\">",
"      Baker RD, Greer FR, Committee on Nutrition American Academy of Pediatrics. Diagnosis and prevention of iron deficiency and iron-deficiency anemia in infants and young children (0-3 years of age). Pediatrics 2010; 126:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/49\">",
"      Holmstr&ouml;m G, el Azazi M, Kugelberg U. Ophthalmological follow up of preterm infants: a population based, prospective study of visual acuity and strabismus. Br J Ophthalmol 1999; 83:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/50\">",
"      Hebbandi SB, Bowen JR, Hipwell GC, et al. Ocular sequelae in extremely premature infants at 5 years of age. J Paediatr Child Health 1997; 33:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/51\">",
"      Quinn GE, Dobson V, Kivlin J, et al. Prevalence of myopia between 3 months and 5 1/2 years in preterm infants with and without retinopathy of prematurity. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology 1998; 105:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/52\">",
"      Repka MX, Summers CG, Palmer EA, et al. The incidence of ophthalmologic interventions in children with birth weights less than 1251 grams. Results through 5 1/2 years. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology 1998; 105:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/53\">",
"      Knight-Nanan DM, O'Keefe M. Refractive outcome in eyes with retinopathy of prematurity treated with cryotherapy or diode laser: 3 year follow up. Br J Ophthalmol 1996; 80:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/54\">",
"      Marks K, Hix-Small H, Clark K, Newman J. Lowering developmental screening thresholds and raising quality improvement for preterm children. Pediatrics 2009; 123:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/55\">",
"      Harper RG, Garcia A, Sia C. Inguinal hernia: a common problem of premature infants weighing 1,000 grams or less at birth. Pediatrics 1975; 56:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/56\">",
"      Johnson CP, Myers SM, American Academy of Pediatrics Council on Children With Disabilities. Identification and evaluation of children with autism spectrum disorders. Pediatrics 2007; 120:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/57\">",
"      Gill FT. Umbilical hernia, inguinal hernias, and hydroceles in children: diagnostic clues for optimal patient management. J Pediatr Health Care 1998; 12:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/58\">",
"      Peevy KJ, Speed FA, Hoff CJ. Epidemiology of inguinal hernia in preterm neonates. Pediatrics 1986; 77:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/59\">",
"      Powell TG, Hallows JA, Cooke RW, Pharoah PO. Why do so many small infants develop an inguinal hernia? Arch Dis Child 1986; 61:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/60\">",
"      Rajput A, Gauderer MW, Hack M. Inguinal hernias in very low birth weight infants: incidence and timing of repair. J Pediatr Surg 1992; 27:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/61\">",
"      American Academy on Pediatric Dentistry Clinical Affairs Committee-Infant Oral Health Subcommittee, American Academy on Pediatric Dentistry Council on Clinical Affairs. Guideline on infant oral health care. Pediatr Dent 2008; 30:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/62\">",
"      Creighton PR. Common pediatric dental problems. Pediatr Clin North Am 1998; 45:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/29/11738/abstract/63\">",
"      Eastman DL. Dental outcomes of preterm infants. Newborn and Infant Nursing Reviews 2003; 3:93.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5005 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.96.59.103-BD52B341D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_29_11738=[""].join("\n");
var outline_f11_29_11738=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OUTPATIENT MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Initial visit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Subsequent visits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Growth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Immunization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Hearing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Vision",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Neurodevelopment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Psychosocial issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Vulnerable child syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Daycare",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Car seats",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - AAP guidelines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Car beds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Hospital readmissions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      COMMON MEDICAL PROBLEMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Respiratory",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Bronchopulmonary dysplasia (BPD)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Apnea of prematurity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Sudden infant death syndrome (SIDS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Gastroesophageal reflux (GER)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Anemia of prematurity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Ophthalmologic conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Neurodevelopmental problems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Surgical",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Dental",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5005\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5005|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/55/25463\" title=\"figure 1\">",
"      Childhood immunization schedule 0 to 6 yrs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/5/11349\" title=\"figure 2\">",
"      Carseat preterm infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5005|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/57/28572\" title=\"table 1\">",
"      HBV immunization management of preterm infants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20792?source=related_link\">",
"      Anemia of prematurity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29209?source=related_link\">",
"      Clinical features of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/7/27765?source=related_link\">",
"      Discharge planning for high-risk newborns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41768?source=related_link\">",
"      Epidemiology and etiology of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34951?source=related_link\">",
"      Evaluation and management of strabismus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26343?source=related_link\">",
"      Evaluation and treatment of speech and language disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/6/23657?source=related_link\">",
"      Gastroesophageal reflux in premature infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23912?source=related_link\">",
"      Growth management in preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/63/37881?source=related_link\">",
"      Hepatitis viruses and the newborn: Clinical manifestations and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/54/5994?source=related_link\">",
"      Hydrocephalus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22713?source=related_link\">",
"      Late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34922?source=related_link\">",
"      Long-term neurodevelopmental outcome of premature infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/46/31465?source=related_link\">",
"      Management and complications of intraventricular hemorrhage in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15962?source=related_link\">",
"      Management and prognosis of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/13/43223?source=related_link\">",
"      Management of apnea of prematurity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25398?source=related_link\">",
"      Outcome of infants with bronchopulmonary dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8153?source=related_link\">",
"      Overview of amblyopia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21561?source=related_link\">",
"      Overview of inguinal hernia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/28/19905?source=related_link\">",
"      Patient information: Retinopathy of prematurity (ROP) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17034?source=related_link\">",
"      Pulmonary outcomes of bronchopulmonary dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28628?source=related_link\">",
"      Refractive errors in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/17/15640?source=related_link\">",
"      Respiratory syncytial virus infection: Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10762?source=related_link\">",
"      Retinopathy of prematurity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40937?source=related_link\">",
"      Rotavirus vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/13/27865?source=related_link\">",
"      Screening the newborn for hearing loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=related_link\">",
"      Seasonal influenza vaccination in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32665?source=related_link\">",
"      Specific learning disabilities in children: Clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37194?source=related_link\">",
"      Sudden infant death syndrome: Risk factors and risk reduction strategies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=related_link\">",
"      Tetanus-diphtheria toxoid vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24505?source=related_link\">",
"      Visual development and vision assessment in infants and children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_29_11739="Risk factors for date rape";
var content_f11_29_11739=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75628&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75628&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk factors for date rape",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Age 16 to 24 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Previous history of physical or sexual victimization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Greater number of dating or sexual partners",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acceptance of rape myths*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Strong belief in traditional gender roles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Date-specific factors (eg, going somewhere to be alone, expenses paid by date)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alcohol or drug use (promotes misinterpretation of behaviors and impairs ability for self defense)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pressure by date to use alcohol or drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beverages spiked with \"date rape\" drugs (eg, flunitrazepam [Rohypnol",
"        <sup>",
"         &reg;",
"        </sup>",
"        ], 3,4-methylendioxymethamphetamine [MDMA or ecstasy], ketamine, gamma hydroxybutyrate [GHB])",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Rape myths are prejudiced, stereotyped, or false beliefs about rape, rape victims, and rapists (eg, \"Most rapists are strangers\", \"Any healthy woman can resist a rapist if she really wants to\").",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_29_11739=[""].join("\n");
var outline_f11_29_11739=null;
var title_f11_29_11740="Dx criteria PCOS";
var content_f11_29_11740=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80095&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80095&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic criteria for polycystic ovary syndrome*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        National Institute of Health criteria (1990)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evidence of anovulation or oligo-ovulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Evidence of clinical or biochemical hyperandrogenism (either)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Clinical: hirsutism, acne, or male pattern balding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Biochemical: high serum androgen concentration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Rotterdam criteria by the European Society of Human Reproduction and Embryology/American Society of Reproductive Medicine (2003)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Two out of three following findings are required for diagnosis:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Evidence of anovulation or oligo-ovulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Evidence of clinical or biochemical hyperandrogenism (either)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Clinical: hirsutism, acne, or male pattern balding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Biochemical: high serum androgen concentration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        A polycystic ovary (by ultrasound)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Androgen Excess and PCOS Society criteria (2006)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Evidence of ovarian dysfunction (either)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Evidence of anovulation or oligo-ovulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        A polycystic ovary (by ultrasound)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Evidence of clinical or biochemical hyperandrogenism (either)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Clinical: hirsutism, acne, or male pattern balding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Biochemical: high serum androgen concentration",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * All criteria involve exclusion of other causes of hyperandrogenism and menstrual irregularity.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_29_11740=[""].join("\n");
var outline_f11_29_11740=null;
var title_f11_29_11741="Platelet transfusion guidelines";
var content_f11_29_11741=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F52206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F52206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ASCO platelet transfusion guidelines",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Platelet products",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The benefits of pooled platelets or single donor platelets are similar; the two products can be used interchangeably. Single donor platelets from selected donors are preferred when histocompatible platelet transfusions (ie, HLA-A and HLA-B antigen matched) are needed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Prophylactic platelet transfusion thresholds",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Acute leukemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        For adult patients, a threshold of 10,000/microL is recommended. Transfusion at higher levels may be necessary in the newborn, or in patients with hemorrhage, high fever, hyperleukocytosis, rapid fall in platelet count, or coagulation abnormalities.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Hematopoietic cell transplantation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Same as for acute leukemia, with similar caveats.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Chronic stable severe thrombocytopenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Many patients can be observed without prophylactic transfusion, reserving transfusion for episodes of hemorrhage or during times of active treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Solid tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Evidence supports the benefit of prophylactic transfusion at a threshold of 10,000/microL or less. A threshold of 20,000/microL should be considered for patients receiving aggressive therapy for bladder cancer, as well as those with demonstrated necrotic tumors.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Surgical or invasive procedures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        A platelet count of 40,000 to 50,000/microL is sufficient to perform major invasive procedures safely, in the absence of associated coagulation abnormalities. Certain procedures, such as bone marrow aspiration/biopsy can be performed safely with counts &lt;20,000/microL; lumbar puncture in children is safe at platelet counts &gt;10,000/microL.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Prevention of RhD alloimmunization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        RhD-negative children (especially girls) and women of child-bearing age should be considered for treatment with either the exclusive use of platelets from RhD-negative donors or via anti-D immunoprophylaxis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Prevention of alloimmunization using leukoreduced blood products",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        It is appropriate to provide leukoreduced blood products to patients with AML from the time of diagnosis to ameliorate the problem of alloantibody-mediated refractoriness to platelet transfusion. Currently, this is not indicated in patients with cancer receiving RBCs or treatments that do not produce significant and sustained thrombocytopenia. Universal leukoreduction of blood products would obviate the need for these decisions in individual patients.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diagnosis of refractoriness to platelet transfusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A corrected count increment (CCI) of &ge;5000 (see text for definitions) is recommended as a definition of a satisfactory response. A rough estimate of a CCI of 5000 is an absolute platelet count increment of 2000/microL per unit of platelet concentrate given to an average-sized adult. For children, an approximate equivalent is an absolute platelet count increment of 3500/microL per meter squared per transfused unit. A diagnosis of refractoriness should be entertained only when at least two consecutive",
"        <strong>",
"         ABO-compatible",
"        </strong>",
"        transfusions, stored less than 72 hours, result in poor increments.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Management of refractoriness to platelet transfusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients with alloimmune refractory thrombocytopenia (ie, poor increments in association with alloantibody detected using lymphocytotoxicity or antiplatelet antibody assays) are best managed with HLA-A and HLA-B antigen selected donors or from compatible donors identified using platelet cross matching techniques. Alloimmunized patients do not benefit from unmatched prophylactic platelet transfusions that fail to raise the platelet count. Such patients should be transfused only for hemorrhagic events.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19:1519.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_29_11741=[""].join("\n");
var outline_f11_29_11741=null;
var title_f11_29_11742="Treatment AL amyloidosis transplant ineligible";
var content_f11_29_11742=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F88826&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F88826&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Approach to therapy in patients with AL amyloidosis not eligible for hematopoietic cell transplantation (HCT)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 282px; background-image: url(data:image/gif;base64,R0lGODlhegEaAcQAAP///wAAAIiIiLu7u0RERCIiIpmZmTMzM2ZmZt3d3e7u7hEREczMzFVVVXd3d6qqqp+fn8/Pz9/f3z8/Pw8PD+/v719fX39/f7+/vwAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAB6ARoBAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b04G8fs/v+/+AgYKDhIWGh4iJiouMjY5/dycBkZSVL5OWIpiZnJ0Am5agnqN3opSmpKlxqKWqrnOsdrExA7MkAgRLBAJKAQMtvl+7RMEruLe5KrawJQQBvAnFLLUux8NH1yQHAQkiCAg90iPUJOIo5izHPdkq6uW/LL7kJdTuAPaSnaIEBdzR8NOWicBnhB2AAQsO8ALwLRxAZQ93EMRhEMVEF+hM2Ls4QuCqZggIEPgHoEGeAwoU/5Jo4IBaAV4KFjy4pSfXsH4BCjC4VxMAgW0BwCUA6gCAgQV5eJkMgLKknoUjEDQwUMAbOBMG9IATgPMA0AdHFdw78OmXswAEFFAbqsdsnrQMgDYoGzfPXBXR8iDAJSBAVr33CvRDqeDsAp9Awd3Mo/MTUAN5g76rtW3Bzr45d8qbxDbPgHoFkKI8NgCngRIe4exDUKvvAAFNFTqYSwCcZWpUjVYdwSCYNagACjjoPdNarloJGsxlsGAAgaIDYwvg2o1dzAcxfzVMkVUB9Wi8QgY/XeC0L64KUgqg1iDZ+QLpFcJ+N98EAsAj1HF92J16TAO1iCUCAcsFwAA7wn3CC/9X9yQzWTC1MbfTbGWxR1aFk6CnwEvHLHDaA4eVow9ITvlyn1YgGgAbiAdNkt0Bp42QW4M+CaDAiUHN+BsA0SRQ3oAAbkMAAzgGtR07fwG2XQkGAMWNOr7lgssDu5l4lQCsTfJjWdthmRxT5g3wJYzpJKNOk3okoM6PDgSwAC/X+LXLjVqVpRuNqH2GyTdJ5oTheJroiWdtuESWRzcdjUhCbTx6BpuAIiywgJoLzEUObCHyZmBJNgnQHQAHINDbTu3V2GhyBQLUwF5NDQTfhsA9J0KAS5KQ4ANPuvfLMTGpVJaGL7GXKrBQMSgNg8ZcuGZRuKqZzJYA9JbAMM3u8mn/qHbmVt+DVknIrXLRbkZjAh52GKMJqb2xmjfBLOUXpwAo8C458gLHLlOddlYAOCcW0OmpnRV1VmPuGpCSmy+NEM1OIrxUJECY9eNsoHg6sICAEL6l1iQMDJYxWt7pESZm767AXFD6MZZrwwDWedYzNeoLTjC5nXxVoOQ0RPLMgnack7gkz0UaTrslykm6LiAEaQ2rjlHRGU8vIa0NSLdRNQsHQEfDWQcgCgauS6cR9RG1JHXD1Wug/craW6iNB9twp61o3HSX4TYad9etNxN5m9H33oAb8TcZjxRu+OGIJ6744owzHvjjwEAu+eRDDE755Zdbjvnmj2vO+ed1ew76/+hri0766ZxIEIEmIkQgAeqwU15BABNAEAAEEwRQQey8Q24BHxb0LjzgEfCx+vDI0517HhMk7zzctucBwfPUv0JBABRUr30qFwRwwfbgdyJBAK+Hb34lGJyv/vrst+/++zQ0Lv/89C8OvxamO5///Tjsj7z//KsBAIU3wADKoIC8Q6ABL7HAFSiwgfGYwTxIMEFJRIQWaMvID8YWDghOYR/cGFAI6YGKCqLrgjAwIUZQKJFkcJAHD/RgCkBYlLx4bRwltIUGk5ZBFupAHS/cQQxlmI9FEeBiDnBGN5aCEtCIZmOV2QnRNCMmPTSRKW5imKueSA3xjKcuAbiLCDrTrv+TeGdS5IKMFTfWj0rloYaJiUxIEtMoM4KRNhpzTB5OU5o9ooaIUFgNAY6SFTVJBzTpCRaEbhacokgjGg+ohVkYSawuPktFFypBqX4lHQA4wCvAgaQkg5OLrJREKJYB4nFG2KgHbEtDKoEZgzwEABaJCJBOWE1WGoCcImVpUL9kCALoBBhfHEhkOaOkC3/pxfKM6VyA4tIerlKACx1zj+QYhkv2oCIXQoMb1/TLM7vEM90YipWfwGUuSdQc5DwKh+PyUDKvxTMEkEVeLbMKMngkzwxVBSHnQpYIwNWb17RKBElMmD3j5Zds8oI9lLzQMHq0UHzm5yWvShjNqkLLIqr/cwnrmlUIC1YPPVhqTwiQWYWQ0o98CpMmdmkRjwZTLpGRwGfb+EXB0NMbALG0oZjQJmeclACbTZQbCPmZimx6lrRk659E++NHQWoDjvzQQWwb4lTdZtUcdNUTWv1oWEE3VlyWlXNnJWJaMbdWD7aVcm9tYFwlN1cD1u+ueM2rIaYau7ry1a5/DSwS/CpY+BG2sO47LGLZp9jFqq+xjjUfZCMLvslStgl6zaxmN6uIy0bQs+cArTJE61HSStW0RkPtLVWbTtamVrWWRV1sRzdbzqmOdQBwHWhv21rdinZ2tbtd7nbnWeDaDne6M+3v9hA80S5XD80lbfH2cDzQTlcP/9Ul7fJoh9rtNk+10bsdasM7PdZeL3uqPa9rAdC976m2vesdX/lQK9/1AiB9rsWvfffL3/4GkLOIYCuAHcdWLtSWCgcebYHbtmC5NTgLCZZChEP7YCxMOJBW21xjL/wEDp8WrjVQ4QrpwcjX0hUIOyzBV/NE4cyRqFGCMoGIWUxjHoVKJNBsLYhJUJg8vMlUMUjxPlFQEQ16eJ2LugpJUDDjeESkHxc8Mt9K8EkRGOBfQfahirEKDBZKecpJHqO4yKinKFLQF34xplzKkpIGDMWeg/zwiUnwSa8lyQA4Os1PAEPmyFyxFkt9y5kBvYs7svkAYsStixfFB0E14EKbmf/kmRdynkx+4gG+OkiJFT05UdxINHq210JF0qLk6EphAYgkzAqKJ5EuZBfbunSmTTznETAKxi6JkbheCs9APfMTCYncok/QnWsIACl+OqqPdD2AcLpUR1idxy5+7SZL0xpyIf2HsMIV41rN41hV8csBuFzaWg90IWGRFSQ9WRVlE9RE9wSqCEYFr14DOTCfaBK5v0zVMOOaY/2AcjLP3JHX2NQXKTloubGtYqL94i9XZky7v1lUj33mpy5lyEmivQlYH3wACV8av3shg6kJrsJ40/ALygazI4x8sBlGuRVe7vKYDxvCMvebyhl887flHME/J9zO8Rf0MdDc5QMuhID/k5649x2dbk8P3XqjDvWp75fqWb261e2L9dKxlreY8O1lwd66+RaXdscdLmiNK9zkkva5eYiuZ+EeALlb13jSxXt39fBd7fKdteQdrx7Km17smdfwroXve70XX/J93fHr1a9qJe/fylv+8q5guubrh+DNe57AQP9f6Ic3165j+IPJK33qR0/Ama8e9aKvguk7zPreqZ4STUZx7d+w4sq5XgaGWpAZjZB7JgukGEL+rIRb0Ce3SKYg9qoGuWWMieJv2YG/586sT6WpnWSN+FezfvIZCPuoxJkEM3KVAsg1kyIE8QRftb4As58CIgWFYZERmrI4vo3GREwzVMEaOCEA/52hGHQUVR0RgAV4EDgxCc10GiTzMiTRVFCURdhXfjLSAAswTFb2FCUBHezAFU9UIqOxC0+iBwzwf3rkF3eGQ4CmghEYHBTXGQ3gcEP1RoExGEtjDXS0Whi4As7ASMwxHWZSNC1CKg3gLRQSRpECFU1DLgeySglgQkx4Svw0hDL1gKxGMb/yKgoxSrc2Q7vXESXTgQfyapSUUdMhHfvBbfNmGZ40F7I0cSTEC0qYhFEig6eySTIlUwTVHP7RUQNhE1Log8tnMvchKiYAa/tHcIHRJ+H2Cz0yAg0oJxRHhfBQiYWUhZeUfnbCJVcSTLWycEiGfhrIgXnCEgMCHED0Df/TdCZFA4lPdW8i1YF6UB67cQwJ0yPQQg65BiRrAk07MonXRnsq0CT2IgBFwRzNtinf12uh4i0F14Qj0DS2dokBEDbFYI3U2Bf4BlBbeGmBUkkodYGHaH45NhVGcTHowX77lEbvNIjzVgzSSDG5ISuOWI/0ViqM0hemhkNisW0FFYz7pGyGGAW20CeS0UcBAB2YoXAs1zU8UUzwkFTPQEbTQnEHY4TFgJF/sQ0zxRS0RDL2xw0fkxYDp2DneC82hRkddRYlFjQDJTLuQJI7M4sQZ283eSLj1iJYlAA0uJFrQRR4Ai00YpDFWIpAIH/M8IM40HunQH8/wJRy8FaaA5X/kXB7pDeGsKOVreeUfSWVOECVWjA2PhN9LYaQI+ZyWjZYPnQw03eQp7cC8ldST1ErYJQwKfBC4xcDY+MuYZOWc+lAelITnqgA7qI18Ldv8NCXKNaYPkQy7SeYaskDoEECS0IuV5Joi4iWRPCXehCYpIhZK4QcMmKEXhGQ1nZ9NOaYP4B8kakHkzmaSpkCoKGDFNSA+BYVNxNrJZBnLThva3YeaCSItjSPamEaDOhHw2BP13QYZ4kRXDlGTqIndlY0vSGaRqEVchQVaYJF77IL/LCAC1gOOMGTIgQylJFFOBINj+FJKAiX5giW1BcYCfAfJPBjdpkHvHYPm2YfZGEQ/7EWDJ80a/LCAFShJnNBSyzCoIexC+IRIPNHnwOlKyznC+lXGizQH4ypCQvSbhL5hJYholqkIAxRAED5HvGxHov0iXMojkEmlidQD5eEat1wmbx5USlwbIxBizxiEmRSDNVkAgoBI1JBgHxwTtMiKYjSJj92QNMZTZtxnZpyQ+hHVAQBm3dyDZqoie+AJ1YyEKJYTrPIFUGhnbRJmgFRlND0Y94oUP1JLnchAGK0bg7Qbop5C5HoSfyQjBsIAJKyE4IIqND0HAiAolUKpRRaEqlimlaGmhI5AJZ2K0+ymqlmj3RohdX4n3YCJa+hhgN3qbM4AoM6nytpmxlSozJyEv/+hJl78BlAMWsDUxU5ORAfx1Nl6IZ3OitRxZB0eKg3qainWgI4NaWr+hTT4mOKGTHghBSMdCIkcY8LgZEY+aWe6hMaM3DQulExMXzSKXuvN6xhCa6xJ65dKaPnuqik45W2F6Xriq5i0Burqa5JcGTyinPkigb3amHu+gX7egXsWgb/Cq/9pq9Mga/92gTuMhLysgDOAIc+IxoIW5lXsLD36SYPuxMRe7D8mq9ZYBI24iY8MRf9wAAD67GDiQUg27AjGxwGcrIJW69ZYKZvxLK40gAsC7P0CnNYQLMNabNhlLMcC7AE6wS9cRh94QBAu6AXQxkTm7JTcLQ8obQie7P/gNq0Q1u0BWsFTPSzVcuEuIJF82quYFaxrEq1h2G1YbsNY0uxO/s5Vhmub4tWMUu3KJtAdTt0c6u3UDuueUsGWKl7ewu4ccmzCdtHL4kf7ueZxlC4vUaWXRW309BGMQKT2MC47eC4tdiHLxC5UhkSOaaf2diOMgF9MxB/+yO56FgCousd8OGOi3u6msu5rymWBnCKYlEvkfIAqkiLIsgUYsFE3mGCaoKCKgieBhCcLfKCjHEZPbGL/iAXNmhjOMgVuJkfNtGDSbm1Voa7DLUQMtG7IRgawEuCw+uPNtm8K5i8NiVSzJsZE4kWetgjNDi9AZOD5Yu9iKG4nEa2fuSS/6l2DWEYGIm0hmIhHwXwC1t4hybKIAbRGtECh7PBarpIcXzoi5Pwh596n4NqHKUml2oqCe8CwA8gwGlYwO+EwApMjxIshx/qoxB8hxScC9D7j5srkICIovipv6TmqP3rtt27gWEzKuLLisvkS7B4rD26UTCMCZAIbfPLDb1YfVpSud3EMgVJcSBcthkoxMRqIEU8ZLWBxMmQfrLIxA/sxHuAi/JYw1Nci1sySATJw1q8vVzMEOdXAkMhJa9buvoLjwelDgsMh9N4j3lKDvq4Kfy4Fdxwwdnoh8OiqvKIlD9cm6B7AntMwLArj4AMKYLMwiWKxoeMCYlMKjbByDbcIv8BmcGRjMV0zH12zL1F8i5/gbPpGZMmNZN7VJPGWydMXKucu5Mb55PbAJRyIZQ32JBsmsWwXMkhzJJ+VMsCYrkwVYU75SDpS5F3AszzIMz4QszRaxfITL3KPMeTXMfOXJtPObuh8LdlknV3ewOBKwvu3LjwXM+dhs/mRrano7pfGbOu2T9tyZYpIJ8qCcQv8H5i0GTRCQMBew6F+RaHmZiZe0JcyDeQuaOyedB92wLDkKToFDRW6og7ys4SRMUqAJgOrbU4w0qemJoH0batNo2fiNEXrREbLYaDe435ZqMjcKc7MS0+RJaWidIpoNLkF6Vk5sPpl50okCQpVScs6Z7/zIkLKEpH5dkR53kS6YmSWGQZ7Ym88JkHDGDQOs3PJ+AuvFCGxAios0kCfrYhPfrTxjsSCfJJntwVX3EQSDGSggG8NhhFPSayDZ3Ui7pJm9EWGWqETz26HdrAILpEqMQAJFoO4YGi/wBLLCppyPfCorrSe0sdprIHSOo16ITJqUaFk3kMcoqoF5Wi4ZELPxYWgehSYJglaGrY/LwlxvqoiUpsWPrYaLwQXcpN1qor5BSqGa0t/YCKwobWv3kVH30ubV2qvPEyGXdRZ3omny2PnToSI7Qy44HB+uSkmKt8h92oLg2pNzqpzFKp6NJ+wz1QjMSNLOap5KhPosrEpJpj/xxtjNWghj0tZl5zp5JIAABRUUClneWSC619Q9faIQvCjpckoSkZLiOt2wh9UxbH1KSdrG6yrCpTVM7qqib5cJlKrUR13BRDgdp6KNyKbApnqgDeAgezABpF3XuQCziSUuOAcRs5At0KvIWSMI/myadGGn0NgZc0zsLEcpz6rfrMcDu9Y1PeOVceOA+drtBNViwNt1kOOFsuW2G+N2Pez2WuN2f+rlWez7L3eXCOOJ0X53TuCF7uWrP3CnmeCnuuCn0+Cn9OCoE+N3i+dYYOW1pX6Fx36Kw16EfzWHVuP3we6Yqj563A55fOBlUWLiWK3k1JE3ehl12w6fSm4R+hYv9VKOpeACugkqeeXpUaISnkcd5UwOrPaOqqEeu0pOpegBB3un50dBRmI2ew3nDHxuoP2elV4OuvG+zIFn2mZwpccewJk+xdcB86Ndn4mKY2d1ExAaz05kVZgO1WCIXbji6Z7u0b+BLhbtJPQA6aKKlooezRrhFVgRmeshsaqgXwzk3yPiToTs8NN5H5zqtdQA72vakiQHa5ZXZrwPC+hSz9IAD76O5MgPD/aY0Q7/BqsPGu0jDPUPEHjwkYOTAMw3bIRVxtgPJqt5tZIXxMoezLTvJEZfIiwPJut/Jo13bEhSwvP5EHIPNoQHd2xwZEzwlHDwdJzwnXlQfZ1QZNHwD/Tx8JUT/1a1D1o+Bdc6D1ncD1ceD1nRB4ciD2nED2cGD2naBedKD2nsD2cuD2nqB4cyD3nUD3cWD34gN5c1Bfo8D3e6/3pEB5ciD4nED4cGD4mJf4ir/44VDn50DpmUU1ji/CkJ9X8dOxAY/pE4qujk7sUh7POiboVIP5nv/oM+BXrND5W/zcoK/6sUyZ5ur66cz6XCn7oQ/anJ95o0+03B6Vp0/6q59LLETUMyoKboP6sI+Qw983FZRBwG9iLyORKqDQCb3Wy58Dzb/7uc9oJ5Hhi0Lrfmn9xof9xn/5LED9MXAfrl2M6xIT543+Dn39Y1n+mz/94D8D6m+lqU8i/+4PAoA4kgAhlKm6psGwDgE7p3Ep0ytOIoGPmoC5IYnhCzhuuhIBAUgsGACB7yANGApH7ECLTWwNiYMvKfAeyIFHEBBQG0oxckHqrSsIvgWg64v7+SgRqeyM9PyInBAyGpUNtjA5QUlRvV1lhQWKhY09nlWpsS2+/cmV1gHcMeTt9XkBehm6MZLMOqQOLKAs1g45IkEKmxwdGBhJIRC4NSgCLcQ98IkIHCg0NDMsDJwlgKEotwWgCPDBxkhhkxQ4xCiMQANIA+z2zc7W3ubW9/rSACextYSEnirHAiRbFqBZG3rRpk2xpk4btwLexgEIR4qcuT/oAKgbwc4dvIf0UP/YEOhv1gI21A6YUOPEwIJEDaooiBGD5kuQODMGsDhsxKwm1MYVENHFzYs2YLYkyGhNVRwTBgQsYzplGakXMaKOSHlGAaIAThwE2PX0CJioKYn6g0ui5YhqMX3MrInx5pucLrBMs8t3ag+hKiMRdDIFqdKkLpw92RIgKoKpBaoSuJr1MVZxXieTEFuA7JGzaQWs9dHW3lAihsA0BZDFRDaEBAJGfHdAQAwUCuJBq6ZbSKGBI4xOiYIQpMKmt0XEO5QVZG1um1907goA1ykRBxAYCKBbMQAjUKpCJ3cvrojXj0XMJlCbwfOXw3sD+B0n+NTdM/C1Jwk1yqXTnCIBRSf/QjgiTORCZ1plh8Jj3IWGw3fhjTeCeQmetFhrQ7DkUkQNcUEGAQyUZdZbWD2QVIrkFRfjcUdcttglWsnm0R0xHIGaGmZct5U4PhQQm1LFeKNGAQjwaNYrROZYyoeulUBXT72UGMCJL65IQItAlfafcYrQGIclVuAYHhc7buHjJ0FG6AaRRtpTRZJEMhlmIEmpScaUNMyCwD68oPAAaAwiIFxYO4BRADlT5QAgLexRWqmlLEhKJQ+DtmEoWCAlCilrIjT66DuRjnmpqqv6kimgKZQFREEYFZQKX1wYgsACp96Knox/shqssHLFhU+sZCZSazpHGPBWRrsyyKyYvw5b/621rk5rLXuSYqutt8VS2u23qRI7rrnhgnsuI9yq2+5K6LoLIrnx0kstIeLGy662D9a7Lrz9zjuptfwCLO+7BdsboLAPEoxwtgc7fBiwcTE8XcSYpnuxwogFW7HGD7f68cYT++OxyAmDKJnKK7Pcsssv68vqWokWoMVUg/m1UzF+0cEATe/YJSy+OsBctNFHHxEwpTOfYfM7OOuExc5zBOUztEEHO/TJ9w7LsEX6KbobfiOA8cBH6tRYo9BbD6s1IV4nAHZ/vGFE9hpnN5O2r6u6zfarC2f14GVc4kAfs6Jt9WXbfmfddeBZDb5FniIY7hEOZySe1OKMX9r3EEELfu6VqClVlh+u3jnxm3+bc9551zAJSZWiRyoIkwKnA/BdfgusvnbrlXqegzZmhe6T5UrVpEWzSIrgALSs//4vq8MnCnkcvaakS1C42tn8875Hn/HHzkJWbfDhl6sx+Q1Bj76/J5Nv6Kntu/++yPGLd239Ie8Pfv9c/49V5wvfAAPIMQOiCoGuUyDIGAgxByoNggaTIMkoiDIKFtCBGWzdBhXYQQ5a8IEhRBoJS2jCE8IshC1AIQtb6MKXqTCGMpwhDWtowxviMIc63CEPe+jDHwIxiEIcIhGLaMQjIjGJSlwiE5voxCdCMYpSnCIVNRYCADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     dFLC: difference between involved and uninvolved serum free light chain levels.",
"     <br/>",
"     * High risk: Mayo stage III (cTnT &gt;0.035 mcg/L and NT-proBNP &gt;332 ng/L).",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Start alternate therapy if organ progression at any time.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: mSMART (",
"     <a href=\"file://msmart.org/\" style=\"font-style: italic;\" target=\"_blank\">",
"      msmart.org",
"     </a>",
"     ).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_29_11742=[""].join("\n");
var outline_f11_29_11742=null;
var title_f11_29_11743="HCC transplantation recs from intl consensus conf";
var content_f11_29_11743=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F83727&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F83727&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of recommendations for transplantation for hepatocellular carcinoma from an International Consensus Conference",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Level of evidence",
"       </td>",
"       <td class=\"subtitle1\">",
"        Strength of recommendation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Assessment of candidates with HCC for liver transplantation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         1.",
"        </strong>",
"        When considering treatment options for patients with HCC, the BCLC staging system is the preferred staging system to assess the prognosis of patients with HCC.",
"       </td>",
"       <td>",
"        2b (P)",
"       </td>",
"       <td>",
"        Strong",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         2.",
"        </strong>",
"        The TNM system (7th edition), including pathological examination of the explanted liver, should be used for determining prognosis after transplantation with the addition of assessment of microvascular invasion.",
"       </td>",
"       <td>",
"        2b (P)",
"       </td>",
"       <td>",
"        Strong",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         3.",
"        </strong>",
"        Either dynamic CT or dynamic MRI with the presence of arterial enhancement followed by washout on portal venous or delayed imaging is the best non-invasive test to make a diagnosis in cirrhotic patients suspected of having HCC and for preoperative staging.",
"       </td>",
"       <td>",
"        1b (D)",
"       </td>",
"       <td>",
"        Strong",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         4.",
"        </strong>",
"        Extrahepatic staging should include CT of the chest and CT or MRI of the abdomen and pelvis.",
"       </td>",
"       <td>",
"        3b (D)",
"       </td>",
"       <td>",
"        Strong",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         5.",
"        </strong>",
"        Tumor biopsy is not required in cirrhotic patients considered for liver transplantation who have high-quality dynamic CT or MRI findings typical for HCC and a lesion larger than 1 cm according to current AASLD guidelines.",
"       </td>",
"       <td>",
"        1b (D)",
"       </td>",
"       <td>",
"        Weak",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         6.",
"        </strong>",
"        For patients with lesions smaller or equal to 10 mm, non-invasive imaging does not allow an accurate diagnosis and should not be used to make a decision for or against transplantation.",
"       </td>",
"       <td>",
"        1b (D)",
"       </td>",
"       <td>",
"        Strong",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Criteria for listing candidates with HCC in cirrhotic livers for DDLT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         7.",
"        </strong>",
"        Liver transplantation should be reserved for HCC patients who have a predicted five-year survival comparable to non-HCC patients.",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        Weak",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         8.",
"        </strong>",
"        Preoperative assessment of the size of the largest tumor or total diameter of tumors should be the main consideration in selecting patients with HCC for liver transplantation.",
"       </td>",
"       <td>",
"        2a (P)",
"       </td>",
"       <td>",
"        Strong",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         9.",
"        </strong>",
"        The Milan criteria are currently the benchmark for the selection of HCC patients for liver transplantation and the basis for comparison with other suggested criteria.",
"       </td>",
"       <td>",
"        2a (P)",
"       </td>",
"       <td>",
"        Strong",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         10.",
"        </strong>",
"        A modest expansion of the number of potential candidates may be considered on the basis of several studies showing comparable survival for patients outside the Milan criteria.",
"       </td>",
"       <td>",
"        3b (P)",
"       </td>",
"       <td>",
"        Weak",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         11.",
"        </strong>",
"        Patients with worse prognosis may be considered for liver transplantation outside the Milan criteria if the dynamics of the waiting list allow it without undue prejudice to other recipients with a better prognosis.",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        Weak",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         12.",
"        </strong>",
"        &alpha;-fetoprotein concentrations add prognostic information in HCC patients and may be used for making decisions regarding transplantation in combination with imaging criteria.",
"       </td>",
"       <td>",
"        2b (P)",
"       </td>",
"       <td>",
"        Weak",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         13.",
"        </strong>",
"        Biomarkers other than &alpha;-fetoprotein cannot yet be used for clinical decision making regarding liver transplantation for HCC.",
"       </td>",
"       <td>",
"        2b (P)",
"       </td>",
"       <td>",
"        Strong",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         14.",
"        </strong>",
"        Indication for liver transplantation in HCC should not rely on microvascular invasion because it cannot be reliably detected prior to transplantation.",
"       </td>",
"       <td>",
"        2b (P)",
"       </td>",
"       <td>",
"        Strong",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Criteria for HCC candidates with non-cirrhotic livers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         15.",
"        </strong>",
"        The Milan criteria and its modifications are not applicable to patients with HCC developing in a non-cirrhotic liver. Such patients with non-resectable HCC and absence of macrovascular invasion and extrahepatic spread may be considered as appropriate candidates for liver transplantation.",
"       </td>",
"       <td>",
"        4 (P)",
"       </td>",
"       <td>",
"        Weak",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         16.",
"        </strong>",
"        Patients with HCC in non-cirrhotic liver who were treated by resection, and have intrahepatic recurrence of HCC and no evidence of lymph node or macrovascular invasion, may be considered for salvage transplantation.",
"       </td>",
"       <td>",
"        4 (P)",
"       </td>",
"       <td>",
"        Weak",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Role of downstaging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         17.",
"        </strong>",
"        Transplantation may be considered after successful downstaging.",
"       </td>",
"       <td>",
"        5 (P)",
"       </td>",
"       <td>",
"        Weak",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         18.",
"        </strong>",
"        Liver transplantation after successful downstaging should achieve a five-year survival comparable to that of HCC patients who meet the criteria for liver transplantation without requiring downstaging.",
"       </td>",
"       <td>",
"        5 (P)",
"       </td>",
"       <td>",
"        Strong",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         19.",
"        </strong>",
"        Criteria for successful downstaging should include tumor size and number of viable tumors.",
"       </td>",
"       <td>",
"        4 (P)",
"       </td>",
"       <td>",
"        Strong",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         20.",
"        </strong>",
"        &alpha;-fetoprotein concentrations before and after downstaging may add additional information.",
"       </td>",
"       <td>",
"        4 (P)",
"       </td>",
"       <td>",
"        Weak",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         21.",
"        </strong>",
"        Based on existing evidence, no recommendation can be made for preferring a specific locoregional therapy for downstaging over others.",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Managing patients on the waiting list",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         22.",
"        </strong>",
"        Periodic waiting-list monitoring should be performed by imaging (dynamic CT, dynamic MRI, or contrast-enhanced ultrasonography) and &alpha;-fetoprotein measurements.",
"       </td>",
"       <td>",
"        5 (P)",
"       </td>",
"       <td>",
"        Strong",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         23.",
"        </strong>",
"        Based on current absence of evidence, no recommendation can be made on bridging therapy in patients with UNOS T1 (&le;2 cm) HCC.",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         24.",
"        </strong>",
"        In patients with UNOS T2 (one nodule 2 to 5 cm or three or more nodules each &le;3 cm) HCC (Milan criteria) and a likely waiting time longer than six months, locoregional therapy may be appropriate.",
"       </td>",
"       <td>",
"        4 (P)",
"       </td>",
"       <td>",
"        Weak",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         25.",
"        </strong>",
"        No recommendation can be made for preferring any type of locoregional therapy to others.",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         26.",
"        </strong>",
"        Patients found to have progressed beyond criteria acceptable for listing for liver transplantation should be placed on hold and considered for downstaging.",
"       </td>",
"       <td>",
"        5 (P)",
"       </td>",
"       <td>",
"        Strong",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         27.",
"        </strong>",
"        Patients with progressive disease in whom locoregional intervention is not considered appropriate, or is ineffective, should be removed from the waiting list.",
"       </td>",
"       <td>",
"        5 (P)",
"       </td>",
"       <td>",
"        Strong",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Role of LDLT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         28.",
"        </strong>",
"        LDLT is acceptable for HCC patients who have an expected five-year survival similar to comparably staged patients receiving a deceased donor liver. In LDLT, careful attention should be given to psychosocial considerations regarding both donor and recipient.",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        Weak",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         29.",
"        </strong>",
"        LDLT must be restricted to centers of excellence in liver surgery and liver transplantation to minimize donor risk and maximize recipient outcome.",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        Strong",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         30.",
"        </strong>",
"        In patients following LDLT for HCC within the accepted regional criteria for DDLT, retransplantation for graft failure is justified.",
"       </td>",
"       <td>",
"        5 (P)",
"       </td>",
"       <td>",
"        Weak",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         31.",
"        </strong>",
"        In patients following LDLT for HCC outside the accepted regional criteria for DDLT, retransplantation for graft failure using a deceased donor organ is not recommended.",
"       </td>",
"       <td>",
"        5 (P)",
"       </td>",
"       <td>",
"        Strong",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Posttransplant management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         32.",
"        </strong>",
"        Posttransplant monitoring may include 6 to 12 monthly contrast-enhanced CT or MRI imaging and &alpha;-fetoprotein measurements.",
"       </td>",
"       <td>",
"        5 (P)",
"       </td>",
"       <td>",
"        Weak",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         33.",
"        </strong>",
"        There is currently insufficient evidence from clinical trials to base a recommendation for choosing the type or dose of immunosuppression therapy to influence the incidence of HCC recurrence or its prognosis.",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         34.",
"        </strong>",
"        Based on current evidence, no recommendation can be made on the use of mTOR inhibitors solely to reduce the risk of HCC recurrence outside clinical trials.",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         35.",
"        </strong>",
"        The current evidence does not justify the routine use of adjuvant antitumor therapy after liver transplantation for HCC outside of a controlled clinical trial.",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        Weak",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         36.",
"        </strong>",
"        HCC recurrence after liver transplantation may be treated by surgery for resectable lesions or by locoregional therapy or systemic therapy (including sorafenib) for unresectable lesions.",
"       </td>",
"       <td>",
"        4 (p)",
"       </td>",
"       <td>",
"        Weak",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         37.",
"        </strong>",
"        Liver retransplantation is not appropriate treatment for recurrent HCC.",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        Strong",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Level of evidence for each recommendation refers to the Oxford classification.",
"    <div class=\"footnotes\">",
"     HCC: hepatocellular carcinoma; BCLC: Barcelona Clinic Liver Cancer; TNM: tumor, node, metastasis; P: prognosis; D: diagnosis; AASLD: American Association for the Study of Liver Diseases; NA: not applicable; OLT: orthotopic liver transplantation; UNOS: United Network for Organ Sharing; LDLT: living donor liver transplantation; DDLT: deceased donor liver transplantation; mTOR: mammalian target of rapamycin.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Clavien PA, Lesurtel M, Bossuyt PM, et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012; 13:e11. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_29_11743=[""].join("\n");
var outline_f11_29_11743=null;
